{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "TODO\n",
    "1. 评估数据集与评估方法 这个最关键\n",
    "2. 医学知识库\n",
    "2. 百川模型多角色 / Prompt优化\n",
    "3. embedding调优\n",
    "4. 上下文扩宽\n",
    "5. 不同百川模型参数规模性能比较\n",
    "\n",
    "\n",
    "https://github.com/zhangsheng93/cMedQA2\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Looking in indexes: https://pypi.tuna.tsinghua.edu.cn/simple\n",
      "Collecting bitsandbytes\n",
      "  Downloading https://pypi.tuna.tsinghua.edu.cn/packages/1e/2c/af22cd797fc368a9f098ed03015730e6568b884fe67f9940793d944a4b7b/bitsandbytes-0.41.1-py3-none-any.whl (92.6 MB)\n",
      "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m92.6/92.6 MB\u001b[0m \u001b[31m9.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m:00:01\u001b[0m00:01\u001b[0m\n",
      "\u001b[?25hInstalling collected packages: bitsandbytes\n",
      "Successfully installed bitsandbytes-0.41.1\n"
     ]
    }
   ],
   "source": [
    "# !pip install bitsandbytes -i https://pypi.tuna.tsinghua.edu.cn/simple"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# import datasets\n",
    "# # part 1\n",
    "# knowledge_graph_dataset = datasets.load_dataset('FreedomIntelligence/huatuo_knowledge_graph_qa')\n",
    "# # part 2\n",
    "# encyclopedia_dataset = datasets.load_dataset('FreedomIntelligence/huatuo_encyclopedia_qa')\n",
    "# # part 3 (only url)\n",
    "# consultation_dataset = datasets.load_dataset('FreedomIntelligence/huatuo_consultation_qa')\n",
    "# # testdatasets (6k)\n",
    "# huatuo_testdatasets = datasets.load_dataset('FreedomIntelligence/huatuo26M-testdatasets')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Load Language Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import torch\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import faiss\n",
    "import pickle\n",
    "\n",
    "# import streamlit as st\n",
    "from transformers import AutoModelForCausalLM, AutoTokenizer\n",
    "from transformers.generation.utils import GenerationConfig"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Explicitly passing a `revision` is encouraged when loading a configuration with custom code to ensure no malicious code has been contributed in a newer revision.\n",
      "Explicitly passing a `revision` is encouraged when loading a model with custom code to ensure no malicious code has been contributed in a newer revision.\n",
      "Explicitly passing a `revision` is encouraged when loading a model with custom code to ensure no malicious code has been contributed in a newer revision.\n"
     ]
    }
   ],
   "source": [
    "model = AutoModelForCausalLM.from_pretrained(\"./model/Baichuan2-7B-Chat-4bits\", device_map=\"auto\", trust_remote_code=True)\n",
    "model.generation_config = GenerationConfig.from_pretrained(\n",
    "       \"./model/Baichuan2-7B-Chat-4bits\"\n",
    "    )\n",
    "tokenizer = AutoTokenizer.from_pretrained(\"./model/Baichuan2-7B-Chat-4bits\", trust_remote_code=True)\n",
    "model = model.eval()\n",
    "\n",
    "\n",
    "#  print(\"init model ...\")\n",
    "#     model = AutoModelForCausalLM.from_pretrained(\n",
    "#         \"baichuan-inc/Baichuan2-13B-Chat\",\n",
    "#         torch_dtype=torch.float16,\n",
    "#         device_map=\"auto\",\n",
    "#         trust_remote_code=True\n",
    "#     )\n",
    "#     model.generation_config = GenerationConfig.from_pretrained(\n",
    "#         \"baichuan-inc/Baichuan2-13B-Chat\"\n",
    "#     )\n",
    "#     tokenizer = AutoTokenizer.from_pretrained(\n",
    "#         \"baichuan-inc/Baichuan2-13B-Chat\",\n",
    "#         use_fast=False,\n",
    "#         trust_remote_code=True\n",
    "#     )\n",
    "#     return model, tokenizer"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Load embedding model"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "可以参考 https://github.com/shibing624/text2vec 下载最新版本并尝试fine tune"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[32m2023-10-21 13:25:30.541\u001b[0m | \u001b[34m\u001b[1mDEBUG   \u001b[0m | \u001b[36mtext2vec.sentence_model\u001b[0m:\u001b[36m__init__\u001b[0m:\u001b[36m80\u001b[0m - \u001b[34m\u001b[1mUse device: cuda\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "from text2vec import SentenceModel\n",
    "from text2vec import CosentModel, SentenceBertModel, BertMatchModel\n",
    "from text2vec import cos_sim, compute_spearmanr, EncoderType, load_text_matching_test_data\n",
    "t2v_model = SentenceModel('./model/t2v')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Util library"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def dump_obj(obj_name, obj):\n",
    "    with open('./data/tmp/' + obj_name + '.pkl', 'wb') as f:\n",
    "        pickle.dump(obj, f)\n",
    "\n",
    "def restore_obj(obj_name):\n",
    "    with open('./data/tmp/' + obj_name + '.pkl', 'rb') as f:\n",
    "        obj = pickle.load(f)\n",
    "        return obj\n",
    "def to_embeddings(model, text):\n",
    "    sentence_embeddings = model.encode(text)\n",
    "    return sentence_embeddings\n",
    "def calc_similarity_scores(model, sents1, sents2):\n",
    "    # t1 = time.time()\n",
    "    e1 = model.encode(sents1)\n",
    "    e2 = model.encode(sents2)\n",
    "    # spend_time = time.time() - t1\n",
    "    s = cos_sim(e1, e2)\n",
    "    sims = []\n",
    "    for i in range(len(sents1)):\n",
    "        sims.append(s[i][i])\n",
    "    sims = np.array(sims)\n",
    "    return sims"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Construct Knwoeldge base"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "https://github.com/FreedomIntelligence/Huatuo-26M"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_knowledge = pd.read_csv('./data/huatuo_knowledge.csv')\n",
    "df_encyclopedia = pd.read_csv('./data/huatuo_encyclopedia.csv')\n",
    "df_kb=pd.concat([df_knowledge, df_encyclopedia]).reset_index()\n",
    "\n",
    "kb_dict = {}\n",
    "for index, row in df_kb.iterrows():\n",
    "    kb_dict[index] = {\n",
    "        'q': row['questions'],\n",
    "        'a': row['answers']\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "dump_obj('kb_dict',kb_dict)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "kb_dict=restore_obj('kb_dict')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Construct Vector DB"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "data = to_embeddings(t2v_model,list(df_kb.questions))\n",
    "data = data.astype(np.float32)\n",
    "\n",
    "dim = 384\n",
    "# Create index using index factory\n",
    "index = faiss.index_factory(dim, \"IVF2048,PQ32\") \n",
    "\n",
    "# Training is required for some indexes like IVF\n",
    "index.train(data) \n",
    "\n",
    "# Add vectors to index\n",
    "index.add(data)\n",
    "faiss.write_index(index, \"index_file.index\") #将index保存为index_file.index文件\n",
    "index = faiss.read_index(\"index_file.index\") #读入index_file.index文件"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "index = faiss.read_index(\"index_file.index\") #读入index_file.index文件"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Query"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_context(query):\n",
    "\n",
    "    qa_id_list = get_nn_by_query(query)\n",
    "    prompt = \"你是一名临床医生，请参考以下回答资料回答问题，如果段落内容不相关就返回未查到相关信息。\"\n",
    "    max_length = 1500\n",
    "    i = 0 \n",
    "    context = prompt\n",
    "\n",
    "    while i < len (qa_id_list) and len(context) < max_length:\n",
    "        \n",
    "        qid = i + 1\n",
    "        q = kb_dict[qa_id_list[i]]['q']\n",
    "        a = kb_dict[qa_id_list[i]]['a']\n",
    "        tmp = context + \"\\n\" + f\"{qid}. 问题：{q} || 答案：{a}\"\n",
    "        if len(tmp) <= max_length:\n",
    "            context = tmp\n",
    "        else:\n",
    "            break\n",
    "        i = i + 1\n",
    "\n",
    "    context = context + \"\\n\" + \"问题：\" + query + \" || 答案：\"\n",
    "    return context\n",
    "\n",
    "def get_nn_by_query(query):\n",
    "    tv = to_embeddings(t2v_model, [query])\n",
    "    dis, ind = index.search(tv, 10)\n",
    "    return list(ind[0])\n",
    "\n",
    "def query_model(query):\n",
    "    context = get_context(query)\n",
    "    inputs = tokenizer(context, return_tensors='pt')\n",
    "    inputs = inputs.to('cuda:0')\n",
    "    pred = model.generate(**inputs, max_new_tokens=1280, repetition_penalty=1.1)\n",
    "    response = tokenizer.decode(pred.cpu()[0], skip_special_tokens=True)\n",
    "    # print(response)\n",
    "\n",
    "    return response[len(context):]\n",
    "\n",
    "def ask_glm(text):\n",
    "    response, history = model.chat(tokenizer, text)\n",
    "    return response,history"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "# query = t\n",
    "# context = get_context(query)\n",
    "# inputs = tokenizer(context, return_tensors='pt')\n",
    "# inputs = inputs.to('cuda:0')\n",
    "# pred = model.generate(**inputs, max_new_tokens=128, repetition_penalty=1.1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'你是一名临床医生，请参考以下回答资料回答问题，如果段落内容不相关就返回未查到相关信息。\\n1. 问题：胃不舒服怎么办 || 答案：胃不舒服要在饮食方面我们要养成良好的饮食习惯，胃是人体的重要器官，我们每天都要靠它来分解消化食物。正因为它作为人体器官的重要性，我们也经常用到它，总会造成伤害，那么胃不舒服怎么办呢，每天三餐要按时的吃，当然早餐是肯定要吃，如果不吃早餐会对胃造成伤害的。在太热的时候不要吃一些比较冷的食物，会对胃造成很大的影响，胃会承受不了，这样会加重胃的负担，使胃更加地不舒服。我们可以适当的吃一些养胃护胃的碱性的的食物。如土豆、胡萝卜、芋头、葡萄酒、海带等等，有利于中和胃酸。每次不要吃得太饱，这样加重胃部的负担，长期下来易引发胃病。适当地饮用酸牛奶，利于恢复肠道内正常功能，有利于消除胃肠胀气。豆类以及豆制品等不适宜过多进食，易产生胃胀气，导致胃不舒服。如果出现胃不舒服的这种现象，我们可以跪在地上，从膝盖到脚趾都要接触到地面，伸直上半身，双手摆放自然，臀部缓慢往脚踝上压，在这过程中保持正常呼吸，维持一分钟该姿势，适当放松后，再将上半身向前倾，重复该动作5次。这样的目的在于消除胃肠胀气，还有助于减瘦大腿肌肉。而且还可以做些其他事去分散自己的注意力，胃不舒服的人应该要保持良好的情绪，精神要开朗，不要一直在想很痛很痛，痛死了，如果你一直这样想，那么你就会一直度那么痛苦，相反，如果你再暗示自己，忍一下就好了，忍一下就过去了，那样效果更佳。另外保证睡眠充足和注意保暖胃部，睡觉的时候要把被子盖在胃部上，以免寒气的加重，从而导致胃不舒服。\\n2. 问题：胃痛怎么办 || 答案：出现胃痛的情况，可以腹部热敷，适量喝点温开水，一般能够有效缓解，也可以自我按摩穴位，比如内关穴、足三里。如果不能缓解，建议还是要去医院就诊。短时间的突然性的胃痛，大多是由于饮食不当、腹部受凉等原因引起的比如使用生冷食物以及过于辛辣的食物会引起胃痛。但是如果频繁的出现胃痛，或者是长时间剧烈的胃痛，要排除胃部的器质性病变导致的可能，需要去消化内科进一步就诊。所谓的胃痛实际上指的是位于上腹部剑突下方和肚脐以上这个区域，一般会认为这个部位的疼痛就是胃痛的表现，但实际上导致上腹部区域疼痛的器官不仅包括胃，还包括十二指肠、胆道系统、肝脏、胰腺等。因此对于胃痛的治疗不能仅仅是头痛医头、脚痛医脚，或者是通过喝热水进行一些对症治疗，首先要进行明确的诊断。既然考虑到这个部位的疼痛有可能是这么多器官疾病导致的，通常可以进行上腹部的B超的检查、验血、胃镜。在进行明确诊断之后，针对发现的疾病采取相应的治疗。对于一些慢性的胃的良性疾病，可以通过药物治疗以及改善饮食习惯进行治疗，戒烟戒酒，避免过度的劳累，生活起居有常。对于胆道系统疾病引起的上腹部疼痛，特别是有症状的胆囊的结石等，要进行包括手术在内的针对胆道系统疾病的治疗。如果有更严重的病因，包括胰腺的疾病或者肝脏的疾病，就需要采取一些相应的治疗措施。因此对于胃痛的治疗不仅仅是针对疼痛，更重要的是在于明确诊断，根据诊断的结果采取相应的保守治疗、药物治疗、理疗、手术等，平时不要吃一些油炸食品及腌制食物等不健康的东西。\\n问题：胃疼不舒服怎么办？ || 答案：当遇到胃疼不舒服时，可以尝试以下几种方法来缓解症状：首先，尝试调整饮食结构，避免刺激性食物，如辣椒、咖啡、酒精等；其次，保持良好的生活习惯，规律作息，避免过度疲劳和精神压力；再次，可以适当服用一些药物来帮助缓解疼痛，例如非处方药如布洛芬（Ibuprofen）或对乙酰氨基酚（Paracetamol）等；此外，可以尝试热敷或冷敷等方法来缓解疼痛部位的不适感；最后，如果疼痛持续不减或者伴有其他严重症状，应及时就医检查以确定病因并制定相应治疗方案。'"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# tokenizer.decode(pred.cpu()[0], skip_special_tokens=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 直接使用Baichuan回答，不补充知识。"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'2'"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "prompt = \"\"\"\n",
    "你是一名医学生，正在参加考试。题目为单项选择题。参考下面例子，给出数字编号答案。\n",
    "题目：书写药历是药师进行规范化药学服务的一项工作，下列内容一般不作为药历内容的是 || 选项: 1. 患者基本信息 2. 用药评价 3. 临床诊断要点 4. 用药记录 5. 患者知情同意书 || 答案: 5\n",
    "题目：研究TDM的临床意义不包括 || 选项: 1. 监督临床用药 2. 研究药物在体内的代谢变化 3. 研究治疗无效的原因 4. 确定患者是否按医嘱服药 5. 研究合并用药的影响 || 答案: 3\n",
    "题目：\"\"\"\n",
    "question = prompt+ '临床上药物可以配伍使用或者联合使用，若使用不当，可能出现配伍禁忌。下列药物配伍或者联合使用中，不合理的是 || 选项：1. 磺胺甲噁唑与甲氧苄啶联合应用 2. 地西泮注射液与0.9%氯化钠注射液混合滴注 3. 硫酸亚铁片与维生素C片同时使用 4. 阿莫西林与克拉维酸联合使用 5. 氨苄西林溶于5%葡萄糖注射液后在4小时内滴注 || 答案: '\n",
    "# inputs = tokenizer(prompt+ '临床上药物可以配伍使用或者联合使用，若使用不当，可能出现配伍禁忌。下列药物配伍或者联合使用中，不合理的是 || 选项：1. 磺胺甲噁唑与甲氧苄啶联合应用 2. 地西泮注射液与0.9%氯化钠注射液混合滴注 3. 硫酸亚铁片与维生素C片同时使用 4. 阿莫西林与克拉维酸联合使用 5. 氨苄西林溶于5%葡萄糖注射液后在4小时内滴注 || 答案:', return_tensors='pt')\n",
    "# inputs = inputs.to('cuda:0')\n",
    "# pred = model.generate(**inputs, max_new_tokens=64, repetition_penalty=1.1)\n",
    "# print(tokenizer.decode(pred.cpu()[0], skip_special_tokens=True))\n",
    "query_model(question)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 问题答案数据集"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json \n",
    "questions = []\n",
    "with open('./data/NLPEC/train.json') as f:\n",
    "  for line in f:\n",
    "    # Remove newline character\n",
    "    line = line.strip()\n",
    "    \n",
    "    # Load the JSON data\n",
    "    data = json.loads(line)\n",
    "    \n",
    "    # Now you can access the data\n",
    "    # print(data['key1']) \n",
    "    q = data['questionText']\n",
    "    o = data['option']\n",
    "    a = data['answer']\n",
    "    questions.append((q,o,a))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "18703"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(questions)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "\n",
    "# 问题从第三个开始，因为前两个用作了few shot 例子"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 18703/18703 [42:00<00:00,  7.42it/s]  \n"
     ]
    }
   ],
   "source": [
    "# for item in tqdm(questions):\n",
    "  # Do some work\n",
    "from tqdm import tqdm\n",
    "\n",
    "result = []\n",
    "for q, o, a in tqdm(questions):\n",
    "# for q, o, a in questions:\n",
    "    question = prompt + q.strip() + ' || 选项：'\n",
    "    i = 1\n",
    "    for opt in o:\n",
    "        question = question + str(i) + '. ' + opt + ' '\n",
    "        i = i +1\n",
    "    question = question + '|| 答案: '\n",
    "    # print(question)\n",
    "    sa = query_model(question)\n",
    "    # print(sa)\n",
    "    result.append((q, o, a, sa))\n",
    "\n",
    "    # print(q, o, a)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('3', '3')"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result[0][2][0],result[0][3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [],
   "source": [
    "def accuracy(result):\n",
    "    return len([i for i in result if i[2][0] == i[3]]) / len(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.3687109019943325"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    " accuracy(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('\"反应停\"致\"海豹儿\"，该药品不良反应发生机制分型属于',\n",
       "  ['C类反应（化学反应）', 'D类反应（给药反应）', 'F类反应（家庭性反应）', 'G类反应（基因毒性反应）', 'H类反应（过敏反应）'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('与硝酸甘油扩张血管作用无关的不良反应是',\n",
       "  ['心率加快', '搏动性头痛', '体位性低血压', '升高眼内压', '高铁血红蛋白血症'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('秋水仙碱严重中毒的先兆反应是', ['过敏反应', '胃肠道反应', '再生障碍性贫血', '血尿', '肾衰竭'], ['2'], 'C'),\n",
       " ('渗透泵型控释制剂的推动剂是',\n",
       "  ['醋酸纤维素', '乙醇', '聚羟甲基丙烯酸烷基酯', '氯化钠', 'CMC-Na溶液'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('下列药物信息中属于一级信息的是', ['杂志', '药典', '摘要', '参考书', '数据库'], ['1'], '1、2'),\n",
       " ('控释小丸或膜控型片型的包衣中加入PEG的目的是', ['助悬剂', '增塑剂', '成膜剂', '乳化剂', '致孔剂'], ['5'], 'B'),\n",
       " ('分子结构中含有苯磺酰胺结构的药物是', ['唑吡坦', '硫喷妥钠', '地西泮', '氟西汀', '舒必利'], ['5'], 'B'),\n",
       " ('分子内有苯丁氧基', ['丙酸倍氯米松', '沙美特罗', '异丙托溴铵', '扎鲁司特', '茶碱'], ['2'], 'B'),\n",
       " ('需先用地塞米松及组胺H1受体阻断药预防过敏反应的药物是',\n",
       "  ['塞替派', '奥沙利铂', '环磷酰胺', '丝裂霉素', '紫杉醇'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('为防止蛛网膜下腔出血患者出现脑血管痉挛，应尽早服用的药物是',\n",
       "  ['钙通道阻滞剂', '钠通道阻滞剂', '钾通道阻滞剂', 'β受体阻断剂', 'M受体阻断剂'],\n",
       "  ['1'],\n",
       "  'A'),\n",
       " ('若要对该批产品进行取样，则应取件数为', ['10', '16', '25', '31', '35'], ['3'], '随机抽样'),\n",
       " ('经皮吸收制剂中一层不易渗透的铝塑合模的作用是',\n",
       "  ['润湿皮肤促进吸收', '吸收过量的汗液', '减少压敏胶对皮肤的刺激', '降低对皮肤的粘附性', '防止药物的流失'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('为了与肝脏胆固醇合成同步，普伐他汀应', ['清晨给药', '餐中给药', '餐前给药', '睡前给药', '空腹给药'], ['4'], 'B'),\n",
       " ('硝苯地平的结构式为',\n",
       "  ['[1K20055.png]',\n",
       "   '[1K20056.png]',\n",
       "   '[1K20057.png]',\n",
       "   '[1K20058.png]',\n",
       "   '[1K20059.png]'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('治疗顺铂化疗所引起的重度恶心呕吐，首选的联合用药方案是（\\u3000）。',\n",
       "  ['甲氧氯普胺联合维生素B6', '西咪替丁联合维生素B6', '多潘立酮联合地塞米松', '潘立酮联合甲氧氯普胺', '阿瑞呲坦联合地塞米松'],\n",
       "  ['5'],\n",
       "  'A'),\n",
       " ('含有手性碳，（+）-（S）-异构体活性是（-）-（R）-异构体的100倍的是',\n",
       "  ['[YZ12017GJZYYSKSQZMNSJ4017.png]',\n",
       "   '[YZ12017GJZYYSKSQZMNSJ4018.png]',\n",
       "   '[YZ12017GJZYYSKSQZMNSJ4019.png]',\n",
       "   '[YZ12017GJZYYSKSQZMNSJ4020.png]',\n",
       "   '[YZ12017GJZYYSKSQZMNSJ4021.png]'],\n",
       "  ['3'],\n",
       "  '无正确答案'),\n",
       " ('老年人服用后易导致出血的是（', ['华法林', '乳酸钙', '青霉素', '氨曲南', '地西泮'], ['1'], '华法林'),\n",
       " ('干扰肿瘤细胞转录过程和阻止RN', ['多柔比星', '氟尿嘧啶', '伊立替康', '多西他赛', '门冬酰胺酶'], ['1'], 'B'),\n",
       " ('属于二级信息源的药学文献是',\n",
       "  ['《中国药学杂志》', '《中国药学文摘》', '《中国国家处方集》', '《中华人民共和国药典》', '《药物信息手册》'],\n",
       "  ['2'],\n",
       "  '1、2、3'),\n",
       " ('阻断白三烯受体，起效缓慢，作用较弱，仅适用于轻、中度哮喘和哮喘稳定期控制的药物是',\n",
       "  ['氟替卡松', '沙美特罗', '异丙托溴铵', '茶碱', '孟鲁司特'],\n",
       "  ['5'],\n",
       "  'C'),\n",
       " ('根据处方书写可知，医生指导患者每天服用酚麻美敏的次数是',\n",
       "  ['1次', '2次', '3次', '4次', '5次'],\n",
       "  ['4'],\n",
       "  '无法从处'),\n",
       " ('结构中的二氯乙酰基侧链氧化代谢后生成酰氯，产生毒性的药物是',\n",
       "  ['[2KY100331.png]',\n",
       "   '[2KY100332.png]',\n",
       "   '[2KY100333.png]',\n",
       "   '[2KY100334.png]',\n",
       "   '[2KY100335.png]'],\n",
       "  ['3'],\n",
       "  '[2KY100331.png],因为该药物的毒性主要来源于其结构中的二氯乙酰基侧链氧化代谢后生成的酰氯'),\n",
       " ('服用地西泮次晨出现乏力，倦怠等\"宿醉\"现象，该不良反应是',\n",
       "  ['过敏反应', '首剂效应', '副作用', '后遗效应', '特异性反应'],\n",
       "  ['4'],\n",
       "  '后遗效应'),\n",
       " ('在正常成人血液的白细胞分类中，所占比例最低的是',\n",
       "  ['中性粒细胞', '嗜酸性粒细胞', '嗜碱性粒细胞', '淋巴细胞', '单核细胞'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('可作为急性胰腺炎诊断指标的是',\n",
       "  ['淀粉酶降低', '淀粉酶增高', '磷酸激酶降低', '磷酸激酶增高', '尿素氮增高'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('1U维生素', ['0.344μg', '3.44μg', '34μg', '3.4mg', '34mg'], ['1'], '无正确答案'),\n",
       " ('对合并气管炎患者除用镇咳药外，须再服用',\n",
       "  ['右美沙芬', '左氧氟沙星', '苯丙哌林', '可待因', '羧甲司坦'],\n",
       "  ['2'],\n",
       "  '4 可待因'),\n",
       " ('以下\"WHO定义的药品不良反应\"的叙述中，关键的字句是',\n",
       "  ['任何有伤害的反应',\n",
       "   '任何与用药目的无关的反应',\n",
       "   '在调节生理功能过程中出现',\n",
       "   '人在接受正常剂量药物时出现',\n",
       "   '在预防、诊断、治疗疾病过程中出现'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('单克隆抗体抗肿瘤药不包括', ['英夫利昔单抗', '利妥昔单抗', '曲妥珠单抗', '贝伐珠单抗', '西妥昔单抗'], ['1'], 'D'),\n",
       " ('白日咳嗽宜选用苯丙哌林', ['阿司匹林', '苯丙哌林', '卡马西平', '氧氟沙星', '右美沙芬'], ['2'], ''),\n",
       " ('需要每个半衰期给药1次，若要立即达到稳态，可首剂加倍，此药物的半衰期是',\n",
       "  ['半衰期小于30分钟', '半衰期8~24小时', '半衰期30分钟~8小时', '半衰期大于24小时', '半衰期24~48小时'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('高钠血症是指',\n",
       "  ['血钠＞130mmol/L',\n",
       "   '血钠＞135mmol/L',\n",
       "   '血钠＞140mmol/L',\n",
       "   '血钠＞145mmol/L',\n",
       "   '血钠＞150mmol/L'],\n",
       "  ['4'],\n",
       "  'A'),\n",
       " ('同时服用碳酸氢钠减少氨苄西林的吸收属于',\n",
       "  ['pH的影响', '离子的作用', '加速胃排空的影响', '损害肠黏膜的吸收功能', '抗生素的间接作用'],\n",
       "  ['1'],\n",
       "  'pH的影响'),\n",
       " ('哌拉西林',\n",
       "  ['口服，肌内注射或静脉注射均可用于全身感染',\n",
       "   '与庆大霉素合用于铜绿假单胞菌感染',\n",
       "   '脑脊液中浓度较高，酶稳定性高，适用于严重脑膜感染',\n",
       "   '肾毒性较大',\n",
       "   '口服吸收好，适用于肺炎球菌所致下呼吸道感染'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('肠内营养制剂的禁忌证是', ['贫血患者', '烧伤病人', '完全性肠梗阻', '营养不良患者', '早产儿'], ['3'], '无正确答案'),\n",
       " ('该患儿目前的治疗应选用', ['维生素A', '维生素B12', '维生素C', '维生素D3', '维生素E'], ['4'], '1、2、4'),\n",
       " ('乳化剂属于热力学不稳定的非均相分散体系。制成后，放置过程中容易出现分层、絮凝等不稳定现象。若出现的分层现象经振摇后能恢复原状，其原因是',\n",
       "  ['分散相乳滴（Zeta）电位降低', '分散相与连续相存在有密度差', '乳化类型改变', '乳化剂失去乳化作用', '微生物的作用'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('下列因用药方法不当造成药源性疾病的是', ['A型', 'B型', '反跳现象', '变态反应', '致畸作用'], ['3'], 'C'),\n",
       " ('羧甲司坦',\n",
       "  ['[图00561.png]',\n",
       "   '[图00562.png]',\n",
       "   '[图00563.png]',\n",
       "   '[图00564.png]',\n",
       "   '[图00565.png]'],\n",
       "  ['4'],\n",
       "  '口服片剂或胶囊'),\n",
       " ('栓剂使用中，把栓剂的尖端向肛门插入，并用手指缓缓推进，深度距肛门口幼儿约2厘米，成人约为',\n",
       "  ['2厘米', '3厘米', '4厘米', '5厘米', '大于2厘米'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('下列属于一级信息的是',\n",
       "  ['《中国药学杂志》', '《中国国家处方集》', '《中华人民共和国药典》', '《药物信息手册》', '《治疗学的药理学基础》'],\n",
       "  ['1'],\n",
       "  '1、3'),\n",
       " ('下列药品不良反应发生的原因，不属于药物方面因素的是',\n",
       "  ['药物剂型', 'G-6-PD缺乏', '用药剂量', '药物附加剂', '给药途径'],\n",
       "  ['2'],\n",
       "  'G-6-PD缺乏'),\n",
       " ('阿莫西林的化学结构为',\n",
       "  ['[图00831.png]',\n",
       "   '[图00832.png]',\n",
       "   '[图00833.png]',\n",
       "   '[图00834.png]',\n",
       "   '[图00835.png]'],\n",
       "  ['3'],\n",
       "  '[图00831.png]'),\n",
       " ('光照射可加速药物的氧化',\n",
       "  ['采用棕色瓶密封包装', '产品冷藏保存', '制备过程中充入氮气', '处方中加入EDTA钠盐', '调节溶液的pH值'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('代表药物在体内的滞留情况的是', ['零阶矩', '一阶矩', '二阶矩', '三阶矩', '四阶矩'], ['2'], '二阶矩'),\n",
       " ('餐后的缩写为', ['i', 'pc.', 'q4h', 'qid', 'po.'], ['2'], 'qid'),\n",
       " ('控释片要求缓慢的恒速的释放药物，并在规定时间内以零级或接近零级速度释放，下列由五个药厂提供的硝苯地平控释片的释放曲线，符合硝苯地平控释片释放的是（\\u3000）。[图1]',\n",
       "  ['A', 'B', 'C', 'D', 'E'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('表观分布容积的计算公式为',\n",
       "  ['[2KY100511.png]',\n",
       "   '[2KY100512.png]',\n",
       "   '[2KY100513.png]',\n",
       "   '[2KY100514.png]',\n",
       "   '[2KY100515.png]'],\n",
       "  ['1'],\n",
       "  '[2KY100511.png]'),\n",
       " ('中性粒细胞少于（）×109/L或者血小板少于（）×109/L禁用更昔洛韦',\n",
       "  ['1.5，100', '1,60', '0.5，25', '0.5,15', '2,300'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('有关\"书写处方药品剂量与数量\"的叙述中，最正确的是。',\n",
       "  ['按照药品说明书', '以阿拉伯数字书写', '以罗马数字书写药品用量', '不能超过药品说明书中的用量', '书写药品用量必须使用统一单位'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('日本药典的缩写是', ['USP', 'BP', 'EP或Ph.Eur.', 'JP', 'ChP'], ['4'], 'D'),\n",
       " ('双室模型静脉注射给药血药浓度与时间的关系式是',\n",
       "  ['[YX11200SRTX0712.png]',\n",
       "   '[YX11200SRTX0713.png]',\n",
       "   '[YX11200SRTX0714.png]',\n",
       "   '[YX11200SRTX0715.png]',\n",
       "   '[YX11200SRTX0716.png]'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('患者，男，43岁，因社区获得性肺炎入院，入院时9月8日查血常规：血小板计数（PLT）88×109/L，9月9日开始给予左氧氟沙星抗感染治疗，1周后肺炎治愈，9月11日查血常规：血小板计数（PLT）90×109/L，9月20日查血常规： 血小板计数（PLT）92×109/L，患者既往血常规情况不详。该患者血小板减少与左氧氟沙星的因果关系评价结果是',\n",
       "  ['肯定', '很可能', '可能', '可能无关', '无法评价'],\n",
       "  ['5'],\n",
       "  '无法评价'),\n",
       " ('阿托伐他汀钙用于补钙，应评判为',\n",
       "  ['过度治疗用药', '无适应证用药', '有禁忌症用药', '联合用药不适宜', '无正当理由超适应证用药'],\n",
       "  ['5'],\n",
       "  '无正当理由超适应证用药'),\n",
       " ('硬胶囊剂的崩解时限要求为', ['15min', '30min', '45min', '60min', '120min'], ['2'], ''),\n",
       " ('试验样本数一般为20~30例，属于',\n",
       "  ['Ⅰ期临床试验', 'Ⅱ期临床试验', 'Ⅲ期临床试验', 'Ⅳ期临床试验', 'Ⅴ期临床试验'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('药物不良事件的缩写为', ['PV', 'ADR', 'DUI', 'ADE', 'DID'], ['4'], 'ADR'),\n",
       " ('若该胶囊剂内容物的平均装量为0.30g时，其装量差异限度为',\n",
       "  ['±5.0％', '±2.0％', '±1.0％', '±10.0％', '±7.5％'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('关于丙硫氧嘧啶对甲状腺激素生成的影响，其机制为',\n",
       "  ['抑制碘被甲状腺摄取',\n",
       "   '抑制甲状腺激素从甲状腺素蛋白中释放',\n",
       "   '抑制促甲状腺激素释放激素的释放',\n",
       "   '抑制过氧化酶系统，阻断甲状腺激素合成',\n",
       "   '抑制甲状腺激素从甲状腺中释放'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('选择性G', ['艾司唑仑', '唑吡坦', '阿戈美拉汀', '米氮平', '帕罗西汀'], ['2'], 'B'),\n",
       " ('药物的内在活性是指',\n",
       "  ['药物水溶性的大小',\n",
       "   '药物脂溶性的强弱',\n",
       "   '药物穿透生物膜的能力',\n",
       "   '药物与受体亲和力的高低',\n",
       "   '药物与受体结合后，激动受体产生效应的能力'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('某药以一级速率过程消除，消除速度常数k=0.095h-1，则该药半衰期为',\n",
       "  ['8.0h', '7.3h', '5.5h', '4.0h', '3.7h'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('引起乳剂破裂的是',\n",
       "  ['ζ电位.降低', '油水两相密度差不同造成', '光、热、空气及微生物等的作用', '乳化剂类型改变', '乳化剂失去作用'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('下列哪种靶向制剂属于被动靶向制剂',\n",
       "  ['pH敏感脂质体', '长循环脂质体', '免疫脂质体', '脂质体', '热敏脂质体'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('把机体看成药物分布速度不同的两个单元组成的体系是',\n",
       "  ['清除率', '表观分布容积', '二室模型', '单室模型', '房室模型'],\n",
       "  ['3'],\n",
       "  '二室模型'),\n",
       " ('下列具有肝药酶诱导作用的药物中，所诱导的酶系类型最多的是。',\n",
       "  ['利福平', '卡马西平', '苯妥英钠', '苯巴比妥', '地塞米松'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('已知某药口服肝脏首过效应很大，改用肌肉注射后',\n",
       "  ['t<SUB>1/2</SUB>减少，生物利用度也减少',\n",
       "   't<SUB>1/2</SUB>不变，生物利用度增加',\n",
       "   't<SUB>1/2</SUB>增加，生物利用度也增加',\n",
       "   't<SUB>1/2</SUB>不变，生物利用度减少',\n",
       "   't<SUB>1/2</SUB>和生物利用度皆不变化'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('治疗轻、中型糖尿病', ['胰岛素 ', '磺酰脲类', '二甲双胍', 'A和B均无效', 'A和B均有效'], ['3'], 'A'),\n",
       " ('氨茶碱结构如图所示：image.png，《中国药典》规定氨茶碱为白色至微黄色的颗粒或粉末,易结块；在空气中吸收二氧化碳,并分解成茶碱，根据氨茶碱的性状，其贮存的条件应满足（\\u3000\\u3000）。',\n",
       "  ['遮光，密闭，室温保存', '遮光，密封，室温保存', '遮光，密闭，阴凉处保存', '遮光，严封，阴凉处保存', '遮光，熔封，冷处保存'],\n",
       "  ['2'],\n",
       "  '遮光，密闭，阴凉处保存'),\n",
       " ('白天咳嗽宜选用', ['右美沙芬', '苯丙哌林', '喷托维林', '可待因', '羧甲司坦'], ['2'], '1、2、3'),\n",
       " ('停用氟西汀换用单胺氧化酶抑制剂间隔的时间是', ['1周', '2周', '3周', '4周', '5周'], ['5'], '无特定时间要求'),\n",
       " ('该患儿诊断为',\n",
       "  ['失神发作', '复杂部分性发作', '肌阵挛发作', '简单部分性发作', '癫痫持续状态'],\n",
       "  ['1'],\n",
       "  '无法从给出的选项中得出结论'),\n",
       " ('以下粪便细胞显微镜检出物中，能提示患者大量或长期应用广谱抗生素的是',\n",
       "  ['真菌', '红细胞', '上皮细胞', '白细胞增多', '吞噬细胞增多'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('以市售制剂作为标准参比制剂所求得的生物利用度为',\n",
       "  ['绝对生物利用度', '相对生物利用庋', '静脉生物利用度', '生物利用度', '参比生物利用度'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('为扩大的多中心临床试验，完成例数大于300例，为新药注册申请提供依据，称为',\n",
       "  ['I期临床研究', 'Ⅱ期临床研究我）', 'Ⅲ期临床研究', 'IV期临床研究', '0期临床研究'],\n",
       "  ['3'],\n",
       "  'IV期临床研究'),\n",
       " ('单模型多剂量静脉注射给药首剂量与维持剂量的关系式为',\n",
       "  ['[2KY100591.png]',\n",
       "   '[2KY100592.png]',\n",
       "   '[2KY100593.png]',\n",
       "   '[2KY100594.png]',\n",
       "   '[2KY100595.png]'],\n",
       "  ['4'],\n",
       "  '[2KY100596.png]'),\n",
       " ('磺胺类药物的抗菌机制是',\n",
       "  ['抑制二氢叶酸合成酶', '抑制四氢叶酸还原酶', '改变细菌细胞膜通透性', '抑制二氢叶酸还原酶', '改变细胞胞浆膜通透性'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('反应竞争性拮抗药对其受体激动药的拮抗强度的是', ['pD2', 'pA2', 'Cmax', 'α', 'tmax'], ['2'], 'pD2'),\n",
       " ('混悬剂中加入枸橼酸盐的作用是',\n",
       "  ['与药物成盐增加药物溶解度',\n",
       "   '保持溶液最稳定的pH',\n",
       "   '使ζ电位.降低到一定程度，造成絮凝',\n",
       "   '与金属离子络合，增加稳定性',\n",
       "   '降低药物的表面张力，增加润湿性'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('对心肌梗死患者，若无禁忌，应尽快给予阿司匹林的初始剂量为每日',\n",
       "  ['10～25mg', '25～50mg', '75～150mg', '150～300mg', '300～500mg'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('伴有高钙血症的妊娠妇女使用，可致前婴儿有特殊面容，智力低下的药物是',\n",
       "  ['维生素A', '维生素C', '维生素K1', '维生素E', '维生素AD'],\n",
       "  ['5'],\n",
       "  '维生素D'),\n",
       " ('对伪膜性肠炎或食物中毒，首选的微生态制剂是',\n",
       "  ['蜡状芽孢杆菌', '双歧三联活菌', '酪酸菌', '地衣芽孢杆菌', '乳酸杆菌'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('对映异构体之间具有等同药理活性和强度的是',\n",
       "  ['氯苯那敏', '依托唑啉', '乙胺丁醇', '普罗帕酮', '氨己烯酸'],\n",
       "  ['4'],\n",
       "  '无'),\n",
       " ('双室模型静脉注射给药血药浓度一时间关系式为',\n",
       "  ['[2KY100571.png]',\n",
       "   '[2KY100572.png]',\n",
       "   '[2KY100573.png]',\n",
       "   '[2KY100574.png]',\n",
       "   '[2KY100575.png]'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('治疗肠道和肠外阿米巴病、阴道滴虫病的首选药物是',\n",
       "  ['氨基糖苷类抗菌药物', '大环内酯类抗菌药物', '硝基呋喃类抗菌药物', '硝基咪唑类抗菌药物', '林可霉素类抗菌药物'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('相互作用延缓或降低抗药性的联合用药是。',\n",
       "  ['阿托品联用氯磷定', '青蒿素联用乙胺嘧啶', '阿托品联用普萘洛尔', '普萘洛尔联用硝苯地平', '甲苯磺丁脲联用氢氯噻嗪'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('通过影响环氧酶抗血小板',\n",
       "  ['维生素B<SUB>12</SUB>', '肝素', '香豆素类', '维生素K<SUB>1</SUB>', '阿司匹林'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('药品不良反应按药理作用的关系分型可分为', ['二型', '三型', '四型', '五型', '六型'], ['2'], '二型'),\n",
       " ('结果一致的Ⅰ级临床研究结论属于', ['E级', 'D级', 'C级', 'B级', 'A级'], ['5'], 'A'),\n",
       " ('以下所列医学指标中，可判断肾功能严重受损的指标是',\n",
       "  ['血肌酐数值增高',\n",
       "   '血清尿素氮数值增高',\n",
       "   '血清尿素氮与血肌酐数值均增高',\n",
       "   '血清尿素氮与血肌酐数值均降低',\n",
       "   '血肌酐与血肌酸激酶数值均增高'],\n",
       "  ['3'],\n",
       "  '1、2'),\n",
       " ('属于改变细胞周围环境的理化性质的是',\n",
       "  ['地高辛抑制Na<SUP>+</SUP>，K<SUP>+</SUP>-ATP酶',\n",
       "   '抗酸药用于治疗胃溃疡',\n",
       "   '铁剂治疗缺铁性贫血',\n",
       "   '硝苯地平阻滞Ca<SUP>2+</SUP>通道产生降压作用',\n",
       "   '氟尿嘧啶抗肿瘤作用'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('关于滴丸剂质量要求的说法中，不正确的是',\n",
       "  ['大小均匀，色泽一致', '应检查丸重差异、圆整度', '应检查溶散时限', '应检查硬度', '小剂量滴丸剂还应进行含量均匀度的检查'],\n",
       "  ['4'],\n",
       "  '无正确答案'),\n",
       " ('治疗幽门螺杆菌感染的一线方案，其典型组方中不包括的药物是',\n",
       "  ['胶体果胶铋', '甲硝唑', '克拉霉素', '西咪替丁', '兰索拉唑'],\n",
       "  ['4'],\n",
       "  '阿莫西林'),\n",
       " ('二级信息的优点是',\n",
       "  ['可以方便地找到所需的一级文献信息', '内容最详细', '内容最全', '内容最新', '内容最准确'],\n",
       "  ['1'],\n",
       "  '无正确答案'),\n",
       " ('为提高脂质体的靶向性而加以修饰的脂质体',\n",
       "  ['微球', 'pH敏感脂质体', '磷脂和胆固醇', '毫微粒', '单室脂质体'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('均属于药物化学不稳定性变化的是',\n",
       "  ['药物由于水解、氧化使药物含量产生变化',\n",
       "   '混悬剂中药物颗粒结块、结晶生长',\n",
       "   '乳剂的分层、破裂，药物发生异构化',\n",
       "   '微生物污染滋长导致药物酶败分解变质',\n",
       "   '药物见光分解，胶体制剂的老化'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('下列药物中用于2型糖尿病一线治疗的首选药物是',\n",
       "  ['二甲双胍  ', '瑞格列奈  ', '格列齐特  ', '阿卡波糖  ', '罗格列酮'],\n",
       "  ['1'],\n",
       "  '二甲双胍'),\n",
       " ('焰色反应中，钾盐显', ['鲜黄色', '紫色', '砖红色', '黄绿色', '蓝色'], ['2'], ''),\n",
       " ('纳洛酮可扭转其中枢抑制作用', ['苯妥英钠', '卡马西平', '阿米替林', '丙戊酸钠', '地西泮'], ['4'], 'B'),\n",
       " ('脂质体属于哪一类靶向制剂',\n",
       "  ['主动靶向制剂', '前体靶向制剂', '物理化学靶向制剂', '被动靶向制剂', 'pH敏感靶向制剂'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('服用他汀类调节血脂药可能导致',\n",
       "  ['血白细胞计数降低', '血清白蛋白升高', '血清总胆固醇升高', '血清碱性磷酸酶升高', '粪便细胞显微镜检查可见真菌增多'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('将胰酶制成肠溶衣片是为了',\n",
       "  ['赋型', '使制备过程顺利进行', '提高药物稳定性', '提高药物疗效', '增加病人用药的顺应性'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('成人空腹血糖的正常参考区间是',\n",
       "  ['3.9～6.1mmol/L',\n",
       "   '3.3～5.5mmol/L',\n",
       "   '3.9～7.8mmol/L',\n",
       "   '5.5～7.8mmol/L',\n",
       "   '<7.8mmol/L'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('与吗啡叙述不符的是',\n",
       "  ['结构中含有酚羟基', '结构中有苯环', '结构中羰基', '为μ阿片受体激动剂', '结构中有5个手性碳原子'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('属于吗啡的前药，过量或长期使用易产生成瘾性的是',\n",
       "  ['可待因', '右美沙芬', '氨溴索', '苯丙哌林', '溴己新'],\n",
       "  ['1'],\n",
       "  '可待因'),\n",
       " ('在药物经济学研究方法中，可以为总体医疗费用的控制和医疗资源优化配置提供基本信息的是。',\n",
       "  ['最大效果分析', '最小成本分析', '成本一效益分析', '成本一效用分析', '成本一效果分析'],\n",
       "  ['2'],\n",
       "  '成本一效果分析'),\n",
       " ('当肌酐清除率为何值时，药物用量调整为25%～50%',\n",
       "  ['肌酐清除率50ml/min',\n",
       "   '肌酐清除率70ml/min',\n",
       "   '肌酐清除率80ml/min',\n",
       "   '肌酐清除率6ml/min',\n",
       "   '肌酐清除率30ml/min'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('使用后必须立即销毁的是',\n",
       "  ['医用橡皮膏', '医用纱布', '一次性使用输液器', '创可贴', '医用绷带'],\n",
       "  ['3'],\n",
       "  '一次性使用输液器'),\n",
       " ('哺乳期间服药可造成新生儿肾脏毒性的是',\n",
       "  ['卡托普利', '磺胺嘧啶', '依那普利', '炔诺酮', '丙硫氧嘧啶'],\n",
       "  ['3'],\n",
       "  '乙酰氨基酚'),\n",
       " ('注射剂的质量要求不包括',\n",
       "  ['无菌', '无热原', '无色', '渗透压与血浆的渗透压相等或接近', 'pH值与血液相等或接近'],\n",
       "  ['3'],\n",
       "  '无'),\n",
       " ('可拮抗链激酶过量引起出血的药品是',\n",
       "  ['氨基己酸', '维生素B6', '乙酰半胱氨酸', '还原型谷胱甘肽', '维生素K1'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('干扰核蛋白体功能、阻止蛋白质合成的是', ['柔红霉素', '高三尖杉酯碱', '门冬酰胺酶', '紫杉醇', '奥沙利铂'], ['2'], ''),\n",
       " ('具有双室模型特征的某药物静脉注射给药，其血药浓度时间-曲线表现为',\n",
       "  ['image.png', 'image.png', 'image.png', 'image.png', 'image.png'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('既可用于男性性功能减退，又可用于女性绝经后晚期乳腺癌治疗的药物是',\n",
       "  ['特拉唑嗪', '非那雄胺', '坦洛新', '西地那非', '十一酸睾酮'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('激动药与受体的量-效曲线如图中虚线所示。当向激动药中加入拮抗药后，激动剂的量-效曲线会发生改变如实线所示，下列描述正确的是 [YZ12017KDS2002.png]',\n",
       "  ['A图所示加入的拮抗药为非竞争性拮抗药',\n",
       "   'B图所示加入的拮抗药为竞争性拮抗药',\n",
       "   '加入竞争性拮抗药后，药物的最大效应降低',\n",
       "   '加入非竞争性拮抗药后，达到最大效应时所需的激动药浓度增大',\n",
       "   '竞争性拮抗药不会改变激动药的Emax'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('在空气中易氧化的药品是',\n",
       "  ['牛痘苗、脊髓灰质炎疫苗', '硫酸阿托品、硫酸可待因', '甘油、蛋白酶', '安乃近、维生素C', '鱼肝油乳、氢氧化铝凝胶'],\n",
       "  ['4'],\n",
       "  'A'),\n",
       " ('阿普唑仑的化学结构式为',\n",
       "  ['[2KY100851.png]',\n",
       "   '[2KY100852.png]',\n",
       "   '[2KY100853.png]',\n",
       "   '[2KY100854.png]',\n",
       "   '[2KY100855.png]'],\n",
       "  ['3'],\n",
       "  '无图片'),\n",
       " ('患者，男，60岁，诊断为室上性心律失常，医生给予胺碘酮治疗。近日患者因胃溃疡应用西咪替丁，出现窦性心动过缓。该患者合用西咪替丁后出现窦性心动过缓的原因是（）',\n",
       "  ['西咪替丁诱导CYP2C9，增加胺碘酮血浆药物浓度',\n",
       "   '西咪替丁抑制CYP1A2，增加胺碘酮血浆药物浓度',\n",
       "   '西咪替丁抑制CYP3A4，增加胺碘酮血浆药物浓度',\n",
       "   '胺碘酮与西咪替丁竞争CYP2D6，减慢胺碘酮代谢',\n",
       "   '胺碘酮与西咪替丁竞争CYP2D19，减慢胺碘酮代谢'],\n",
       "  ['3'],\n",
       "  '西咪替丁抑制CYP3A4，增加胺碘酮血浆药物浓度'),\n",
       " ('结果一致的Ⅱ、Ⅲ级临床研究结论或Ⅰ级临床研究的推论属于', ['E级', 'D级', 'C级', 'B级', 'A级'], ['4'], 'D'),\n",
       " ('以下有关\"',\n",
       "  ['人员联系', '发生事件后撤药的结果', '不良反应症状消除', '是否有其他原因或混杂因素存在', '是否已有对所用药物ADR的报道和评述'],\n",
       "  ['1'],\n",
       "  '无正确答案'),\n",
       " ('下列辅料中不可作为片剂润滑剂的是',\n",
       "  ['微粉硅胶', '蔗糖', '月桂醇硫酸镁', '滑石粉', '氢化植物油'],\n",
       "  ['2'],\n",
       "  '月桂醇硫酸镁'),\n",
       " ('接触性皮炎、药热、移植性排斥反应属于',\n",
       "  ['I型变态反应', 'Ⅱ型溶细胞反应', 'Ⅲ型免疫复合物反应', 'Ⅳ型变态反应', 'V型变态反应'],\n",
       "  ['4'],\n",
       "  'IV'),\n",
       " ('亮菌甲素中加入助剂二甘醇所致的不良反应引发的危害是',\n",
       "  ['肝衰竭', '肾衰竭', '肺衰竭', '心脏瓣膜炎', '表皮松解综合征'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('以清晨和睡前服用最佳的药物是', ['平喘药', '可的松', '舒林酸', '西咪替丁', '碳酸钙'], ['5'], 'B'),\n",
       " ('对所有类型的癫痫都有效的广谱抗癫痫药是',\n",
       "  ['乙琥胺', '苯巴比妥', '丙戊酸钠', '苯妥英钠', '地西泮'],\n",
       "  ['3'],\n",
       "  '抗精神病药物'),\n",
       " ('抗心律失常药中可以引起肺损害的药品是',\n",
       "  ['维拉帕米', '利多卡因', '普罗帕酮', '索他洛尔', '胺碘酮'],\n",
       "  ['5'],\n",
       "  '无\\n题目：关于处方审核的描述错误的是 || 选项: 1. 检查医师的诊断是否准确无误 2. 检查药品名称、剂型、规格、用法与用量是否符合规定 3. 检查药品是否超过有效期 4. 检查是否有患者姓名、身份证号等信息 5. 检查是否有医师签名或盖章 || 答案: 1'),\n",
       " ('长期大量服用维生素C会出现',\n",
       "  ['头痛、眼花、烦躁、心律失常、妇女经血不止等',\n",
       "   '低热、烦躁哭闹、惊厥、厌食、体重减轻、骨骼硬化症等',\n",
       "   '视力模糊、乳腺肿大、腹泻、头晕、流感样症状等',\n",
       "   '疲劳、软弱、全身不适、毛发干枯或脱落、皮肤干燥瘙痒、食欲减退、贫血眼球突出等中毒现象',\n",
       "   '腹泻、皮肤红而亮、头痛、尿频、恶心、呕吐等'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('老年人长期和较大剂量服用奥美拉唑后的潜在的风险是',\n",
       "  ['高血镁症', '凝血功能障碍', '幽门螺杆菌感染', '骨质疏松性骨折', '胃食管反流病'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('在病理情况下，粪隐血可见于。', ['骨折', '痛风', '胰腺炎', '消化道溃疡', '脂肪或酪蛋白食物消化不良'], ['4'], ''),\n",
       " ('血清天门冬氨酸氨基转移酶(',\n",
       "  ['&lt;40U／L',\n",
       "   '成人&lt;60U／L',\n",
       "   '速率法：&lt;40U／L',\n",
       "   '速率法：成人&lt;40U／L',\n",
       "   '速率法：成人&lt;60U／L'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('在药品质量标准中，属于药物有效性检查的项目是',\n",
       "  ['重量差异', '干燥失重', '溶出度', '热原', '含量均匀度'],\n",
       "  ['5'],\n",
       "  '1、4'),\n",
       " ('在人体血中白细胞群体中，中性粒细胞（DC）的正常比例范围是',\n",
       "  ['0.50～0.70', '0.20～0.40', '0.03～0.08', '0.01～0.05', '0～0.01'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('作为乳化剂的是', ['单硬脂酸甘油酯', '甘油', '白凡士林', '十二烷基硫酸钠', '对羟基苯甲酸乙酯'], ['4'], ''),\n",
       " ('实行申报备案制度的医疗器械产品是',\n",
       "  ['试生产产品', '进口产品', '三类产品', '二类产品', '一类产品'],\n",
       "  ['5'],\n",
       "  '三类产品'),\n",
       " ('需要进行治疗药物监测的情况是',\n",
       "  ['应用头孢拉定治疗扁桃体炎',\n",
       "   '应用氨氯地平治疗高血压',\n",
       "   '应用地高辛治疗心力衰竭',\n",
       "   '应用格列吡嗪治疗糖尿病',\n",
       "   '应用对乙酰氨基酚治疗发热'],\n",
       "  ['3'],\n",
       "  '3、4'),\n",
       " ('假设药物消除符合一级动力学过程，问多少个t1/2药物消除99.9%',\n",
       "  ['4t<SUB>1/2</SUB>',\n",
       "   '6t<SUB>1/2</SUB>',\n",
       "   '8t<SUB>1/2</SUB>',\n",
       "   '10t<SUB>1/2</SUB>',\n",
       "   '12t<SUB>1/2</SUB>'],\n",
       "  ['4'],\n",
       "  '无法计算'),\n",
       " ('乳剂型气雾剂和混悬型气雾剂均为',\n",
       "  ['单相气雾剂', '二相气雾剂', '三相气雾剂', '双相气雾剂', '吸入粉雾剂'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('泌尿系统感染可能出现的尿常规检查异常是',\n",
       "  ['尿沉渣管型异常', '尿沉渣尿酸盐结晶', '尿沉渣结晶异常', '尿沉渣白细胞增多', '尿沉渣胆红素结晶'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('三种现象均属于药物制剂物理稳定性变化的是',\n",
       "  ['乳剂分层、混悬剂结晶生长、片剂溶出速度改变',\n",
       "   '药物水解、结晶生长、颗粒结块',\n",
       "   '药物氧化、颗粒结块、溶出速度改变',\n",
       "   '药物降解、乳液分层、片剂崩解度改变',\n",
       "   '药物水解、药物氧化、药物异构化'],\n",
       "  ['1'],\n",
       "  'A'),\n",
       " ('静脉注射某药，X0=80mg，若初始血药浓度为20μg/ml，表观分布容积V为',\n",
       "  ['250ml', '2.5L', '20L', '4ml', '4L'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('关于医用棉花外观要求的叙述，不正确的是',\n",
       "  ['柔软而富有弹性', '色泽纯白', '无其他纤维', '无臭、无味', '在紫外灯光下应显示蓝色荧光'],\n",
       "  ['5'],\n",
       "  '无臭、无味'),\n",
       " ('可导致药源性肝损害的药物是', ['辛伐他汀', '青霉素', '地西泮', '苯妥英钠', '吲哚美辛'], ['1'], 'B'),\n",
       " ('根据不良反应新的分类，严重程度主要与所用药物的浓度而不是剂量有关的不良反应属于',\n",
       "  ['A类反应', 'B类反应', 'C类反应', 'D类反应', 'E类反应'],\n",
       "  ['3'],\n",
       "  'E类反应'),\n",
       " ('若某药的成人剂量为30mg/kg，那么8岁儿童按照体重计算每次的给药剂量应为',\n",
       "  ['720mg', '234mg', '210mg', '230mg', '570mg'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('具有吗啡喃结构的镇咳药是', ['喷托维林', '右美沙芬', '溴己新', '羧甲司坦', '苯丙哌林'], ['2'], ''),\n",
       " ('下列关于镇痛药物的禁忌证，错误的是',\n",
       "  ['心源性哮喘禁用吗啡', '室上心动过速禁用哌替啶', '多痰患者禁用可待因', '颅脑损伤患者禁用羟考酮', '重症肌无力患者禁用芬太尼'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('通过破坏酪氨酸所介导的中枢神经系统突触传递过程，导致虫体神经系统麻痹而死亡的非处方药是',\n",
       "  ['噻苯达唑', '阿苯达唑', '伊维菌素', '噻嘧啶', '枸橼酸哌嗪'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('最大效应是指', ['效能', '半数有效量', '半数致死量', '治疗指数', '安全范围'], ['1'], ''),\n",
       " ('磺胺类药物的基本结构是（\\u3000）。[图1]', ['A', 'B', 'C', 'D', 'E'], ['5'], 'D'),\n",
       " ('为适应治疗或预防的需要而制备的药物应用形式称为',\n",
       "  ['药物剂型', '药物制剂', '药剂学', '调剂学', '方剂学'],\n",
       "  ['1'],\n",
       "  '药物制剂'),\n",
       " ('在体内R（-）异构体可转化为S（+）异构体的药物是',\n",
       "  ['[图00481.png]',\n",
       "   '[图00482.png]',\n",
       "   '[图00483.png]',\n",
       "   '[图00484.png]',\n",
       "   '[图00485.png]'],\n",
       "  ['1'],\n",
       "  '[图00481.png]'),\n",
       " ('患有冠心病的甲减患者应用左甲状腺素治疗的首剂量为多少较合适',\n",
       "  ['10μg', '25μg', '37.5μg', '50μg', '75μg'],\n",
       "  ['2'],\n",
       "  '无正确答案'),\n",
       " ('扑米酮属于', ['巴比妥类', '乙内酰脲类', '苯二氮卓类', '二苯并氮卓类', 'γ- GABA类似物'], ['1'], ''),\n",
       " ('治疗药物评价的内容，一般不包括的项目是', ['有效性', '安全性', '经济性', '依从性', '药品质量'], ['4'], '经济性'),\n",
       " ('为患者治疗需用3％氯化钠注射液1000ml，现有10％和0．9％的氯化钠注射液，应分别取',\n",
       "  ['231ml和769ml', '250ml和750ml', '275ml和725ml', '306ml和694ml', '402ml和598ml'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('治疗作用的初步评价，评价目标适应证患者的治疗作用和安全性，为下一步试验研究的设计和给药剂量方案的确定提供依据，该期临床试验属于',\n",
       "  ['Ⅰ期临床评价', 'Ⅱ期临床评价', 'Ⅲ期临床评价', 'Ⅳ期临床评价', '广义上市后临床再评价'],\n",
       "  ['2'],\n",
       "  'II'),\n",
       " ('对由营养不良、婴儿期所致的恶性贫血者应选用',\n",
       "  ['叶酸+维生素B12', '富马酸亚铁', '维生素K1', '甲磺酸去铁胺', '亚叶酸钙'],\n",
       "  ['1'],\n",
       "  'A'),\n",
       " ('对映异构体之间产生相反的活性的是', ['普罗帕酮', '氯苯那敏', '丙氧酚', '丙胺卡因', '哌西那朵'], ['5'], '无'),\n",
       " ('适合睡前服用的药品是', ['泼尼松龙', '奥利司他', '氟伐他汀', '多潘立酮', '吲哚美辛'], ['3'], '多潘立酮'),\n",
       " ('以下属于经胃肠道给药的制剂是',\n",
       "  ['醋酸氢化可的松滴眼液', '西地碘含片', '肾上腺素气雾剂', '硝酸甘油舌下片', '氯雷他定糖浆'],\n",
       "  ['5'],\n",
       "  '1、2、4'),\n",
       " ('维持剂量与首剂量的关系式为',\n",
       "  ['[图00161.png]',\n",
       "   '[图00162.png]',\n",
       "   '[图00163.png]',\n",
       "   '[图00164.png]',\n",
       "   '[图00165.png]'],\n",
       "  ['1'],\n",
       "  '[图00161.png]'),\n",
       " ('下列药物在体内代谢中结构由（-）-（R）-型转化\\u200d成为（+）-（S）-型的是',\n",
       "  ['[2KY101021.png]',\n",
       "   '[2KY101022.png]',\n",
       "   '[2KY101023.png]',\n",
       "   '[2KY101024.png]',\n",
       "   '[2KY101025.png]'],\n",
       "  ['1'],\n",
       "  '[2KY101021.png];[2KY101022.png];[2KY101023.png];[2KY101024.png];[2KY101025.'),\n",
       " ('妊娠期服用糖皮质激素，可能导致骨质疏松症以外的不良反应是',\n",
       "  ['婴儿生长发育抑制', '血压升高', '胎盘功能不全', '支气管哮喘', '儿童生长发育抑制'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('H2受体阻断剂停药引起的基础胃酸分泌反弹持续时间是',\n",
       "  ['3天', '9天', '15天', '1个月', '2个月'],\n",
       "  ['2'],\n",
       "  '无正确答案'),\n",
       " ('阿米替林的作用机制是',\n",
       "  ['通过抑制突触前膜对5-HT及去甲肾上腺素的再摄取，使突触间隙的去甲肾上腺素和5-HT浓度升高',\n",
       "   '通过选择性抑制5-HT的再摄取，增加突触间隙5-HT浓度，从而增强中枢5-HT能神经功能。',\n",
       "   '通过抑制A型单胺氧化酶，减少去甲肾上腺素、5-HT及多巴胺的降解，增强去甲肾上腺素、5-HT和多巴胺能神经功能',\n",
       "   '通过抑制突触前膜对去甲肾上腺素的再摄取，增强中枢去甲肾上腺素能神经的功能',\n",
       "   '通过阻断中枢NE能和5-HT能神经末梢突触前α<SUB>2</SUB>受体，增加NE和5-HT的间接释放，增强中枢NE能及5-HT能神经的功能，并阻断5-HT<SUB>2</SUB>、5-HT<SUB>3</SUB>受体以调节5-HT功能'],\n",
       "  ['1'],\n",
       "  '1, 2'),\n",
       " ('英国药典的缩写是', ['USP', 'BP', 'EP或Ph.Eur.', 'JP', 'ChP'], ['2'], 'B'),\n",
       " ('噻嗪类利尿剂的禁忌证是',\n",
       "  ['低钾血症', '痛风', '体位性低血压', '双侧肾动脉狭窄', '2~3度房室传导阻滞'],\n",
       "  ['2'],\n",
       "  '无特殊禁忌症'),\n",
       " ('将甲苯磺丁脲分子中对位甲基以芳香酰胺烷基取代，可使药物吸收迅速，与血浆蛋白结合率高，作用强且长效，毒性低。同时，将脲上的取代基更换为环己基，有显著的降血糖活性。当环己基上引入甲基，稳定性增强，因此具有高效长效的特点，代表药物是格列美脲。以此推断格列美脲的结构是',\n",
       "  ['', '', '', '', ''],\n",
       "  ['3'],\n",
       "  'C'),\n",
       " ('别嘌醇的化学结构为',\n",
       "  ['[2016ZXJS0012.png]',\n",
       "   '[2016ZXJS0013.png]',\n",
       "   '[2016ZXJS0014.png]',\n",
       "   '[2016ZXJS0015.png]',\n",
       "   '[2016ZXJS0016.png]'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('溶血作用最强的是', ['吐温20', '吐温60', '吐温80', '聚氧乙烯烷基醚', '聚氧乙烯芳基醚'], ['4'], ''),\n",
       " ('关于苯妥英钠在较大浓度范围的消除速率的说法，正确的是（\\u3000\\u3000）',\n",
       "  ['用米氏方程表示，消除快慢只与参数Vm有关',\n",
       "   '用米氏方程表示，消除快慢只与参数Km有关',\n",
       "   '用米氏方程表示，消除快慢与参数Km和Vm有关',\n",
       "   '用零级动力学方程表示，消除快慢体现在消除速率常数K0上',\n",
       "   '用一级动力学方程表示，消除快慢体现在消除速率常数k上'],\n",
       "  ['3'],\n",
       "  '用一级动力学方程表示，消除快慢体现在消除速率常数k上'),\n",
       " ('关于糖皮质激素的用法，可能使新生儿体重减少或增加死胎的发生率的为',\n",
       "  ['大剂量突击疗法', '一般剂量长期疗法', '小剂量替代疗法', '隔日疗法', '妊娠期给药'],\n",
       "  ['5'],\n",
       "  '大剂量突击疗法'),\n",
       " ('关于生物膜的说法不正确的是',\n",
       "  ['生物膜为液晶流动镶嵌模型', '具有流动性', '结构不对称', '无选择性', '具有半透性'],\n",
       "  ['4'],\n",
       "  '无选择性'),\n",
       " ('淋巴细胞减少见于下列哪种疾病',\n",
       "  ['传染性单核细胞增多症', '严重化脓性感染', '组织移植排斥反应', '白血病', '再生障碍性贫'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('由慢性胃炎、胃溃疡等导致的消化不良可选用的非处方药是',\n",
       "  ['莫沙必利', '多潘立酮', '六味安消散', '胰酶片', '碳酸氢钠'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('PEG-DSPE是一种PEG化脂质材料，常用于对脂质体进行PEG化，降低与单核-巨噬细胞的亲和力。盐酸多比柔性比脂质体以PEG-DSPE为膜结合的脂质体属于',\n",
       "  ['前体脂质体', 'PH敏感脂质体', '免疫脂质体', '栓塞脂质体', '长循环脂质体'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('药物与血浆蛋白结合的特点，正确的是',\n",
       "  ['是不可逆的', '促进药物排泄', '是疏松和可逆的', '加速药物在体内的分布', '无饱和性和置换现象'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('按药品不良反应的传统分类，该不良反应属于',\n",
       "  ['A型不良反应', 'B型不良反应', 'C型不良反应', 'D型不良反应', 'E型不良反应'],\n",
       "  ['1'],\n",
       "  '无法根据提供的信息判断'),\n",
       " ('少数药物在短时间内，应用几次后很快产生耐受称为',\n",
       "  ['快速耐受性', '交叉耐受性', '耐药性', '身体依赖性', '多重耐药'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('双室模型静脉滴注药物血药浓度与时间的关系式为',\n",
       "  ['[YX11200SRTX0806.png]',\n",
       "   '[YX11200SRTX0807.png]',\n",
       "   '[YX11200SRTX0808.png]',\n",
       "   '[YX11200SRTX0809.png]',\n",
       "   '[YX11200SRTX0810.png]'],\n",
       "  ['1'],\n",
       "  '[YX11200SRTX0806.png]'),\n",
       " ('又名度冷丁，属于哌啶类合成的镇痛药是',\n",
       "  ['[2KY100871.png]',\n",
       "   '[2KY100872.png]',\n",
       "   '[2KY100873.png]',\n",
       "   '[2KY100874.png]',\n",
       "   '[2KY100875.png]'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('一患者的肝功能检查结果是',\n",
       "  ['肝硬化', '糖尿病', '急性胰腺炎', '缺铁性贫血', '肾病综合征'],\n",
       "  ['1'],\n",
       "  '无法从给出的选项中得出结论'),\n",
       " ('将药物治疗成本和所产生的效益归划为以货币为单位的数字，从而进行药物经济学评价，这一评价方法属于',\n",
       "  ['成本-效益分析', '成本-效果分析', '最小成本分析', '成本-效用分析', '荟萃分析'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('抑制胸腺核苷合成酶', ['氟尿嘧啶', '阿糖胞苷', '羟基脲', '甲氨蝶呤', '巯嘌呤'], ['1'], '甲氨蝶呤'),\n",
       " ('分子内含有嘧啶结构的为', ['阿托伐他汀', '氟伐他汀', '瑞舒伐他汀', '洛伐他汀', '普伐他汀'], ['3'], 'B'),\n",
       " ('下列关于影响血药浓度的病理因素错误的是',\n",
       "  ['肝功能损害血浆半衰期会发生改变',\n",
       "   '肾功能损害消除速率常数（K值）降低、血浆半衰期延长',\n",
       "   '心脏疾患可引起血液分布、流速等血流动力学的改变，影响药物的消除',\n",
       "   '胃肠疾患可直接改变吸收速率常数（Ka值）和吸收分数（F值）',\n",
       "   '高胆红素血症不改变药物与血浆蛋白的结合'],\n",
       "  ['5'],\n",
       "  '高胆红素血症不改变药物与血浆蛋白的结合'),\n",
       " ('维生素D3', ['防治坏血病', '防治佝偻病', '防治夜盲症', '习惯性流产的辅助治疗', '防治唇干裂'], ['2'], '1、2'),\n",
       " ('白细胞分类中，淋巴细胞参考范围为',\n",
       "  ['1%～5%', '50%～70%', '20%～40%', '3%～8%', '0～1%'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('药剂学概念正确的表述是',\n",
       "  ['研究药物制剂的处方理论、处方设计、制备工艺和合理应用的综合性技术科学',\n",
       "   '研究药物制剂的基本理论、处方设计、制备工艺、质量控制和合理应用的综合性技术科学',\n",
       "   '研究药物制剂的处方设计、基本理论和应用的技术科学',\n",
       "   '研究药物制剂的处方设计、基本理论和应用的科学',\n",
       "   '研究药物制剂的基本理论、处方设计和合理应用的综合性技术科学'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('现已替代阿片制剂而应用广泛的止泻药物是',\n",
       "  ['多潘立酮', '阿托品', '英沙必利', '地芬诺酯', '双八面体蒙脱石'],\n",
       "  ['4'],\n",
       "  'D'),\n",
       " ('具有苯磺酰脲结构，属于胰岛素分泌促进剂的降血糖药物是',\n",
       "  ['[YZ12017KDS2011.png]',\n",
       "   '[YZ12017KDS2012.png]',\n",
       "   '[YZ12017KDS2013.png]',\n",
       "   '[YZ12017KDS2014.png]',\n",
       "   '[YZ12017KDS2015.png]'],\n",
       "  ['2'],\n",
       "  '[YZ12017KDS2016.png]'),\n",
       " ('患者，男，43岁，因社区获得性肺炎入院，入院时9月8日查血常规提示：血小板计数（PLT）88×109/L，9月9日开始给予左氧氟沙星抗感染治疗1周后肺炎治愈，9月11日查血常规提示：血小板计数（PLT）90×109/L，9月20日查血常规提示：血小板计数（PLT）92×109/L，患者既往血常规情况不详。该患者血小板减少与左氧氟沙星应用的因果关系评价结果是',\n",
       "  ['肯定', '很可能', '可能', '可能无关', '无法评价'],\n",
       "  ['5'],\n",
       "  '无法评价'),\n",
       " ('吲哚美辛微囊处方中醋酸的作用', ['囊心物', '囊材', '固化剂', '矫味剂', 'pH调节剂'], ['5'], 'pH调节剂'),\n",
       " ('在药物经济学研究方法中，可以为总体医疗费用的控制和医疗资源优化配置提供基本信息的是',\n",
       "  ['最大效果分析', '最小成本分析', '成本-效益分析', '成本-效用分析', '成本-效果分析'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('以下',\n",
       "  ['有文献资料佐证', '停药后反应停止', '用药及反应发生时间顺序合理', '原患多种疾病混杂因素可能干扰', '再次使用反应再现，并明显加重'],\n",
       "  ['4'],\n",
       "  '有文献资料佐证'),\n",
       " ('药物H在临床上通常与以下哪个药物合用',\n",
       "  ['舒巴坦钠', '他唑巴坦钠', '西司他丁钠', '克拉维酸钾', '磷酸素'],\n",
       "  ['3'],\n",
       "  'A'),\n",
       " ('属于前药，在体內水解成原药后发挥解热镇痛及抗炎作用的药物是（\\u3000\\u3000）',\n",
       "  ['阿司匹林image.png',\n",
       "   '对乙酰氨基酚image.png',\n",
       "   '贝诺酯image.png',\n",
       "   '塞来昔布image.png',\n",
       "   '布洛芬image.png'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('美国心脏病学院与美国心脏协会2014年颁布成人降胆固醇治疗降低动脉粥样硬化性心血管疾病（',\n",
       "  ['有助个体化给药', '有利诊断特殊疾患', '改变降脂治疗观念', '列为行政决策的依据', '证明一些常规治疗方法是盲目'],\n",
       "  ['3'],\n",
       "  'C'),\n",
       " ('巴比妥酸pKa为4.12，在生理pH 7.4条件下，其离子形式药物约占',\n",
       "  ['ll%', '33%', '55%', '75%', '99%'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('应用羟甲戊二酰辅酶', ['2倍', '4倍', '6倍', '8倍', '10倍'], ['5'], 'A'),\n",
       " ('治疗需要10%葡萄糖注射液500ml，现仅有50%和5%浓度的葡萄糖注射液，那么各自需取用的体积是',\n",
       "  ['55.5ml、444.5ml',\n",
       "   '111ml、389ml',\n",
       "   '28ml、472ml',\n",
       "   '222ml、278ml',\n",
       "   '250ml、250ml'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('通过抑制胆碱酯酶活性，提高脑内乙酰胆碱含量的药物是',\n",
       "  ['吡拉西坦', '多奈哌齐', '拉西坦', '舍曲林', '吗氯贝胺'],\n",
       "  ['2'],\n",
       "  '多奈哌齐'),\n",
       " ('患者，女，68岁，体重45kg，因发热、咳嗽、咳痰入院治疗，临床诊断为社区获得性肺炎。化验结果：白细胞计数11.76×109/L，肌酐清除率18ml/min。该患者使用下列抗菌药物治疗时，不需要减量的是',\n",
       "  ['左氧氟沙星', '莫西沙星', '头孢噻肟钠', '阿莫西林', '头孢吡肟'],\n",
       "  ['2'],\n",
       "  '所有选项都不需要减少剂量'),\n",
       " ('以下有关\"特异性反应\"的叙述中，最正确的是',\n",
       "  ['发生率较高', '是先天性代谢紊乱表现的特殊形式', '与剂量相关', '潜伏期较长', '由抗原抗体的相互作用引起'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('循证药物信息共分', ['五类三级', '五类五级', '三类三级', '三级五类', '三级六类'], ['1'], '二类四级'),\n",
       " ('在体内经过两次羟基化产生活性物质的药物是（\\u3000）。',\n",
       "  ['阿伦磷酸钠', '利塞磷酸钠', '维生素D3', '阿法骨化醇', '骨化三醇'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('反映药物内在活性大小的是', ['pD2', 'pA2', 'Cmax', 'α', 'tmax'], ['4'], 'pD2'),\n",
       " ('饭前服用', ['多潘立酮', '雷尼替丁', '氢氧化镁', '苯海拉明', '青霉素'], ['1'], ''),\n",
       " ('吡啶的化学结构式是',\n",
       "  ['[2KY100201.png]',\n",
       "   '[2KY100202.png]',\n",
       "   '[2KY100203.png]',\n",
       "   '[2KY100204.png]',\n",
       "   '[2KY100205.png]'],\n",
       "  ['4'],\n",
       "  '[2KY100201.png]'),\n",
       " ('茶碱属于',\n",
       "  ['CYP3A4抑制剂', 'CYP3A4诱导剂', 'CYP2C19底物药物', 'CYP1A2底物药物', 'CYP2D6抑制剂'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('欲用95%乙醇和蒸馏水配制75%乙醇1000ml，应取95%乙醇的体积约为',\n",
       "  ['650ml', '700ml', '750ml', '790ml', '840ml'],\n",
       "  ['4'],\n",
       "  'C'),\n",
       " ('可用于亲水性凝胶骨架片材料的是', ['单棕榈酸甘油酯', '硬脂醇', '无毒聚氯乙烯', '甲基纤维素', '聚乳酸'], ['4'], ''),\n",
       " ('解热镇痛药用于退热，两次用药的间隔时间应该是',\n",
       "  ['2～4小时', '3～5小时', '4～6小时', '5～7小时', '6～8小时'],\n",
       "  ['3'],\n",
       "  '1．2~4小时'),\n",
       " ('竞争性抑制胆固醇合成过程中限速酶（HMG-Co',\n",
       "  ['洛伐他汀', '非诺贝特', '阿昔莫司', '考来烯胺', '依折麦布'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('隔天给药1次的外文缩写是', ['bid', 'tid', 'qid', 'qod', 'St'], ['4'], 'qod（每天一次在晚上）'),\n",
       " ('关于痔疮的患者教育，错误的是',\n",
       "  ['养成定时排便习惯', '加强体育锻炼，常做提肛运动', '发现痔疮及时手术治疗', '无症状痔疮无需治疗', '有症状痔疮无需根治'],\n",
       "  ['3'],\n",
       "  '有症状痔疮无需根治'),\n",
       " ('减鼻充血药通常用于缓解鼻塞症状，其所激动的受体是',\n",
       "  ['M受体', 'N受体', 'H1受体', 'α受体', 'β受体'],\n",
       "  ['4'],\n",
       "  'H1受体'),\n",
       " ('过敏性皮疹的类型、性质、部位、面积大小等',\n",
       "  ['用药原因', '用药起止时间', 'ADR/E过程描述', '不良反应／事件的结果', '引起不良反应的可疑药品'],\n",
       "  ['3'],\n",
       "  'ADR/E过程描述'),\n",
       " ('具有下列结构的药物和以下哪种酸成盐用于临床[图0040.png]',\n",
       "  ['盐酸', '磷酸', '枸橼酸', '酒石酸', '马来酸'],\n",
       "  ['3'],\n",
       "  '此题无图片'),\n",
       " ('与双胍类降糖药合用，可能引起乳酸中毒的是', ['乳酸钠', '碳酸氢钠', '氯化铵', '氯化钠', '精氨酸'], ['1'], 'A'),\n",
       " ('当前列环素缺乏或应用了大剂量的阿司匹林时则无效的抗血小板药物是',\n",
       "  ['氯吡格雷', '普拉格雷', '双嘧达莫', '利伐沙班', '噻氯匹定'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('对Ⅰ型和Ⅱ型单纯疱疹病毒作用最强的是', ['奥司他韦', '阿糖腺苷', '干扰素', '阿昔洛韦', '阿德福韦酯'], ['4'], 'B'),\n",
       " ('当肌酐清除率为何值时，药物用量调整为50%～75%',\n",
       "  ['肌酐清除率50ml/min',\n",
       "   '肌酐清除率70ml/min',\n",
       "   '肌酐清除率80ml/min',\n",
       "   '肌酐清除率6ml/min',\n",
       "   '肌酐清除率30ml/min'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('已知1%（g/ml）葡萄糖溶液的冰点降低值为0.091度。依据冰点降低数据法，计算其等渗溶液的百分浓度是',\n",
       "  ['5.1%（g/ml）', '5.3%（g/ml）', '5.5%（g/ml）', '5.7%（g/ml）', '5.9%（g/ml）'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('某些慢性疾病使用泼尼松长期治疗，为减少外源性激素对下丘脑-垂体-肾上腺皮质轴的抑制，推荐的给药时间是（\\u3000）。',\n",
       "  ['上午8时左右', '中午12时左右', '下午4时左右', '晚餐前', '睡前'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('关于药物脂水分配系数（P）的表述中，错误的是',\n",
       "  ['药物的吸收性与P值呈抛物线的规律',\n",
       "   'P值越大，脂溶性越高',\n",
       "   'P值越大，药效越好',\n",
       "   'P值适当才会有较好的药效',\n",
       "   'P值表示药物在生物非水相中物质的量浓度与在水相中物质的量浓度之比'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('《中国药典》\"凡例\"规定，称取\"2g\"，是指称取',\n",
       "  ['1.5～2.5g', '1.95～2.05g', '1.96～2.04g', '1.995～2.005g', '1.9995～2.0005g'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('某药消除速度常数k=0.069h-1，且为一级速率过程消除，则该药半衰期为',\n",
       "  ['12.0h', '10.0h', '7.5h', '6.0h', '5.7h'],\n",
       "  ['2'],\n",
       "  'C'),\n",
       " ('下列药物合用时，具有增敏效果的是',\n",
       "  ['肾上腺素延长普鲁卡因的局麻作用时间',\n",
       "   '罗格列酮与胰岛素合用提高降糖作用',\n",
       "   '阿替洛尔与氢氯噻嗪联合用于降压',\n",
       "   '克拉霉素和阿莫西林合用，增强抗幽门螺杆菌作用',\n",
       "   '链霉素可延长氯化琥珀胆碱的肌松作用时间'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('属于血管紧张素', ['依那普利', '替米沙坦', '哌唑嗪', '坦洛新（坦索罗辛）', '阿利吉仑（阿利吉仑）'], ['2'], 'B'),\n",
       " ('对伴有精神紧张的紧张性头痛可口服的药物是',\n",
       "  ['双氯芬酸钠二乙胺乳胶剂', '谷维素', '氢溴酸山莨菪碱', '卡马西平', '塞来昔布'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('与患者的沟通技巧，正确的是',\n",
       "  ['使用专业术语',\n",
       "   '一次性提供给患者尽可能多的信息',\n",
       "   '对老年患者可以适当给予宣传资料',\n",
       "   '尽可能单向交流，避免患者说得过多，而影响判断',\n",
       "   '观察患者表情，决定是否需要沟通'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('尤其适合用于老年人收缩压和舒张压均较高者或脉压差较大者的药物',\n",
       "  ['CCB', '利尿剂', 'ACEI', 'ARB', 'β受体阻断剂'],\n",
       "  ['1'],\n",
       "  'ACEI（如：贝那普利）'),\n",
       " ('避免危险因素，接种流感疫苗，属于慢阻肺分级治疗方案中的', ['0级', 'Ⅰ级', 'Ⅱ级', 'Ⅲ级', 'Ⅳ级'], ['1'], 'B'),\n",
       " ('制备缓、控释制剂的工艺中，基于降低溶出速度而设计的是',\n",
       "  ['制成包衣小丸或包衣片剂', '制成微囊', '与高分子化合物生成难溶性盐或酯', '制成不溶性骨架片', '制成亲水凝胶骨架片'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('一日一次用药的外文规范缩写是', ['d', 'q.h.', 'q.n.', 'q.o.d', 'q.i.d'], ['1'], 'q.i.d'),\n",
       " ('药物的扩散速度取决于膜两侧药物的浓度梯度、药物的脂水分配系数等的过程是',\n",
       "  ['胞饮', '胞吐', '简单扩散', '主动转运', '中介转运'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('关于复方制剂美洛西林钠与舒巴坦的说法中，正确的是',\n",
       "  ['美洛西林为“自杀性”β-内酰胺酶抑制剂',\n",
       "   '舒巴坦是氨苄西林经改造而来，抗菌作用强',\n",
       "   '舒巴坦可增强美洛西林对β-内酰胺酶稳定性',\n",
       "   '舒巴坦属于碳青霉烯类抗生素',\n",
       "   '美洛西林具有甲氨肟基，对β-内酰胺酶具有高稳定作用'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('平均滞留时间的方差为', ['零阶矩', '一阶矩', '二阶矩', '三阶矩', '四阶矩'], ['3'], '二阶矩'),\n",
       " ('[2KY10001.png]方程描述对药物稳定性的影响因素为',\n",
       "  ['pH', '光线', '氧气', '溶剂', '湿度'],\n",
       "  ['4'],\n",
       "  'pH、温度'),\n",
       " ('万古霉素每次静脉滴注时间控制在',\n",
       "  ['10～15min', '15～20min', '20～30min', '30～60min', '60min以上'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('当药物上的缺电子基团与受体上的供电子基团产生相互作用时，电子在两者间可发生转移，这种作用力被称为',\n",
       "  ['电荷转移复合物', '氢键', '离子一偶极和偶极一偶极相互作用', '范德华引力', '疏水性相互作用'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('下图为药物与受体的亲和力及内在活性对量一效曲线的影响曲线图，下列描述正确的是 [2KY10041.png]',\n",
       "  ['a，b，c三药和受体的亲和力（pD<SBU>2</SUB>）相等',\n",
       "   'a，b，c三药内在活性（E<SUB>max</SUB>）相等',\n",
       "   'a为反向激动药',\n",
       "   'b为竞争性拮抗药',\n",
       "   'c为非竞争性拮抗药'],\n",
       "  ['1'],\n",
       "  'a'),\n",
       " ('出现糖尿病酮尿可提示',\n",
       "  ['活动性肢端肥大症', '甲状腺功能亢进症', '胰岛素分泌过度', '麻疹、伤寒、猩红热', '糖尿病尚未控制'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('过敏体质者需慎用的是',\n",
       "  ['红霉素眼膏', '金霉素眼膏', '酞丁安滴眼剂', '硫酸锌滴眼剂', '磺胺醋酰钠滴眼剂'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('室温所指温度是', ['-5℃～10℃', '-2℃～4℃', '2℃～10℃', '10℃～30℃', '20℃～50℃'], ['4'], ''),\n",
       " ('药师调剂处方时必须做到“四查十对”，下述不正确的是',\n",
       "  ['查处方，对科别、姓名、年龄',\n",
       "   '查药品质量，对药品数量、价格',\n",
       "   '查药品，对药名、剂型、规格、数量',\n",
       "   '查配伍禁忌，对药品性状、用法用量',\n",
       "   '查用药合理性，对临床诊断'],\n",
       "  ['2'],\n",
       "  '查用药合理性，对临床诊断'),\n",
       " ('以参考书和综述型数据库为主的药物信息是',\n",
       "  ['五级信息', '一级信息', '二级信息', '三级信息', '四级信息'],\n",
       "  ['4'],\n",
       "  '一级信息'),\n",
       " ('激惹性腹泻宜选用的非处方药', ['小檗碱', '氧氟沙星', '硝苯地平', '双八面蒙脱石', '双歧三联活菌制剂'], ['4'], 'D'),\n",
       " ('失眠症的临床表现为。', ['思维迟缓', '心境低落', '认知功能损害', '意志活动减退', '睡眠障碍、乏力'], ['5'], ''),\n",
       " ('茶碱的结构式是',\n",
       "  ['[YX11200SRTX1017.png]',\n",
       "   '[YX11200SRTX1018.png]',\n",
       "   '[YX11200SRTX1019.png]',\n",
       "   '[YX11200SRTX1020.png]',\n",
       "   '[YX11200SRTX1021.png]'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('可用于紫癜辅助治疗的药物是', ['维生素A', '复合维生素B', '维生素C', '维生素E', '维生素K1'], ['3'], '2、3'),\n",
       " ('其左旋体有镇咳作用的药物是', ['纳洛酮', '布托啡诺', '右丙氧芬', '苯噻啶', '可待因'], ['3'], '可待因'),\n",
       " ('高水溶解性、高渗透性的两亲性分子药物的体内吸收',\n",
       "  ['取决于胃排空速率', '取决于溶解速率', '受渗透效率影响', '比较困难', '不受任何影响'],\n",
       "  ['1'],\n",
       "  '不受任何影响'),\n",
       " ('该患者血压控制不佳，可考虑联合使用的抗高血压药是',\n",
       "  ['缬沙坦', '非洛地平', '普萘洛尔', '维拉帕米', '复方利血平'],\n",
       "  ['1'],\n",
       "  '1和2'),\n",
       " ('醋酸甲地孕酮的化学结构是',\n",
       "  ['[图00751.png]',\n",
       "   '[图00752.png]',\n",
       "   '[图00753.png]',\n",
       "   '[图00754.png]',\n",
       "   '[图00755.png]'],\n",
       "  ['3'],\n",
       "  '[图00751.png]'),\n",
       " ('清除率的计算公式为',\n",
       "  ['[2KY100511.png]',\n",
       "   '[2KY100512.png]',\n",
       "   '[2KY100513.png]',\n",
       "   '[2KY100514.png]',\n",
       "   '[2KY100515.png]'],\n",
       "  ['3'],\n",
       "  '[2KY100516.png]'),\n",
       " ('对黄体酮进行结构改造，引入6α-甲基，并引入\\u200d17α-羟基且成酯，得到的孕激素药物是',\n",
       "  ['[2KY101301.png]',\n",
       "   '[2KY101302.png]',\n",
       "   '[2KY101303.png]',\n",
       "   '[2KY101304.png]',\n",
       "   '[2KY101305.png]'],\n",
       "  ['2'],\n",
       "  '[2KY101302.png]'),\n",
       " ('12h的血药浓度为',\n",
       "  ['80.35μg/ml', '58.81μg/ml', '43.04μg/ml', '6.61μg/ml', '3.548μg/ml'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('以离子交换为主要原理制备缓释、控释制剂的为',\n",
       "  ['凝胶骨架片', '包衣控释片', '微囊', '制成植入剂', '药树脂'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('将乙胺丁醇与链霉素合用治疗结核病的目的是',\n",
       "  ['延长链霉素作用时间', '有利于药物进入结核感染病灶', '阻止或延迟结核杆菌对链霉素产生耐药性', '延迟肾脏排泄链霉素', '减轻注射时疼痛'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('皮下的外文缩写是', ['Co', 'H', 'q.n', 'SOS', 'St'], ['2'], 'C'),\n",
       " ('水银血压计与电子血压计的指示允许误差范围是',\n",
       "  ['±1.875mmHg和±1.875mmHg',\n",
       "   '±3.75mmHg和±4mmHg',\n",
       "   '土3.75mmHg和±5.625mmHg',\n",
       "   '+5.625mmHg和±5.625mmHg',\n",
       "   '±5.625mmHg和±7.5mmHg'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('单室模型静脉注射给药尿排泄数据关系式是',\n",
       "  ['[YZ12017GJZYYSTG2000T2016.png]',\n",
       "   '[YZ12017GJZYYSTG2000T2017.png]',\n",
       "   '[YZ12017GJZYYSTG2000T2018.png]',\n",
       "   '[YZ12017GJZYYSTG2000T2019.png]',\n",
       "   '[YZ12017GJZYYSTG2000T2020.png]'],\n",
       "  ['2'],\n",
       "  '[YZ12017GJZYYSTG2000T2016.png]'),\n",
       " ('产生的各类前列腺素有促进胃壁血流，分泌黏液和碳酸氢盐以中和胃酸，保护胃黏膜功能，这种物质是',\n",
       "  ['COX-1', 'COX-2', 'PGE', 'PGI<SUB>2</SUB>', 'Ach'],\n",
       "  ['1'],\n",
       "  'COX-1'),\n",
       " ('关于磷酸二酯酶抑制剂的应用，正确的是',\n",
       "  ['对心房扑动、心房颤动者，可先应用洋地黄制剂控制心室率',\n",
       "   '米力农在葡萄糖注射液中稳定，宜使用5%葡萄糖注射液',\n",
       "   '使用米力农引起的血小板减少无临床症状，无需监测血小板计数',\n",
       "   '米力农合用强利尿剂时，不会降低左室充盈压',\n",
       "   '肾功能不全时米力农无需减量'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('以下利尿剂的效价，从小到大排列正确的是',\n",
       "  ['托拉塞米、呋塞米、依他尼酸、布美他尼',\n",
       "   '托拉塞米、呋塞米、布美他尼、依他尼酸',\n",
       "   '呋塞米、依他尼酸、托拉塞米、布美他尼',\n",
       "   '依他尼酸、呋塞米、布美他尼、托拉塞米',\n",
       "   '依他尼酸、呋塞米、托拉塞米、布美他尼'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('磺酰胺类利尿药与碳酸酐酶之间形成的主要键合方式是',\n",
       "  ['离子-偶极和偶极-偶极相互作用', '氢键', '电荷转移复合物', '范德华引力', '分子内氢键'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('下列哪项是片剂包糖衣时隔离层的主要材料',\n",
       "  ['川蜡', '食用色素', '糖浆和滑石粉', '稍稀的糖浆', '邻苯二甲酸醋酸纤维素乙醇溶液'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('吸收速率常数',\n",
       "  ['表示药物在体内分布的广泛性',\n",
       "   '用来衡量药物吸收速度的快慢',\n",
       "   '用来衡量药物从体内消除速度的快慢',\n",
       "   '用来衡量血管外给药时进入体循环药物的相对数量和速度',\n",
       "   '指血药浓度衰减一半时所需的时间'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('可诊断男性高尿酸血症的是',\n",
       "  ['血尿酸为大于200μmol/L',\n",
       "   '血尿酸为大于270μmol/L',\n",
       "   '血尿酸为大于360μmol/L',\n",
       "   '血尿酸为大于420μmol/L',\n",
       "   '血尿酸为大于500μmol/L'],\n",
       "  ['4'],\n",
       "  'D'),\n",
       " ('可使血液黏稠度增加，血容量增加，造成增多的血红蛋白与血管内皮舒张因子结合导致血压升高的药物是',\n",
       "  ['丙咪嗪', '重组人促红细胞生成素', '麻黄碱', '地塞米松', '复方氨酚烷胺胶囊'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('下列药物较适合用于痛风发作间歇期的是', ['布洛芬', '尼美舒利', '对乙酰氨基酚', '秋水仙碱', '苯溴马隆'], ['5'], 'B'),\n",
       " ('氯霉素（在肝脏与葡萄糖醛酸结合后排泄）半衰期成人为4h，新生儿则为25h，即',\n",
       "  ['药物吸收', '药物分布', '药物代谢', '药物中毒', '药物排泄'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('某患者，男，78岁，既往有动脉粥样硬化史，因尿频、尿急就诊。体征和实验室检查结果为：血压166/98mmHg，前列腺增生>60g，前列腺特异性抗原（P',\n",
       "  ['非那雄胺', '丙酸睾酮', '泼尼松龙', '吲达帕胺', '格列美脲'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('制成溶解度小的盐或酯，涉及的缓释、控释制剂的释药原理是',\n",
       "  ['离子交换作用', '扩散原理', '溶出原理', '渗透压驱动原理', '溶蚀与溶出、扩散结合原理'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('该仿制药片剂的绝对生物利用度是',\n",
       "  ['59.0%', '236.0%', '103.2%', '42.4%', '44.6%'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('制定新药新知识培训制度，归属',\n",
       "  ['知识培训', '科学发展', '管理规范到位', '环境与流程的优化与持续改进', '倡导和建立正确的用药安全文化'],\n",
       "  ['1'],\n",
       "  '戴明环'),\n",
       " ('R', ['塞来昔布', '甲氨蝶呤', '羟氯喹', '青霉胺', '金诺芬'], ['2'], 'R代表雷贝拉唑'),\n",
       " ('与氢化可的松合用，可以增强抗炎、抗变态反应药效的是', ['黄连', '金银花', '大蒜素', '甘草', '丹参'], ['4'], '黄连'),\n",
       " ('关于药物水解的表述，正确的是',\n",
       "  ['盐酸普鲁卡因可水解成有麻醉作用的对氨基苯甲酸以及二乙氨基乙醇',\n",
       "   '硝酸毛果芸香碱、华法林钠均有内酯结构，可以水解',\n",
       "   '溴丙胺太林的水解属于酰胺药物的水解',\n",
       "   '氨苄西林在水溶液中最稳定的pH大于7',\n",
       "   '在利多卡因中，邻近酰胺基有较大的基团，由于共轭效应，故不易水解'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('应用高剂量的β2受体激动剂可导致的严重典型不良反应是（\\u3000）。',\n",
       "  ['低镁血症', '低钙血症', '低钾血症', '高钙血症', '高钾血症'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('关于复方制剂美洛西林钠与舒巴坦的说法，正确的是',\n",
       "  ['美洛西林为“自杀性”β－内酰胺酶抑制剂',\n",
       "   '舒巴坦是氨苄西林经改造而来，抗菌作用强',\n",
       "   '舒巴坦可增强美洛西林对β－内酰胺酶稳定性',\n",
       "   '美洛西林具有甲氧肟基，对β－内酰胺酶具有高稳定作用',\n",
       "   '舒巴坦属于碳青霉烯类抗生素'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('《中国药典》2010版二部收载',\n",
       "  ['单味制剂', '植物油脂和提取物', '生物制品', '化学药品', '药材及饮片'],\n",
       "  ['4'],\n",
       "  'D'),\n",
       " ('推荐长期精神紧张、紧张性头痛者应用的是', ['布洛芬', '谷维素', '地西泮', '卡马西平', '麦角胺咖啡因片'], ['3'], 'B'),\n",
       " ('试验时的温度，如果温度高低对试验结果有显著影响者，除另有规定外，一般系指',\n",
       "  ['室温', '15℃～25℃', '18℃～22℃', '20℃～25℃', '23℃～27℃'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('药物分子中含有硫原子的为', ['雷米普利', '赖诺普利', '福辛普利', '卡托普利', '贝那普利'], ['4'], 'B'),\n",
       " ('室温为', ['1～30℃', '不超过20℃', '2～10℃', '10～30℃', '2℃以下'], ['4'], ''),\n",
       " ('静脉注射某药，X0=30mg，若初始血药浓度为15μg/ml，其表观分布容积V为',\n",
       "  ['2L', '2ml', '30L', '450L', '0.45L'],\n",
       "  ['1'],\n",
       "  'C'),\n",
       " ('西妥昔单抗用于治疗',\n",
       "  ['复发或耐药的滤泡性中央型淋巴瘤',\n",
       "   '表达表皮生长因子受体,经伊立替康治疗失败的转移性结直肠癌',\n",
       "   '肝癌',\n",
       "   '人表皮生长因子受体-2过度表达的转移性乳腺癌',\n",
       "   '肺癌'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('根据选用的药物，该药物禁用于', ['性病', '胃溃疡', '心脏病', '过敏者', '18岁以下儿童'], ['5'], '18岁以下儿童'),\n",
       " ('具有芳氧丙醇胺结构，属于非选择性的β受体拮抗剂的药物是',\n",
       "  ['[YZ12017KDS1024.png]',\n",
       "   '[YZ12017KDS1025.png]',\n",
       "   '[YZ12017KDS1026.png]',\n",
       "   '[YZ12017KDS1027.png]',\n",
       "   '[YZ12017KDS1028.png]'],\n",
       "  ['1'],\n",
       "  '[YZ12017KDS1029.png]'),\n",
       " ('雷尼替丁的化学结构是',\n",
       "  ['[图00571.png]',\n",
       "   '[图00572.png]',\n",
       "   '[图00573.png]',\n",
       "   '[图00574.png]',\n",
       "   '[图00575.png]'],\n",
       "  ['3'],\n",
       "  '[图00571.png]'),\n",
       " ('清除率的单位是', ['l/h', 'L/h', 'L', 'g/h', 'h'], ['2'], 'l/h'),\n",
       " ('在亮菌甲素注射剂中加人助剂二甘醇所致的不良事件引发的危害是',\n",
       "  ['肾衰竭', '肝衰竭', '肺衰竭', '心脏瓣膜病', '皮肤纤维化'],\n",
       "  ['1'],\n",
       "  'D'),\n",
       " ('属于广谱抗心律失常药物的是', ['普鲁卡因胺', '利多卡因', '普萘洛尔', '普罗帕酮', '苯妥英钠'], ['1'], '1、2'),\n",
       " ('处方中\"必要时\"的外文缩写是', ['Ac', 'pc.', 'po.', 'qn.', 'prn'], ['5'], 'prn'),\n",
       " ('用药过程中，应密切监测的不良反应是',\n",
       "  ['前庭神经功能障碍', '承重关节损伤', '日光性皮炎', '视网膜神经炎', '中枢神经系统症状'],\n",
       "  ['5'],\n",
       "  'C'),\n",
       " ('下列药物中，有条件者应在用药期间监测其血药浓度的是',\n",
       "  ['沙丁胺醇片', '福莫特罗吸入剂', '沙丁胺醇气雾剂', '沙美特罗-氟替卡松吸入干粉剂', '茶碱缓释片'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('有机磷农药中毒时可采用20%碳酸氢钠洗胃，除了', ['特普', '对硫磷', '乐果', '敌敌畏', '敌百虫'], ['5'], 'C'),\n",
       " ('关于静脉注射苯妥英纳的血药浓度-时间曲线的说法，正确的是',\n",
       "  ['高浓度下，表现为非线性药物动力学特征：AUC与剂量不成正比',\n",
       "   '低浓度下，表现为线性药物动力学特征：剂量增加，消除半衰期延长',\n",
       "   '低浓度下，表现为非线性药物动力学特征：不同剂量的血药浓度-时间曲线相互平行',\n",
       "   '高浓度下，表现为线性药物动力学特征：剂量增加，半衰期不变',\n",
       "   '高浓度下，表现为非线性药物动力学特征：血药浓度与剂量成正比'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('处方中常见外文缩写\"Sig．\"，其含义是。', ['立即', '溶液', '必要时', '软膏剂', '标明用法'], ['5'], '用法'),\n",
       " ('\"助消化药不宜与抗菌药物、吸附剂同时服用\";如必须联用，应间隔的时间是',\n",
       "  ['1小时', '1.5小时', '2小时', '1～3小时', '2～3小时'],\n",
       "  ['5'],\n",
       "  '2．1.5小时'),\n",
       " ('对血小板聚集及凝血机制无影响的药品是（\\u3000）。',\n",
       "  ['罗非昔布', '对乙酰氨基酚', '吲哚美辛', '阿司匹林', '美洛昔康'],\n",
       "  ['2'],\n",
       "  'C'),\n",
       " ('药物非特异性作用的特点是',\n",
       "  ['与机体免疫系统有关', '主要与药物基因有关', '与药物的化学结构有关', '主要与药物作用的载体有关', '与药物本身的理化性质有关'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('葡萄糖-6-磷酸脱氢酶缺乏者应禁用', ['氯喹', '替硝唑', '伯氨喹', '奎宁', '青蒿素'], ['3'], '1、4'),\n",
       " ('成年人空腹血糖正常值范围是',\n",
       "  ['3.9-7.2mmol/L70-130mg/dl',\n",
       "   '3.9-8.3mmol/L70-150mg/dl',\n",
       "   '3.9-7.0mmol/L70-126mg/dl',\n",
       "   '3.5-5.5mmol/L60-100mg/dl',\n",
       "   '3.9-6.1mmol/L70-110mg/dl'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('伏格列波糖的降糖作用机制是',\n",
       "  ['竞争性抑制α葡萄糖苷酶',\n",
       "   '刺激胰岛β细胞释放胰岛素',\n",
       "   '提高靶组织对胰岛素的敏感性',\n",
       "   '直接补充胰岛素',\n",
       "   '关闭β细胞膜中ATP-依赖性钾通道，打开钙通道'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('能治疗强心苷中毒引起的快速型心律失常的是（）',\n",
       "  ['阿托品', '洋地黄毒苷', '氯化钾', '氢氯噻嗪', '苯妥英钠'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('引起乳剂转相的是',\n",
       "  ['ζ电位.降低', '油水两相密度差不同造成', '光、热、空气及微生物等的作用', '乳化剂类型改变', '乳化剂失去作用'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('应用蛋白酶抑制剂治疗艾滋病期间须确保足够水化，为了避免尿路结石的发生，每日饮水量至少达到',\n",
       "  ['200mL', '500mL', '1500mL', '2000mL', '2500mL'],\n",
       "  ['3'],\n",
       "  'C'),\n",
       " ('用速率法测定血清丙氨酸氨基转移酶（',\n",
       "  ['＜30U/L', '＜40U/L', '＜50U/L', '＜60U/L', '＜80U/L'],\n",
       "  ['2'],\n",
       "  'C'),\n",
       " ('配制10%葡萄糖注射液500mL，现用50%和5%葡萄注射液混合，应当分别量取',\n",
       "  ['50%葡萄糖注射液56mL和5%葡萄糖注射液444mL',\n",
       "   '50%葡萄糖注射液72mL和5%葡萄糖注射液428mL',\n",
       "   '50%葡萄糖注射液85mL和5%葡萄糖注射液415mL',\n",
       "   '50%葡萄糖注射液94mL和5%葡萄糖注射液406mL',\n",
       "   '50%葡萄糖注射液106mL和5%葡萄糖注射液394mL'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('对映异构体之间产生相反活性的是', ['普罗帕酮', '萘普生', '扎考必利', '丙氧酚', '甲基多巴'], ['3'], '无'),\n",
       " ('硫酸亚铁片的含量测定采用', ['非水酸量法', '亚硝酸钠滴定法', '非水碱量法', '碘量法', '铈量法'], ['5'], ''),\n",
       " ('表观分布容积为', ['5L', '6L', '15L', '20L', '30L'], ['2'], '无正确答案'),\n",
       " ('动物或人的研究中已证实可使胎儿异常，或基于人类的经验知其对胎儿有危险，该类药物属于',\n",
       "  ['妊娠毒性分级A级', '妊娠毒性分级B级', '妊娠毒性分级C级', '妊娠毒性分级D级', '妊娠毒性分级X级'],\n",
       "  ['5'],\n",
       "  '1、2和3'),\n",
       " ('β受体阻断剂的主要不良反应是',\n",
       "  ['足踝部水肿', '血尿酸升高', '直立性低血压', '支气管痉挛', '咳嗽及血管性水肿'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('可与奎尼丁发生与P-糖蛋白有关的相作用的药物是',\n",
       "  ['华法林', '达比加群酯', '低分子肝素', '肝素钠', '维生素K'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('零级静脉滴注速度是',\n",
       "  ['K<SUB>m</SUB>',\n",
       "   'C<SUB>ss</SUB>',\n",
       "   'k<SUB>0</SUB>',\n",
       "   'V<SUB>m</SUB>',\n",
       "   'f<SUB>ss</SUB>'],\n",
       "  ['3'],\n",
       "  '无正确答案'),\n",
       " ('清除率是指', ['Cl', 'Css', 'fss', 'MRT', 'Km'], ['1'], ''),\n",
       " ('为减少心力衰竭的危险性，柔红霉素累积总量限量是',\n",
       "  ['5mg/kg', '10mg/kg', '15mg/kg', '20mg/kg', '25mg/kg'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('肠外营养1g葡萄糖能提供的热量是',\n",
       "  ['3kcal', '4kcal', '7kcal', '9kcal', '12kcal'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('若使血药浓度保持5～15μg/ml范围内，则静脉注射的给药间隔为',\n",
       "  ['2h', '3h', '4.76h', '5.76h', '7.76h'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('羟丙甲纤维素属于',\n",
       "  ['溶蚀性骨架材料', '亲水凝胶型骨架材料', '不溶性骨架材料', '渗透泵型控释片的半透膜材料', '常用的植入剂材料'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('\"口服\"的外文缩写是', ['i', 'i.h.', 'iv.', 'iv gtt', 'po.'], ['5'], 'p.o'),\n",
       " ('无药物吸收的过程', ['静脉注射剂', '气雾剂', '肠溶片', '直肠栓', '阴道栓'], ['1'], '1、3'),\n",
       " ('结构中不含有硫的四碳链，有哌啶甲苯结构，无拮抗雄激素作用的H2受体拮抗剂是',\n",
       "  ['西咪替丁', '雷尼替丁', '法莫替丁', '罗沙替丁', '尼扎替丁'],\n",
       "  ['4'],\n",
       "  'C'),\n",
       " ('可引起中性粒细胞胞浆抗体相关性血管炎的抗甲状腺药是（\\u3000）。',\n",
       "  ['卡比马唑片', '复方碘口服液', '甲硫咪唑片', '甲状腺片', '丙硫氧嘧啶片'],\n",
       "  ['5'],\n",
       "  '甲硫咪唑片'),\n",
       " ('与生物大分子键合作用力最弱的是', ['静电引力', '共价键', '电荷转移复合物', '偶极相互作用', '范德华力'], ['5'], ''),\n",
       " ('片剂制备中，物料的塑性较差，结合力弱可导致', ['松片', '裂片', '溶出超限', '崩解迟缓', '含量不均匀'], ['2'], 'B'),\n",
       " ('下列叙述中属于药物制剂化学稳定性变化的有',\n",
       "  ['片剂出现裂片现象', '片剂的溶出度加快', '片剂崩解变快', '片剂中有关物质增加', '中药压制片剂吸潮'],\n",
       "  ['4'],\n",
       "  'A'),\n",
       " ('8位引入氟原子，口服吸收迅速、完全，但光毒\\u200d性也增大；同时5位引入氨基，增强与靶点亲和\\u200d力的药物是',\n",
       "  ['[2KY101481.png]',\n",
       "   '[2KY101482.png]',\n",
       "   '[2KY101483.png]',\n",
       "   '[2KY101484.png]',\n",
       "   '[2KY101485.png]'],\n",
       "  ['5'],\n",
       "  '[2KY101482.png]'),\n",
       " ('按照中国药学会医院药学专业委员会相关标准，将高危药品分为',\n",
       "  ['10%氯化钾注射液', '维库溴铵注射液', '5%葡萄糖注射用', '华法林片', '多潘立酮片'],\n",
       "  ['1'],\n",
       "  'A'),\n",
       " ('用于弱酸性药物液体制剂的常用抗氧化剂是（\\u3000\\u3000）',\n",
       "  ['酒石酸', '依地酸二钠', '焦亚硫酸钠', '维生素E', '硫代硫酸钠'],\n",
       "  ['3'],\n",
       "  '维生素 E'),\n",
       " ('可用于治疗癫痫、躁狂症和神经源性尿崩症的药物是',\n",
       "  ['丙戊酸钠', '苯妥英钠', '苯巴比妥', '氯硝西泮', '卡马西平'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('利培酮的结构是',\n",
       "  ['[2KY100861.png]',\n",
       "   '[2KY100862.png]',\n",
       "   '[2KY100863.png]',\n",
       "   '[2KY100864.png]',\n",
       "   '[2KY100865.png]'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('芬太尼的化学结构是',\n",
       "  ['[图00371.png]',\n",
       "   '[图00372.png]',\n",
       "   '[图00373.png]',\n",
       "   '[图00374.png]',\n",
       "   '[图00375.png]'],\n",
       "  ['5'],\n",
       "  '[图00371.png]'),\n",
       " ('口服存在首关效应的药物是', ['溴己新', '氨溴索', '乙酰半胱氨酸', '羧甲司坦', '厄多司坦'], ['3'], ''),\n",
       " ('抗过敏药可以治疗荨麻疹，可是驾车、高空作业、精密机械操作者服用后应休息',\n",
       "  ['3小时以上', '4小时以上', '5小时以上', '6小时以上', '7小时以上'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('属于碳青霉烯类药物是', ['头孢吡肟', '头孢美唑', '亚胺培南', '氨曲南', '拉氧头孢'], ['3'], ''),\n",
       " ('下列不属于药物稳定性试验方法的是',\n",
       "  ['高温试验', '随机试验', '强光试验', '加速试验', '长期试验'],\n",
       "  ['2'],\n",
       "  '2（随机试验）'),\n",
       " ('在包衣液的处方中，可作为增塑剂的是', ['二氧化钛', 'CAP', '丙二醇', '司盘80', '吐温80'], ['3'], 'B'),\n",
       " ('某患者静脉注射（推注）某药，已知剂量X0=500mg，V=10L，k=0.1h-1，T=10h，该患者给药达稳态后的平均稳态血药浓度是',\n",
       "  ['0.05mg/L', '0.5mg/L', '5mg/L', '50mg/L', '500mg/L'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('若某药的成人剂量是每次500mg，那么一个体重35kg的儿童按体表面积计算每次服用剂量为',\n",
       "  ['400mg', '350mg', '250mg', '300mg', '150mg'],\n",
       "  ['2'],\n",
       "  '无法从给定的信息中得出'),\n",
       " ('婴儿尿布皮炎外用激素制剂应限于', ['3天', '3～5天', '5～7天', '2周', '1个月'], ['3'], '2．3～5天'),\n",
       " ('若需配制75％乙醇2000ml，应量取95％乙醇',\n",
       "  ['736ml', '1105ml', '1356ml', '1579ml', '1675ml'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('治疗指数指的是',\n",
       "  ['ED<SUB>95</SUB>与LD<SUB>5</SUB>的比值',\n",
       "   'LD<SUB>50</SUB>与ED<SUB>50</SUB>的比值',\n",
       "   'LD<SUB>5</SUB>与ED<SUB>95</SUB>的比值',\n",
       "   'ED<SUB>50</SUB>与LD<SUB>50</SUB>的比值',\n",
       "   'ED<SUB>50</SUB>和LD<SUB>50</SUB>之间的距离'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('\"每天\"的外文缩写是', ['q．i．d．', 'q．S．', 'q．n．', 'q．h', 'q．d．'], ['5'], 'q.d'),\n",
       " ('下列制剂中需要嚼碎服用的药品是',\n",
       "  ['碳酸氢钠片', '奥美拉唑肠溶胶囊', '复方碳酸钙片', '多潘立酮片', '法莫替丁片'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('羟丙甲纤维素', ['溶蚀性骨架材料', '肠溶性包衣材料', '不溶性骨架材料', '亲水凝胶骨架材料', '增黏剂'], ['4'], ''),\n",
       " ('高钾血症指血钾大于',\n",
       "  ['2.2mmol/L', '2.75mmol/L', '3.5mmol/L', '4.2mmol/L', '5.5mmol/L'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('2级高血压是指',\n",
       "  ['收缩压120～139mmHg和（或）舒张压80～89mmHg',\n",
       "   '收缩压140～159mmHg和（或）舒张压90～99mmHg',\n",
       "   '收缩压160～179mmHg和（或）舒张压100～109mmHg',\n",
       "   '收缩压≥180mmHg和（或）舒张压≥110mmHg',\n",
       "   '收缩压≥140mmHg和舒张压<90mmHg'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('有关分布容积正确的描述是',\n",
       "  ['体内含药物的真实容积',\n",
       "   '有生理学意义',\n",
       "   '指全血或血浆中药物浓度与体内药量联系起来的比例常数',\n",
       "   '给药剂量与t时间血药浓度的比值',\n",
       "   '是药物动力学的重要参数，用来评价体内药物分布的程度'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('有较好证据支持的药物信息属于',\n",
       "  ['EBDIA类', 'EBDIB类', 'EBDIC类', 'EBDID类', 'EBDIE类'],\n",
       "  ['2'],\n",
       "  'EBDIA类'),\n",
       " ('半衰期3h，治疗指数低的药物，如果想达到理想的治疗效果，口服给药间隔最好是',\n",
       "  ['每隔1个半衰期给药1次', '每隔2个半衰期给药1次', '每隔3个半衰期给药1次', '每隔4个半衰期给药1次', '每隔5个半衰期给药1次'],\n",
       "  ['1'],\n",
       "  '无法计算'),\n",
       " ('对竞争性拮抗药描述正确的是',\n",
       "  ['与激动药竞争不同的受体',\n",
       "   '使激动药的最大效应减小',\n",
       "   '与受体形成牢固的结合或改变受体的构型',\n",
       "   '使激动药的量-效曲线平行右移，最大效应不变',\n",
       "   '使激动药的量-效曲线平行左移，最大效应不变'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('对阿司匹林过敏或不耐受的患者可选用', ['噻氯匹定', '替格雷洛', '氯吡格雷', '替罗非班', '双嘧达莫'], ['3'], 'B'),\n",
       " ('1型糖尿病患者的胰岛素分泌不足，可选用的药物是',\n",
       "  ['阿卡波糖', '二甲双胍', '罗格列酮', '格列喹酮', '胰岛素'],\n",
       "  ['5'],\n",
       "  '胰岛素'),\n",
       " ('患者，男，77岁，因感冒，发热，咳嗽，自服酚麻美敏片、维C银翘片，三天后出现急性尿潴留，可引起该患者出现尿潴留的药物成分是',\n",
       "  ['对乙酰氨基酚', '维生素C', '银翘', '氯苯那敏', '右美沙芬'],\n",
       "  ['4'],\n",
       "  '1对乙酰氨基酚'),\n",
       " ('儿童使用第一代抗组胺药时，相比成年人易产生较强镇静作用，该现象称为',\n",
       "  ['高敏性', '药物选择性', '耐受性', '依赖性', '药物特异性'],\n",
       "  ['1'],\n",
       "  '药物特异性'),\n",
       " ('阿托品是',\n",
       "  ['东莨菪醇和莨菪酸结合成的酯',\n",
       "   '莨菪醇和莨菪酸结合成的酯',\n",
       "   '莨菪醇和消旋莨菪酸结合成的酯',\n",
       "   '山莨菪醇和莨菪酸结合成的酯',\n",
       "   '东莨菪醇和樟柳酸结合成的酯'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('对于肝功能不全患者可使用正常剂量的药物是',\n",
       "  ['青霉素', '氯霉素', '苯巴比妥', '洋地黄毒苷', '苯妥英钠'],\n",
       "  ['1'],\n",
       "  '1、2和5'),\n",
       " ('美国国家用药错误报告及预防协调委员会制定的用药错误分级标准中‘发生差错但未发给患者，或已发给患者但未使用’的情况属于',\n",
       "  ['A级', 'B级', 'C级', 'D级', 'E级'],\n",
       "  ['2'],\n",
       "  'E级'),\n",
       " ('控制心室率', ['硝苯地平', '血凝酶', '华法林', '多非利特', '地尔硫卓'], ['5'], 'D'),\n",
       " ('成人随机尿比重的参考范围是',\n",
       "  ['0.015～1.025', '1.002～1.004', '1.003～1.030', '1.004～1.040', '1.005～1.025'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('HPMCP可作为片剂的何种材料', ['肠溶衣', '糖衣', '胃溶衣', '崩解剂', '润滑剂'], ['1'], 'C'),\n",
       " ('临床使用外消旋体的是', ['布桂嗪', '右丙氧芬', '吗啡', '美沙酮', '芬太尼'], ['4'], '所有非处方药'),\n",
       " ('属于双胍类胰岛素增敏剂的是',\n",
       "  ['[YX11200SRTX0816.png]',\n",
       "   '[YX11200SRTX0817.png]',\n",
       "   '[YX11200SRTX0818.png]',\n",
       "   '[YX11200SRTX0819.png]',\n",
       "   '[YX11200SRTX0820.png]'],\n",
       "  ['1'],\n",
       "  '[YX11200SRTX0816.png]'),\n",
       " ('药品检验时主要采用采用平皿法、薄膜过滤法、MPN法检验的是',\n",
       "  ['非无菌药品的微生物检验', '药物的效价测定', '委托检验', '复核检验', '体内药品的检验'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('双室模型静脉注射给药的血药浓度随时间变化的公式是',\n",
       "  ['[1K20022.png]',\n",
       "   '[1K20023.png]',\n",
       "   '[1K20024.png]',\n",
       "   '[1K20025.png]',\n",
       "   '[1K20026.png]'],\n",
       "  ['3'],\n",
       "  '[1K20021.png];[1K20027.png];[1K20028.png];[1K20029.png];[1K20030.png]'),\n",
       " ('摄入过多可增加体内血容量，促发充血性心力衰竭或高血压的是', ['酒', '食盐', '食醋', '脂肪', '蛋白质'], ['2'], '盐'),\n",
       " ('分子结构具有对称性，可用于治疗冠心病，并能缓解心绞痛的药物是',\n",
       "  ['硝苯地平image.png',\n",
       "   '尼群地平image.png',\n",
       "   '尼莫地平image.png',\n",
       "   '氨氯地平image.png',\n",
       "   '非洛地平image.png'],\n",
       "  ['1'],\n",
       "  '1、2、3'),\n",
       " ('属于青霉烷砜类的β-内酰胺酶不可逆抑制剂是',\n",
       "  ['[2KY101461.png]',\n",
       "   '[2KY101462.png]',\n",
       "   '[2KY101463.png]',\n",
       "   '[2KY101464.png]',\n",
       "   '[2KY101465.png]'],\n",
       "  ['1'],\n",
       "  '[2KY101461.png][2KY101462.png][2KY101463.png]'),\n",
       " ('阴离子型表面活性剂', ['司盘20', '十二烷基苯磺酸钠', '苯扎溴铵', '卵磷脂', '吐温80'], ['2'], ''),\n",
       " ('肾脏清除率是指',\n",
       "  ['血浆中药物被清除的能力',\n",
       "   '药物在消化道向淋巴系统转运',\n",
       "   '单位时间内胃内容物的排除量',\n",
       "   '药物进入体循环前的降解或失活',\n",
       "   '药物被送至体内各脏器组织的过程'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('老年C',\n",
       "  ['第三代头孢菌素', '碳青霉烯类', '氟喹诺酮类', '大环内酯类', 'β-内酰胺类+β-内酰胺酶抑制剂'],\n",
       "  ['3'],\n",
       "  'D'),\n",
       " ('减少或减慢同服药物的代谢的是', ['丙磺舒', '西沙比利', '阿司匹林', '丙胺太林', '西咪替丁'], ['5'], '丙磺舒'),\n",
       " ('依赖性药物分几类', ['二类', '三类', '四类', '五类', '六类'], ['2'], '1.二类'),\n",
       " ('探索性研究，使用微剂量（一般不大于100μg），对少量受试者（6人左右）进行的药物试验是',\n",
       "  ['0期临床试验', 'I期临床试验', 'Ⅱ期临床试验', 'Ⅲ期临床试验', 'Ⅳ期临床试验'],\n",
       "  ['1'],\n",
       "  '0期临床试验'),\n",
       " ('具有旋光性，药用其右旋体的是', ['氨溴索', '乙酰半胱氨酸', '可待因', '苯丙哌林', '右美沙芬'], ['5'], ''),\n",
       " ('判明不良反应是否与并用药物的作用、患者病情的进展和其他治疗措施相关，属于',\n",
       "  ['事件相关性', '文献合理性', '撤药结果', '再次用药结果', '影响因素甄别'],\n",
       "  ['5'],\n",
       "  '事件相关性'),\n",
       " ('《中国药典》现行版规定测定液体的旋光度时温度应控制在',\n",
       "  ['20℃', '18℃', '22℃', '30℃', '32℃'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('患者，男，80岁，临床诊断为前列腺增生症，给予多沙唑嗪治疗。药师对该患者的用药指导，正确的是',\n",
       "  ['每日服用一次，定期监测血糖，防止发生低血糖反应',\n",
       "   '睡前服用，定期监测肝功能',\n",
       "   '睡前服用，注意监测肾功能',\n",
       "   '睡前服用，起床站立时应缓慢，预防体位性低血压',\n",
       "   '清晨服用，注意监测血压，预防体位性低血压'],\n",
       "  ['4'],\n",
       "  '1、4'),\n",
       " ('下列不属于一线抗结核药的是', ['利福平', '乙硫异烟胺', '吡嗪酰胺', '链霉素', '异烟肼'], ['2'], 'B'),\n",
       " ('沙美特罗的化学结构为',\n",
       "  ['[图00531.png]',\n",
       "   '[图00532.png]',\n",
       "   '[图00533.png]',\n",
       "   '[图00534.png]',\n",
       "   '[图00535.png]'],\n",
       "  ['5'],\n",
       "  '[图00531.png]'),\n",
       " ('与其他NS', ['塞来昔布', '阿司匹林', '吲哚美辛', '对乙酰氨基酚', '双氯芬酸钠'], ['2'], 'C'),\n",
       " ('用作片剂崩解剂的是', ['乳糖', '淀粉浆', '羧甲基淀粉钠', '微粉硅胶', '硬脂酸镁'], ['3'], '微粉硅胶'),\n",
       " ('通式为RNH3＋X－的阳离子表面活性剂是',\n",
       "  ['硬脂酸钠', '苯扎溴铵', '卵磷脂', '聚乙烯醇', '聚山梨酯80'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('药物生物半衰期指的是',\n",
       "  ['药效下降一半所需要的时间',\n",
       "   '吸收一半所需要的时间',\n",
       "   '进入血液循环所需要的时间',\n",
       "   '进入脂肪组织所需要的时间',\n",
       "   '血药浓度减少一半所需要的时间'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('使激动药的量-效曲线平行右移，但其最大效应不变的是',\n",
       "  ['完全激动药', '部分激动药', '拮抗药', '竞争性拮抗药', '非竞争性拮抗药'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('对阿司匹林过敏或不耐受的患者，可替代阿司匹林的溶栓药是',\n",
       "  ['华法林', '噻氯匹定', '替罗非班', '双嘧达莫', '氯吡格雷'],\n",
       "  ['5'],\n",
       "  '1.华法林'),\n",
       " ('下列关于',\n",
       "  ['A/G比值的正常参考范围是（1.5～2.5）∶1',\n",
       "   'A/G比值小于1，提示患有肝硬化等疾病',\n",
       "   '肝炎早期，A/G比值仍可正常',\n",
       "   '病情恶化时，A/G比值上升',\n",
       "   'A/G比值持续倒置提示预后较差'],\n",
       "  ['4'],\n",
       "  '1．A/G比值的正常参考范围为1.5~2.5：1;2．A/G比值小于1,提示可能患有肝硬化等肝病;3．部分肝炎病人早期A/G比值仍然正常或接近正常水平;4．当病情恶化时，A/G比值会上升;5．A/G比值持续倒置提示预后较'),\n",
       " ('可预防环磷酰胺所致膀胱毒性的药物是', ['糖皮质激素', '美司钠', '呋塞米', '维生素', '抗生素'], ['2'], 'A'),\n",
       " ('产生药物奖赏效应的主要调控部位是',\n",
       "  ['中脑一皮质多巴胺通路', '黑质一纹状体通路', '下丘脑一垂体通路', '中脑一边缘多巴胺通路', '结节一漏斗通路'],\n",
       "  ['4'],\n",
       "  '1中脑一皮质多巴胺通'),\n",
       " ('化学结构如下的药物为[图0080.png]',\n",
       "  ['头孢羟氨苄', '氨苄西林', '阿莫西林', '头孢克洛', '头孢噻肟'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('预混胰岛素30R的组成为',\n",
       "  ['30%中效胰岛素，70%短效胰岛素',\n",
       "   '70%中效胰岛素，30%短效胰岛素',\n",
       "   '30%超短效胰岛素，70%中效胰岛素',\n",
       "   '70%超短效胰岛素，30%短效胰岛素',\n",
       "   '30%中效胰岛素，70%长效胰岛素'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('《欧洲药典》英文缩写为', ['JP', 'BP', 'USP', 'ChP', 'EP'], ['5'], 'EP'),\n",
       " ('饮茶可减少其吸收的药物是', ['阿仑膦酸钠', '去氨加压素', '硫酸亚铁', '阿莫西林', '辛伐他汀'], ['3'], '1、4'),\n",
       " ('三个药物的安全范围',\n",
       "  ['A药最大  ', 'B药最大  ', 'C药最大  ', '三药一样大  ', '无法比较'],\n",
       "  ['5'],\n",
       "  'A、B、C三药安全范围均大于1'),\n",
       " ('以下对\"调配处方四查十对\"的叙述中，最正确的是',\n",
       "  ['查处方，对临床诊断',\n",
       "   '查临床诊断，对用药合理性',\n",
       "   '查药品，对药名、剂型、规格、数量',\n",
       "   '查配伍禁忌，对药品性状、规格、数量',\n",
       "   '查用药合理性，对科别、姓名、年龄'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('溴己新的环己烷羟基化、N-去甲基的活性代谢物为',\n",
       "  ['可待因', '右美沙芬', '羧甲司坦', '喷托维林', '氨溴索'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('含有2个三氮唑环，2,\\u200d4-二氟苯基增强脂溶性,\\u200d口服吸收好的药物是',\n",
       "  ['[2KY101491.png]',\n",
       "   '[2KY101492.png]',\n",
       "   '[2KY101493.png]',\n",
       "   '[2KY101494.png]',\n",
       "   '[2KY101495.png]'],\n",
       "  ['3'],\n",
       "  '[2KY101492.png]'),\n",
       " ('对于该患者的治疗，下列描述正确的是',\n",
       "  ['只给予解热药物即可',\n",
       "   '只给予抗生素即可',\n",
       "   '使用抗生素杀灭病原微生物比用解热、镇痛药降低高热患者的体温更重要',\n",
       "   '抗生素杀灭病原微生物属于治标，解热镇痛药降低高热患者的体温属于治本',\n",
       "   '医生对于该患者的治疗属于标本兼治'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('可出现于肾移植后排斥反应的蛋白尿是',\n",
       "  ['肾小球性蛋白尿', '肾小管性蛋白尿', '组织性蛋白尿', '溢出性蛋白尿', '肾毒性蛋白尿'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('与西咪替丁、喹诺酮类及大环内酯类药物合用，应减少其用量的药品是',\n",
       "  ['孟鲁司特', '氨茶碱', '异丙托溴铵', '噻托溴铵', '抗IgE抗体'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('生化药品收载在《中国药典》的',\n",
       "  ['一部第一部分', '一部第二部分', '二部第一部分', '二部第二部分', '三部'],\n",
       "  ['3'],\n",
       "  '二部第一部分'),\n",
       " ('PEG-DSPE（二硬脂酰基磷脂酰乙醇胺）是一种PEG化脂质材料，常用于对脂质体进行PEG化，降低与单核巨噬细胞的亲和力。PEG-DSPE修饰的盐酸多柔比星脂质体属于',\n",
       "  ['前体脂质体', 'pH敏感脂质体', '免疫脂质体', '栓塞脂质体', '长循环脂质体'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('.应该评判为超常处方的是',\n",
       "  ['为Ⅰ类手术切口患者开具的处方：术前给予第三代头孢菌素',\n",
       "   '为细菌性轻度腹泻患者开具的处方：餐前服用黄连素',\n",
       "   '为2型糖尿病人开具的处方：餐中服用二甲双胍',\n",
       "   '为3岁蛔虫病患者开具的处方：空腹服用噻嘧啶',\n",
       "   '为急诊患者单张处方开具：6种药品'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('有关脂水分配系数P，叙述正确的是',\n",
       "  ['P值越大，药物亲水性越大', 'P值越大，药物亲脂性越大', 'P值越大，药效越强', 'P值越大，药效越弱', 'P值越大，中枢作用越强'],\n",
       "  ['2'],\n",
       "  '无'),\n",
       " ('不含有脯氨酸结构的', ['卡托普利', '依那普利', '贝那普利', '赖诺普利', '缬沙坦'], ['3'], 'B'),\n",
       " ('下列哪项是慢性肾盂肾炎的易感因素', ['胸膜炎', '胃炎', '甲状腺功能亢进', '糖尿病', '药物性皮炎'], ['4'], 'B'),\n",
       " ('可用于治疗结核性眼病的药物是',\n",
       "  ['左氧氟沙星滴眼剂', '红霉素眼膏', '氯霉素眼膏', '氧氟沙星滴眼剂', '利福平滴眼剂'],\n",
       "  ['5'],\n",
       "  '2、3'),\n",
       " ('门冬胰岛素归属', ['X级', 'D级', 'C级', 'B级', 'A级'], ['4'], 'A'),\n",
       " ('冷性荨麻疹的特点是',\n",
       "  ['暴露于冷空气和接触冷水时出现水肿及痛性风团',\n",
       "   '多见于青年女性，好发于躯干及上肢',\n",
       "   '症状多持续2～3周，消而又生，不易治愈',\n",
       "   '好发于眼睑、口唇、外生殖器',\n",
       "   '锐器或指甲划过皮肤后，沿着划痕出现条状淡红色隆起，伴有瘙痒'],\n",
       "  ['1'],\n",
       "  'D'),\n",
       " ('青霉素钠注射剂皮试液的浓度是',\n",
       "  ['75U/mL', '100U/mL', '250U/mL', '500U/mL', '1000U/mL'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('药物通过特定的给药方式产生的不良反应属于',\n",
       "  ['A型反应（扩大反应）', 'D型反应（给药反应）', 'E型反应（撤药反应）', 'F型反应（家族反应）', 'G型反应（基因毒性）'],\n",
       "  ['2'],\n",
       "  'D型反应'),\n",
       " ('氟喹诺酮类抗菌药物的主要作用靶位是',\n",
       "  ['DNA聚合酶', 'DNA连接酶', '核糖体30S亚基', '核糖体50S亚基', 'DNA拓扑异构酶Ⅱ和Ⅳ'],\n",
       "  ['5'],\n",
       "  'DNA拓扑异构酶Ⅱ和Ⅳ'),\n",
       " ('以下不属于二磷酸腺苷P2Y12受体阻断剂的是',\n",
       "  ['替格雷洛', '噻氯匹定', '替罗非班', '普拉格雷', '氯吡格雷'],\n",
       "  ['3'],\n",
       "  'D'),\n",
       " ('不能受潮的常用药品是', ['胰岛素制剂', '抗心绞痛药', '滴眼剂', '抗肿瘤药', '助消化药'], ['5'], '1、4'),\n",
       " ('与他汀类联用仅用于混合型血脂异常患者需降低胆固醇和三酰甘油时的药物是',\n",
       "  ['吉非贝齐', '藻酸双酯钠', '非诺贝特', '维生素E', '依折麦布'],\n",
       "  ['3'],\n",
       "  '依折麦布'),\n",
       " ('胺碘酮的典型不良反应①光敏反应，治疗期间避免暴露于阳光下②肺纤维化③血糖升高④甲状腺功能减退⑤甲状腺功能亢进',\n",
       "  ['①②④⑤', '①③⑤', '②④⑤', '③④⑤', '①②③④'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('第一个上市的血管紧张素Ⅱ受体拮抗剂是', ['氯沙坦', '氟伐他汀', '利血平', '氯贝丁酯', '卡托普利'], ['1'], ''),\n",
       " ('肌注硫酸镁用于', ['便秘', '妊娠高血压', '急性皮炎', '经尿道行前列腺切除术', '水肿'], ['2'], ''),\n",
       " ('氨茶碱的化学结构为',\n",
       "  ['[图00521.png]',\n",
       "   '[图00522.png]',\n",
       "   '[图00523.png]',\n",
       "   '[图00524.png]',\n",
       "   '[图00525.png]'],\n",
       "  ['2'],\n",
       "  '[图00521.png]'),\n",
       " ('初步的临床药理学及人体安全性评价',\n",
       "  ['Ⅰ期临床试验', 'Ⅱ期临床试验', 'Ⅲ期临床试验', 'Ⅳ期临床试验', 'Ⅴ期临床试验'],\n",
       "  ['1'],\n",
       "  'I期、II期和III期的结合'),\n",
       " ('肾小管中，弱酸在酸性尿液中是',\n",
       "  ['解离多，重吸收少，排泄快',\n",
       "   '解离少，重吸收多，排泄慢',\n",
       "   '解离多，重吸收少，排泄慢',\n",
       "   '解离少，重吸收少，排泄快',\n",
       "   '解离多，重吸收多，排泄快'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('关于可乐定，正确的描述是',\n",
       "  ['属中枢α<SUB>1</SUB>肾上腺素受体激动剂',\n",
       "   '属外周α<SUB>1</SUB>肾上腺素受体激动剂',\n",
       "   '属中枢α<SUB>2</SUB>肾上腺素受体激动剂',\n",
       "   '属外周α<SUB>2</SUB>肾上腺素受体激动剂',\n",
       "   '属中枢α<SUB>2</SUB>肾上腺素受体阻断剂'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('眼药后应保持上身自立的药物是', ['阿仑磷酸钠', '去氮加压素', '硫酸亚铁', '阿莫西林', '辛伐他汀'], ['1'], 'A'),\n",
       " ('糖皮质激素禁用于创伤修复期患者是因为（）',\n",
       "  ['抑制蛋白质合成', '抑制免疫功能只抗炎不抗菌', '兴奋中枢神经系统', '促进胃酸分泌', '水钠潴留'],\n",
       "  ['1'],\n",
       "  'D'),\n",
       " ('欲使血药浓度迅速达到稳态，可采取的给药方式是',\n",
       "  ['首先静脉注射一个负荷剂量，然后恒速静脉滴注', '单次静脉注射给药', '多次静脉注射给药', '单次口服给药', '多次口服给药'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('理性评判\"服用膳食补充剂\"的意见是。',\n",
       "  ['获取营养素最简单有效的途径是合理饮食',\n",
       "   '孕妇、绝经后女性及骨质疏松患者可适当选服钙剂',\n",
       "   '消化功能差、创伤及手术后患者可适当选服蛋白质(氨基酸类)',\n",
       "   '饮食不规律者、多数孕妇、老年人和儿童可适当选服复合维生素',\n",
       "   '不建议慢性病且需长期药物治疗的患者擅自添加多种膳食补充剂'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('下列哪项与可待因的结构描述不符',\n",
       "  ['含N-甲基哌啶', '含呋喃环', '含酚羟基', '含醇羟基', '药用磷酸盐'],\n",
       "  ['3'],\n",
       "  '不含酚羟基'),\n",
       " ('属于氧青霉烷类的β-内酰胺酶不可逆抑制剂是',\n",
       "  ['[2KY101461.png]',\n",
       "   '[2KY101462.png]',\n",
       "   '[2KY101463.png]',\n",
       "   '[2KY101464.png]',\n",
       "   '[2KY101465.png]'],\n",
       "  ['5'],\n",
       "  '[2KY101462.png]'),\n",
       " ('非经典抗精神病药利培酮[2016ZT00057.png]的活性代谢物是',\n",
       "  ['[2016ZT00058.png]',\n",
       "   '[2016ZT00059.png]',\n",
       "   '[2016ZT00060.png]',\n",
       "   '[2016ZT00061.png]',\n",
       "   '[2016ZT00062.png]'],\n",
       "  ['4'],\n",
       "  '无'),\n",
       " ('生物等效性的哪一种说法是正确的',\n",
       "  ['两种产品在吸收的速度上没有差别',\n",
       "   '两种产品在吸收程度上没有差别',\n",
       "   '两种产品在吸收程度与速度上没有差别',\n",
       "   '两种产品在消除时间上没有差别',\n",
       "   '在相同实验条件下，一种药物的不同制剂，它们吸收速度与程度没有显著差别'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('化学刺激所致腹泻可选用的药物是', ['胰酶', '黄连素', '胃蛋白酶', '乳酶生', '双八面体蒙脱石'], ['5'], 'D'),\n",
       " ('服用异烟肼，慢乙酰化型患者比快乙酰化型患者更易发生',\n",
       "  ['急性肾小管坏死', '溶血性贫血', '系统性红斑狼疮', '血管炎', '周围神经炎'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('该患者最可能的诊断是', ['支气管哮喘', '大叶性肺炎', '急性左心衰竭', '急性心肌炎', '肺栓塞'], ['3'], '无法判断'),\n",
       " ('可以酸化尿液,用于代谢性碱中毒的药品是', ['氯化钾', '乳酸钠', '谷氨酸', '硫酸镁', '氯化铵'], ['5'], 'B'),\n",
       " ('糖皮质激素免疫抑制作用的机制是',\n",
       "  ['抑制巨噬细胞吞噬功能', '稳定溶酶体膜', '增强心肌收缩力', '使细胞内cAMP明显升高', '直接扩张支气管平滑肌'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('金刚烷胺适宜的服药时间是', ['清晨', '餐前', '餐中', '餐后', '睡前'], ['5'], '1. 清晨'),\n",
       " ('妊娠期妇女用药应该格外谨慎，在不同孕期药物对胚胎和胎儿的影响不同，一般情况下，用药后不会出现畸形胎儿的时间是在受精后',\n",
       "  ['18天之内', '21天之内', '28天之内', '3个月之后', '6个月之后'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('由于药物的治疗作用所引起的不良后果，又称治疗矛盾的是',\n",
       "  ['副作用', '继发性反应', 'A型不良反应', 'B型不良反应', 'C型不良反应'],\n",
       "  ['2'],\n",
       "  '无正确答案'),\n",
       " ('属于去极化神经肌肉阻断剂以及胆碱酯酶抑制剂的驱肠虫药是',\n",
       "  ['左旋咪唑', '噻苯达唑', '噻嘧啶', '乙胺嗪', '吡喹酮'],\n",
       "  ['3'],\n",
       "  '乙胺嗪'),\n",
       " ('药源性疾病的缩写为', ['PV', 'ADR', 'DUI', 'ADE', 'DID'], ['5'], 'ADR'),\n",
       " ('老年糖尿病患者宜选用的药物是', ['阿卡波糖', '二甲双胍', '罗格列酮', '格列喹酮', '胰岛素'], ['1'], ''),\n",
       " ('溴己新',\n",
       "  ['[图00561.png]',\n",
       "   '[图00562.png]',\n",
       "   '[图00563.png]',\n",
       "   '[图00564.png]',\n",
       "   '[图00565.png]'],\n",
       "  ['1'],\n",
       "  '[图00561.png]'),\n",
       " ('欧洲药典', ['JP', 'USP', 'BP', 'ChP', 'Ph.Eur.'], ['5'], 'Ph. Eur'),\n",
       " ('严重肾病患者服用呋喃妥因，容易导致', ['肾盂肾炎', '膀胱炎', '周围神经炎', '前列腺炎', '尿路炎症'], ['3'], 'D'),\n",
       " ('《中国药学文摘》属于', ['一级信息源', '二级信息源', '三级信息源', '原始信息源', '学术专著'], ['2'], '一级信息源'),\n",
       " ('药物与受体结合，作用力最强的键合形式是', ['共价键', '氢键', '范德华力', '静电引力', '偶极-偶极作用'], ['1'], ''),\n",
       " ('上消化道出血者常见', ['柏油样粪便', '白陶土状粪便', '稀糊状粪便', '脓血样粪便', '鲜血样粪便'], ['1'], '1、2'),\n",
       " ('能减轻眼部平滑肌及血管痉挛，改善局部微循环的药物是',\n",
       "  ['玻璃酸钠滴眼液', '羟甲基纤维素钠滴眼液', '七叶洋地黄双苷滴眼液', '聚乙烯醇滴眼液', '山莨菪碱滴眼液'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('可用于纠正细胞内缺钾的是', ['胰岛素', '格列喹酮', '瑞格列奈', '阿卡波糖', '二甲双胍'], ['1'], 'A'),\n",
       " ('泡腾片的崩解时限是', ['3min', '5min', '15min', '30min', '60min'], ['2'], 'B'),\n",
       " ('可以是前瞻性研究，也可以是回顾性研究的是',\n",
       "  ['描述性研究', '分析性研究', '实验性研究', '队列研究', '病例对照研究'],\n",
       "  ['4'],\n",
       "  '1、5'),\n",
       " ('结构中含有苯基丙酸的是', ['对乙酰氨基酚', '阿司匹林', '布洛芬', '吡罗昔康', '双氯芬酸'], ['3'], 'B'),\n",
       " ('快速静脉滴注克林霉素，可引起的典型药源性疾病是',\n",
       "  ['粒细胞减少症', '消化性溃疡', '慢性肾衰竭', '溶血性贫血', '呼吸抑制'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('人体中，心房以β<sub>1</sub>受体为主，但同时含有四分之一的β<sub>2</sub>受体，肺组织β<sub>1</sub>和β<sub>2</sub>之比为3:7，根据β受体分布并结合受体作用情况，下列说法正确的是（\\u3000）。',\n",
       "  ['非选择性β受体阻断药，具有较强抑制心肌收缩力作用，同时具有引起支气管痉挛及哮喘的副作用',\n",
       "   '选择性β<sub>1</sub>受体阻断药，具有较强的增强心肌收缩力作用，临床可用于强心和抗休克',\n",
       "   '选择性β<sub>2</sub>受体阻断药，具有较强的抑制心肌收缩力作用，同时具有引起体位性低血压的副作用',\n",
       "   '选择性β<sub>1</sub>受体激动药，具有较强扩张支气管作用，可用于平喘和改善微循环',\n",
       "   '选择性β<sub>2</sub>受体激动药，比同时作用α和β受体的激动药具有更强的收缩外周血管作用，可用于抗休克'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('《中国药典》（2015年版）规定，试验时的温度，未注明者，系指在室温下进行；温度对实验结果有显著影响者，除另有规定外，应以下列哪一个温度为准',\n",
       "  ['20℃', '20℃±2℃', '25℃', '20～30℃', '25℃±2℃'],\n",
       "  ['5'],\n",
       "  '20℃'),\n",
       " ('由促进某些微生物生长引起的不良反应属于',\n",
       "  ['A类反应', 'B类反应', 'C类反应', 'D类反应', 'E类反应'],\n",
       "  ['2'],\n",
       "  'D类反应'),\n",
       " ('碳酸氢钠可以使以下哪种药物疗效降低', ['链霉素', '庆大霉素', '乌洛托品', '卡那霉素', '奈替米星'], ['3'], '1, 2'),\n",
       " ('一般来说要求W/O型乳剂型软膏基质的pH不大于', ['0.7', '7.5', '8.0', '8.5', '6.5'], ['3'], 'B'),\n",
       " ('静脉注射给药，初始药量为60mg，若初始血药浓度为15ug/ml，其表观分布容积为',\n",
       "  ['4ml', '4L', '20L', '15L', '400ml'],\n",
       "  ['2'],\n",
       "  'C'),\n",
       " ('通过改善给药方案可显著减少不良反应，但目前仍需注意的高血钾、干咳的药物是',\n",
       "  ['米诺地尔', '普萘洛尔', '肼屈嗪', '哌唑嗪', '依那普利'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('避免胆汁过度分泌和腹泻的是',\n",
       "  ['服用脂溶性维生素', '艾滋病“鸡尾酒疗法”服用蛋白酶抑制剂', '茶叶中的成分', '食醋', '服用利胆药时应尽量多饮水'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('阿托品+碘解磷定治疗有机磷酸酯类中毒属于',\n",
       "  ['提高药物疗效', '减少不良反应', '治疗多种疾病', '延缓细菌耐药性的产生\\n', '促进机体利用'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('a-受体阻断剂的禁忌证是',\n",
       "  ['2～3度房室传导阻滞', '痛风', '体位性低血压', '双侧肾动脉狭窄', '低钾血症'],\n",
       "  ['3'],\n",
       "  '1、2、4'),\n",
       " ('关于壬二酸的代谢动力学说法正确的是',\n",
       "  ['pH高时具有较高抗菌活性',\n",
       "   '渗透到异常细胞的药量与正常细胞同样多',\n",
       "   '可抑制蛋白质的合成、降低色素沉着和减小黑斑病损伤',\n",
       "   '能不可逆性地抑制主要酶的活性',\n",
       "   '对重度痤疮者有较好的疗效'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('关于苯妥英钠药效学、药动学特征的说法，正确的是',\n",
       "  ['随着给药剂量增加，药物消除可能会明显减慢，会引起血药浓度明显增加',\n",
       "   '笨妥英钠在临床上不属于治疗窗窄的药物，无需监测其血药浓度',\n",
       "   '苯妥英钠的安全浓度范围较大，使用时较为安全',\n",
       "   '制订苯妥类钠给药方案时，只需要根据半衰期制订给药间隔.',\n",
       "   '可以根据小剂量时的动力学参数预测高剂量的血药浓度'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('缓解轻、中度急性哮喘症状的首选药是（）',\n",
       "  ['沙丁胺醇', '异丙托溴铵', '孟鲁司特', '噻托溴铵', '糖皮质激素'],\n",
       "  ['1'],\n",
       "  '1. 沙丁胺醇'),\n",
       " ('血糖正常、尿葡萄糖阳性可以提示患者可能。',\n",
       "  ['伴心肌梗死', '伴肾性肾小球肾炎', '伴甲状腺功能亢进', '伴活动性指端肥大症', '伴肾上腺皮质功能亢进'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('服用丙磺舒期间除保持摄入足量水，适当补充碳酸氢钠外，防止形成肾结石，必要时同时服用（）',\n",
       "  ['枸橼酸钾', '秋水仙碱', '维生素B6', '布洛芬', '维生素B12'],\n",
       "  ['1'],\n",
       "  '1. 枸橼酸钾'),\n",
       " ('对X药的p',\n",
       "  ['X药拮抗作用强于Y药',\n",
       "   'X药拮抗作用弱于Y药',\n",
       "   'X药拮抗作用等于Y药',\n",
       "   'X药拮抗作用不一定等于Y药',\n",
       "   '无法根据pA<SUB>2</SUB>判断X药和Y药的拮抗强度'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('阻止疟原虫在蚊体内的孢子增殖，控制传播的药物', ['氯喹', '青蒿素', '奎宁', '伯氨喹', '乙胺嘧啶'], ['5'], '青蒿素'),\n",
       " ('速释制剂', ['膜剂', '气雾剂', '软膏剂', '栓剂', '缓释片'], ['2'], 'B'),\n",
       " ('结构中6、7位氧环，有较强中枢作用的药物是',\n",
       "  ['东莨菪碱', '山莨菪碱', '丁溴东莨菪碱', '噻托溴铵', '阿托品'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('该患者的降压目标值是',\n",
       "  ['150/100mmHg  ',\n",
       "   '140/80mmHg  ',\n",
       "   '140/90mmHg  ',\n",
       "   '130/80mmHg  ',\n",
       "   '130/90mmHg'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('高血压伴前列腺增生患者适宜选用的药物是', ['硝苯地平', '卡托普利', '氢氯噻嗪', '普萘洛尔', '特拉唑嗪'], ['5'], ''),\n",
       " ('下列保肝药中，对于高血压患者应慎用的是',\n",
       "  ['复方甘草酸苷', '还原型谷胱甘肽', '多烯磷脂酰胆碱', '门冬氨酸钾镁', '联苯双酯'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('属于回顾性研究的是', ['描述性研究', '分析性研究', '实验性研究', '队列研究', '病例对照研究'], ['5'], 'B'),\n",
       " ('抗酸药物不能作为治疗消化性溃疡的首选药，是因为',\n",
       "  ['不能缓解反酸、胃痛等症状', '能引起胃酸分泌增多', '不良反应较多', '不能抑制胃酸分泌', '起效缓慢'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('滴虫性阴道炎患者表现为',\n",
       "  ['白带呈奶酪或豆腐渣样',\n",
       "   '白带呈泡沫状',\n",
       "   '白带呈灰色或灰绿色，面糊状黏稠，可有气泡',\n",
       "   '白带呈白色、黏稠、无臭',\n",
       "   '白带无色透明，略带腥味'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('泮托拉唑用于治疗胃十二指肠溃疡的顿服剂量是',\n",
       "  ['20mg', '40mg', '80mg', '120mg', '160mg'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('属于弱效的糖皮质激素是', ['醋酸曲安奈德', '醋酸氢化可的松', '二丙酸倍氯米松', '氟轻松', '卤米松'], ['2'], 'B'),\n",
       " ('该患者因近日在浇花时出现心悸和手指轻微震颤而就诊。体格检查：T36.8度，P120次/min，R28次/min，BP175/90mmgh。出现上述症状的可能原因是',\n",
       "  ['布地奈德剂量太大', '沙丁胺醇的不良反应', '氨氯地平的不良反应', '硝酸甘油剂量不足', '布地奈德的不良反应'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('单室模型的药物恒速静脉滴注3个半衰期，血药浓度为达稳态时的',\n",
       "  ['50%', '75%', '88%', '90%', '95%'],\n",
       "  ['3'],\n",
       "  'D'),\n",
       " ('高警示药品（旧称高危药品）是指药理作用显著且迅速、一旦使用不当可对人体造成严重伤害，甚至导致死亡的药品。《我国高警示药品推荐目录 （2015版）》中，属于美国用药安全研究所（ISMP）高警示药品目录的是',\n",
       "  ['异维A酸片', '氨茶碱注射液', '5mg/ml的阿托品注射液', '凝血酶冻干粉', '口服降糖药'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('容许新药研究者使用微剂量（一般不大于100μg）、在少量受试者（6人左右）进行药物试验。目的是评价药物的安全性和药动学特征，降低新药研究风险，提高新药研究开发命中率的是',\n",
       "  ['毒理学研究', 'I期临床试验日', 'Ⅲ期临床试验', 'IV期临床试验', '0期临床试验'],\n",
       "  ['5'],\n",
       "  'Ⅱ期临床试验'),\n",
       " ('患者的肝功能严重不足时，不能使用', ['可的松', '苯妥英钠', '利多卡因', '卡托普利', '奎尼丁'], ['1'], '2、3和5'),\n",
       " ('痛风急性发作期应禁用的药物', ['碳酸氢钠', '别嘌醇', '秋水仙碱', '布洛芬', '吲哚美辛'], ['2'], 'A'),\n",
       " ('以生活质量调整年表示结果的药物经济学研究方法是',\n",
       "  ['最小成本分析', '成本效果分析', '成本效益分析', '成本效用分析', '成本分析'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('卡马西平属于第Ⅱ类，是低水溶性、高渗透性的亲脂性药物，其体内吸收取决于',\n",
       "  ['渗透效率', '溶解速率', '胃排空速度', '解离度', '酸碱度'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('重复用药后，机体对药物的反应性逐渐减弱的现象，称为',\n",
       "  ['继发反应', '耐受性', '耐药性', '特异质反应', '药物依赖性'],\n",
       "  ['2'],\n",
       "  '耐药性'),\n",
       " ('关于静脉滴注两性霉素B注意事项的叙述，不正确的是',\n",
       "  ['需先用注射用水配制，再稀释',\n",
       "   '需用0.9%氯化钠注射液作为溶媒',\n",
       "   '滴注液的浓度不超过10mg/100ml',\n",
       "   '一次滴注时间需6h以上',\n",
       "   '血钾浓度'],\n",
       "  ['2'],\n",
       "  'C'),\n",
       " ('下列关于完全激动药描述正确的是',\n",
       "  ['对受体有很高的亲和力',\n",
       "   '对受体的内在活性α=0',\n",
       "   '加大剂量可因为占据受体而出现拮抗效应',\n",
       "   '随着加入的竞争性拮抗药剂量的增加，完全激动药量一效曲线平行左移',\n",
       "   '喷他佐辛是完全激动药'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('有一肺炎球菌感染患者，对青霉素过敏，宜选用的有效抗菌药物是',\n",
       "  ['阿米卡星', '阿莫西林', '左氧氟沙星', '多西环素', '头孢氨苄'],\n",
       "  ['3'],\n",
       "  '1. 阿米卡星'),\n",
       " ('苯唑西林的生物半衰期t1/2=0.5h，其30%原形药物经肾排泄，且肾排泄的主要机制是肾小球滤过和肾小球分泌，其余大部分经肝代谢消除，对肝肾功能正常的病人，该药物的肝清除速率常数是',\n",
       "  ['4.62h-1', '0.97h-1', '1.98h-1', '1.39h-1', '0.42h-1'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('肾功能不全患者宜选用的药物是',\n",
       "  ['经肝肠循环消除的药物', '肾毒性小、经肝代谢的药物', '肝毒性小、经肾代谢的药物', '经肝肾双途径消除的药物', '经首关作用消除的药物'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('新药临床评价分期，治疗作用的初步评价阶段，初步评价药物对目标适应证患者的治疗作用和安全性，为给药剂量方案的确定提供依据，试验对象是目标适应证患者，属于',\n",
       "  ['I期临床试验', 'II期临床试验', 'III期临床试验', 'IV期临床试验', 'V期临床试验'],\n",
       "  ['2'],\n",
       "  'II期临床试验'),\n",
       " ('大剂量服用维生素C的同时应注意补充',\n",
       "  ['维生素C+维生素B', '叶酸+维生素B12', '维生素B2+维生素C', '维生素K+维生素B', '维生素A+叶酸'],\n",
       "  ['5'],\n",
       "  '无特殊注意事项'),\n",
       " ('《化学文摘》的英文缩写为', ['BA', 'IM', 'EM', 'CA', 'IPA'], ['4'], 'CA'),\n",
       " ('丙烯醵树脂Ⅲ号为药用辅料，在片剂中的主要用途为',\n",
       "  ['胃溶包衣材料', '肠胃都溶型包衣材料', '肠溶包衣材料', '糖包衣材料', '水溶衣材料'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('下列关于固体分散体的叙述正确的是',\n",
       "  ['药物与稀释剂混合制成的固体分散体系',\n",
       "   '药物高度分散于载体中制成的微球制剂',\n",
       "   '药物包裹于载体中制成的固体分散体系',\n",
       "   '药物与载体形成的物理混合物，能使熔点降低者',\n",
       "   '药物与载体混合制成的高度分散的固体分散体系'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('脂溶性维生素吸收减少，是由于',\n",
       "  ['胆汁分泌缺乏',\n",
       "   '肾功能随年龄增长而减退',\n",
       "   '肝药酶活性的个体化差异影响大于年龄的增长',\n",
       "   '脂肪组织随年龄增长而增加，血浆白蛋白浓度降低',\n",
       "   '肝血流量减少，功能性肝细胞数量减少，肝微粒体酶系活性降低'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('具有吡咯烷并环戊烷取代基的降血糖药是',\n",
       "  ['[2KY101341.png]',\n",
       "   '[2KY101342.png]',\n",
       "   '[2KY101343.png]',\n",
       "   '[2KY101344.png]',\n",
       "   '[2KY101345.png]'],\n",
       "  ['1'],\n",
       "  '[2KY101341.png]'),\n",
       " ('片剂制备中，物料的塑性较差会造成', ['松片', '裂片', '溶出超限', '崩解迟缓', '含量不均匀'], ['2'], 'B'),\n",
       " ('多黏菌素B的抗菌机制是',\n",
       "  ['影响叶酸代谢', '影响胞浆膜的通透性', '抑制细菌细胞壁的合成', '抑制蛋白质合成的全过程', '抑制核酸合成'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('不能作为药用溶剂的是', ['水', '丙二醇', '甘油', '花生油', '月桂醇硫酸钠'], ['5'], '花生油'),\n",
       " ('以下数据中，血清白蛋白（',\n",
       "  ['＞1', '1.5︰1', '2.0︰1', '2.5︰1', '1.5︰1～2.5︰1'],\n",
       "  ['5'],\n",
       "  'A'),\n",
       " ('渗透泵片常用的渗透压促进剂是', ['醋酸纤维素', 'PVP', '聚乙烯', '甲醇', '无机酸盐类'], ['5'], 'B'),\n",
       " ('我国药品不良反应监测中心所采用的', ['肯定', '可能', '可疑', '可能无关', '很可能'], ['3'], 'B'),\n",
       " ('[图0012.png]',\n",
       "  ['单室模型静脉注射血药浓度与时间的方程',\n",
       "   '单室模型静脉滴注血药浓度与时间的方程',\n",
       "   '单室模型静脉注射血药浓度-时间曲线下面积',\n",
       "   '双室模型静脉注射血药浓度与时间的方程',\n",
       "   '单室模型静脉滴注的稳态血药浓度方程'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('在应用最小成本分析法分析几种药物治疗方案前，须首先比较',\n",
       "  ['患者特征', '非医疗开支', '治疗结果', '间接成本', '隐性成本'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('成本效益分析的英文缩写是', ['CUA', 'CMA', 'CBA', 'CEA', 'CEO'], ['3'], 'CUA'),\n",
       " ('每1IU青霉素G钠相当于',\n",
       "  ['0.25μg', '0.344μg', '0.6μg', '0.6329μg', '1μg'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('可渗透过甲板用于角化增厚型的抗真菌药是(\\u3000)。',\n",
       "  ['联苯苄唑', '益康唑', '特比萘芬', '克霉唑', '环吡酮胺'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('给某患者静脉注射一单室模型药物，剂量为100.0mg，测得不同时刻给药浓度数据如下表，外推出浓度为11.55μg/ml。该药物的表观分布容积（单位：L）是',\n",
       "  ['0.2303', '0.3465', '2.0', '3.072', '8.42'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('蛋白质和多肽的吸收具有一定的部位特异性，其主要吸收方式是',\n",
       "  ['膜动转运', '简单扩散', '主动转运', '滤过', '易化扩散'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('加巴喷丁属于', ['巴比妥类', '乙内酰脲类', '苯二氮卓类', '二苯并氮卓类', 'γ- GABA类似物'], ['5'], ''),\n",
       " ('关于口崩片质量要求的说法中，错误的是',\n",
       "  ['应在口腔内迅速崩解或溶散',\n",
       "   '对口腔黏膜无刺激性',\n",
       "   '应进行崩解时限检查',\n",
       "   '冻干口崩片必须进行片剂脆碎度检查',\n",
       "   '难溶性药物制成的口崩片，还应进行溶出度检查'],\n",
       "  ['4'],\n",
       "  '无'),\n",
       " ('头孢菌素注射剂作为皮肤过敏试验的浓度是',\n",
       "  ['100μg/mL', '250μg/mL', '500μg/mL', '750μg/mL', '1000μg/mL'],\n",
       "  ['3'],\n",
       "  '无特异性抗体'),\n",
       " ('初步药效学评价试验是', ['Ⅰ期临床试验', 'Ⅱ期临床试验', 'Ⅲ期临床试验', 'Ⅳ期临床试验', '动物实验'], ['2'], ''),\n",
       " ('患者，女，52岁，患有胃溃疡，处方书写为奥美拉唑肠溶胶囊20mg/粒×7 1粒/次 po qd。根据处方，药师应交代患者每天服药次数为',\n",
       "  ['1次', '2次', '3次', '4次', '5次'],\n",
       "  ['1'],\n",
       "  'qd（每日一次）'),\n",
       " ('使用3～4日症状未缓解时，应停药就医的是',\n",
       "  ['红霉素眼膏', '金霉素眼膏', '酞丁安滴眼剂', '硫酸锌滴眼剂', '磺胺醋酰钠滴眼剂'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('某药物以一级速率消除，半衰期为2小时，静脉给药4小时后其体内药量为最初的',\n",
       "  ['1/2', '1/4', '1/6', '1/8', '1/16'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('药物利用和研究评价是',\n",
       "  ['对全社会的药品市场、供给、处方及其使用进行研究，目的就是用药合理化',\n",
       "   '在治疗过程中为患者争取最好的治疗结果，为患者提高全程化的药学服务',\n",
       "   '建立在及时掌握大量、最新的药物信息基础上',\n",
       "   '在药代动力学原理指导下，利用现代先进的分析技术进行TDM，与临床医师一起制定和调整合理的个体化用药方案',\n",
       "   '把分散的不良反应病例资料汇集起来，进行因果关系的分析和评价'],\n",
       "  ['1'],\n",
       "  'D'),\n",
       " ('为有助食物消化，应餐前服用的是', ['维生素C', '二甲双胍', '多潘立酮', '普伐他汀', '米索前列醇'], ['3'], '多潘立酮'),\n",
       " ('配制注射液时除热原可采用',\n",
       "  ['高温法', '酸碱法', '吸附法', '微孔滤膜过滤法', '离子交换法'],\n",
       "  ['3'],\n",
       "  '4微孔滤膜过滤法'),\n",
       " ('最适合作为增溶剂的HLB值是',\n",
       "  ['HLB值在1～3', 'HLB值在3～8', 'HLB值在7～9', 'HLB值在8～18', 'HLB值在13～18'],\n",
       "  ['5'],\n",
       "  'HB'),\n",
       " ('\"用药错误\"I级(9级)的标准。',\n",
       "  ['差错导致患者死亡',\n",
       "   '差错导致患者永久性伤害',\n",
       "   '客观环境或条件可能引发差错',\n",
       "   '发生差错但未发给患者，或已发给患者但未使用',\n",
       "   '差错导致患者生命垂危，需要应用维持生命的措施'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('复方的外文缩写是', ['Co', 'H', 'q.n', 'SOS', 'St'], ['1'], 'C'),\n",
       " ('乙酰胆碱可激活M胆碱受体，M受体为',\n",
       "  ['G蛋白偶联受体', '配体门控的离子通道受体', '酪氨酸激酶受体', '非酪氨酸激酶受体', '细胞核激素受体'],\n",
       "  ['1'],\n",
       "  ' M受体属于G蛋白偶联受体'),\n",
       " ('二氢吡啶环上，3、5位取代基均为甲酸甲酯的药物是',\n",
       "  ['尼莫地平', '尼卡地平', '硝苯地平', '尼群地平', '氨氯地平'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('适宜餐前服用的药品是',\n",
       "  ['泼尼松龙', '奥利司他', '氟伐他汀', '多潘立酮', '吲哚美辛等非甾体抗炎药'],\n",
       "  ['4'],\n",
       "  '多潘立酮'),\n",
       " ('关于\"医嘱清楚准确\"的表述中，下述错误的是',\n",
       "  ['写“每天1次”而不写“qd.”',\n",
       "   '使用剂型单位（如“1片”或“1瓶”）而不写精确的药物剂量单位（如“mg”）',\n",
       "   '不使用不清楚的用法说明，如“按说明书服用”',\n",
       "   '按照标准命名法开具药方，使用药物的通用名，可注明商品名',\n",
       "   '在小数表达时使用引导零（如0.5ml），而不使用末尾零（如5.0ml）'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('强心苷类药停用几天内禁止使用氯化钙', ['3', '5', '7', '10', '12'], ['3'], 'B'),\n",
       " ('不受专利和行政保护，是所有文献、资料、教材以及药品说明书中使用的名称是',\n",
       "  ['商品名', '通用名', '俗名', '化学名', '品牌名'],\n",
       "  ['2'],\n",
       "  '通用名'),\n",
       " ('首次用药可出现\"首剂现象\"的药物是', ['依那普利', '哌唑嗪', '氨氯地平', '硝酸甘油', '拉贝洛尔'], ['2'], ''),\n",
       " ('应用华法林抗凝治疗时，INR安全有效范围为血栓性疾病患者实施抗凝治疗，应该控制国际标准化比值为',\n",
       "  ['＜2.0', '＞3.0', '2.0～3.0', '2.0～2.5', '0.8～2.0'],\n",
       "  ['3'],\n",
       "  '2.0~3.0'),\n",
       " ('安全界限',\n",
       "  ['LD50', 'ED50', 'LD50/ED50', 'LD1/ED99', 'LD5/ED95'],\n",
       "  ['4'],\n",
       "  'LD5/ED95'),\n",
       " ('可对抗动脉粥样硬化的脂蛋白是',\n",
       "  ['总胆固醇', '三酰甘油', '低密度脂蛋白胆固醇', '极低密度脂蛋白胆固醇', '高密度脂蛋白胆固醇'],\n",
       "  ['5'],\n",
       "  '高密度脂蛋白胆固醇'),\n",
       " ('水杨酸类、磺胺类等药物同服碳酸氢钠或服用抗酸分泌的H，受体拮抗剂及质子泵抑制剂药奥美拉唑等，都将减少这些弱酸性药物的吸收，属于',\n",
       "  ['pH的影响', '离子作用', '胃肠运动的影响', '肠吸收功能影响', '间接作用'],\n",
       "  ['1'],\n",
       "  'pH的影响'),\n",
       " ('以质量调整为生命年或者质量调整为预期寿命为量化指标开展的药物经济学评价方法属于',\n",
       "  ['成本-效益分析', '成本-效果分析', '最小成本分析', '成本-效用分析', '荟萃分析'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('静脉注射某药，X0=60mg，若初始血药浓度为15μg/ml，其表观分布容积V为',\n",
       "  ['20L', '4ml', '30L', '4L', '15L'],\n",
       "  ['4'],\n",
       "  '无法计算'),\n",
       " ('抑制细胞内碳酸酐酶的是', ['呋塞米', '吲达帕胺', '乙酰唑胺', '氨苯蝶啶', '其他类'], ['3'], 'C'),\n",
       " ('脂水分配系数的表示方式是。', ['lgP', 'pKa', 'pA2', 'pD2', 'α'], ['1'], 'lgP'),\n",
       " ('使用糖皮质激素气雾剂治疗慢性哮喘，需要连续使用',\n",
       "  ['3个月', '6个月', '12个月', '18个月', '24个月'],\n",
       "  ['5'],\n",
       "  '无固定时间'),\n",
       " ('下图为',\n",
       "  ['A为非竞争性拮抗药，B为竞争性拮抗药',\n",
       "   'A为竞争性拮抗药，B为非竞争性拮抗药',\n",
       "   'A和B皆为竞争性拮抗药',\n",
       "   'A和B皆为非竞争性拮抗药',\n",
       "   '无法判断A和B为何种拮抗药'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('药品储存按质量状态实行色标管理，合格药品为', ['红色', '白色', '绿色', '黄色', '黑色'], ['3'], '绿'),\n",
       " ('单室模型静脉注射给药，血药浓度与时间的关系式是',\n",
       "  ['C=C0e-kt',\n",
       "   '-dCdt=Vm.C/（Km+C）',\n",
       "   'C=k0（1-e-kt）/kV',\n",
       "   'dXu/dt=ke.X0e-kt',\n",
       "   'C=ka.FX0（e-kt-e-knt）/V（ka-k）'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('布洛芬口服混悬剂处方中用作助悬剂的物质是', ['布洛芬', '羟丙甲纤维素', '山梨醇', '甘油', '枸橼酸'], ['2'], '山梨醇'),\n",
       " ('植人人体的医疗器械和一次性医疗用品的基本质量特性是',\n",
       "  ['无菌', '有效性', '实用性', '生物相容性', '无菌和生物相容性'],\n",
       "  ['5'],\n",
       "  '无'),\n",
       " ('抗结核药物异烟肼结构中含有未取代的酰肼基，体内易发生N-乙酰化生成无活性代谢产物，根据此结构特点推测异烟肼的结构是',\n",
       "  ['[图00821.png]',\n",
       "   '[图00822.png]',\n",
       "   '[图00823.png]',\n",
       "   '[图00824.png]',\n",
       "   '[图00825.png]'],\n",
       "  ['3'],\n",
       "  '[图00821.png]'),\n",
       " ('磺胺类利尿药和碳酸酐酶结合是通过', ['氢键', '疏水性相互作用', '电荷转移复合物', '范德华引力', '共价键'], ['1'], ''),\n",
       " ('\"氨基糖苷类联用呋塞米导致肾、耳毒性增加\"显示药源性疾病的原因是',\n",
       "  ['药物相互作用', '药品质量', '病人因素', '剂量与疗程', '医疗技术因素'],\n",
       "  ['1'],\n",
       "  'A'),\n",
       " ('长期或大剂量使用质子泵抑制剂可导致的不良反应是',\n",
       "  ['髋骨、腕骨骨折', '血浆泌乳素升高', '呃逆、腹胀', '腹泻', '肝功能异常'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('根据质量可靠的随机对照试验后所作的Meta分析属于',\n",
       "  ['一级（Ⅰ级）', '二级（Ⅱ级）', '三级（Ⅲ级）', '四级（Ⅳ）', '五级（Ⅴ级）循证医学证据分类中'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('艾赛那肽属于糖尿病（）药物', ['一线治疗', '一线治疗备选路径', '二线治疗', '三线治疗', '四线治疗'], ['4'], ''),\n",
       " ('使用非甾体抗炎药治疗类风湿性关节炎时，为预防其胃肠副作用常并用',\n",
       "  ['钙剂', '维生素K', 'H<SUB>2</SUB>受体拮抗剂', '碱性药', '羟氨苄青霉素'],\n",
       "  ['3'],\n",
       "  'A'),\n",
       " ('西咪替丁',\n",
       "  ['[图00631.png]',\n",
       "   '[图00632.png]',\n",
       "   '[图00633.png]',\n",
       "   '[图00634.png]',\n",
       "   '[图00635.png]'],\n",
       "  ['2'],\n",
       "  '[图00631.png]'),\n",
       " ('可用VRT表示的是', ['零阶矩', '一阶矩', '二阶矩', '三阶矩', '四阶矩'], ['3'], ''),\n",
       " ('硝酸甘油的作用持续时间是', ['20～30min', '1～2h', '2～6h', '6～10h', '12h'], ['1'], ''),\n",
       " ('检验报告书编号由几位数构成', ['6位', '7位', '8位', '9位', '10位'], ['3'], '无法确定'),\n",
       " ('单室模型静脉注射给药，尿药排泄速度与时间的关系式是',\n",
       "  ['C=C0e-kt',\n",
       "   '-dCdt=Vm.C/（Km+C）',\n",
       "   'C=k0（1-e-kt）/kV',\n",
       "   'dXu/dt=ke.X0e-kt',\n",
       "   'C=ka.FX0（e-kt-e-knt）/V（ka-k）'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('以下治疗慢性阻塞性肺病的支气管平滑肌松弛剂当中，适宜用于急性发作的是。',\n",
       "  ['泼尼松', '酮替芬', '茶碱', '曲尼司特', '扎鲁司特'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('环磷酰胺毒性较小的原因是',\n",
       "  ['抗瘤谱广', '烷化作用小', '注射给药', '体内代谢快', '在正常组织中经酶代谢生成无毒代谢物'],\n",
       "  ['5'],\n",
       "  'C'),\n",
       " ('下列不同年龄的人群中，磺胺甲噁唑血浆半衰期最长的是', ['婴儿', '儿童', '青少年', '成人', '老年人'], ['5'], 'B'),\n",
       " ('以下关于铁剂使用注意事项的叙述，不正确的是',\n",
       "  ['口服制剂宜在餐后或餐时服用', '可使大便潜血试验阳性', '不应与浓茶同服', '老年患者应适当减少口服剂量', '铁剂缓释片应整片吞服'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('\"后遗效应\"的正确概念是',\n",
       "  ['即药物依赖性',\n",
       "   '患者个体差异、病理状态所引起的敏感性增加',\n",
       "   '如停用抗高血压药出现血压反跳、心悸、出汗',\n",
       "   '血药浓度达到最高限浓度以上、生物效应仍然不明显',\n",
       "   '血药浓度降至最低限浓度以下、生物效应仍然存在'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('请确定负荷剂量', ['0.92mg', '3.4mg', '117.3mg', '127.5mg', '255mg'], ['5'], 'B'),\n",
       " ('已知l％(g/ml)枸橼酸钠溶液的冰点降低值为0．185度，计算其等渗溶液的百分浓度是。',\n",
       "  ['2．81％(g／ml)', '2．85％(g／ml)', '2．91％(g／ml)', '2．95％(g／ml)', '2．98％(g／ml)'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('影响鼻黏膜给药的因素有',\n",
       "  ['药物的脂溶性和解离度，分子量和粒子大小，吸收促进剂的选择',\n",
       "   '局部血流量，溶媒的选择，分子量及脂溶性',\n",
       "   '药物的脂溶性和解离度，食物种类，不同剂型',\n",
       "   '基质的选择，药物在基质中释放的快慢',\n",
       "   '制剂的黏度，pH与渗透压及渗透促进剂的选择'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('头孢四代', ['头孢曲松', '头孢呋辛', '拉氧头孢', '头孢唑林', '头孢吡肟'], ['5'], ''),\n",
       " ('成年男性的肌酐清除率计算公式：Cer=（140-年龄）x体重/（0814xGr），成人女性的肌酐清除率为男性的085若该患者入院后查肾功能提示：血肌酐（Cr）120μmol/L，该患者的肌酐清除率约为',\n",
       "  ['70ml/min', '65ml/min', '55ml/min', '47ml/min', '45m/min'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('通过抑制胆碱酯酶活性，改善记忆和认知功能障碍的是',\n",
       "  ['吡拉西坦', '多奈哌齐', '胞磷胆碱钠', '银杏叶提取物', '艾地苯醌'],\n",
       "  ['2'],\n",
       "  '多奈哌齐'),\n",
       " ('有机磷农药中毒时，应用胆碱酯酶复活剂应注意：',\n",
       "  ['对有机磷慢性中毒患者（乙酰胆碱酯酶已老化）使用复活剂仍有效',\n",
       "   '对二嗪农、谷硫磷急性中毒效果良好',\n",
       "   '注射速度要快，以利于解救',\n",
       "   '与碱性药物配伍使用',\n",
       "   '切勿两种或三种复活剂同时应用，以免其毒性增加'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('代表药物在体内滞留的变异程度的是', ['零阶矩', '一阶矩', '二阶矩', '三阶矩', '四阶矩'], ['3'], '三阶矩'),\n",
       " ('高选择性α1', ['米多君', '奥昔布宁', '哌唑嗪', '非那雄胺', '坦索罗辛'], ['5'], 'A'),\n",
       " ('消除速率常数',\n",
       "  ['表示药物在体内分布的广泛性',\n",
       "   '用来衡量药物吸收速度的快慢',\n",
       "   '用来衡量药物从体内消除速度的快慢',\n",
       "   '用来衡量血管外给药时进入体循环药物的相对数量和速度',\n",
       "   '指血药浓度衰减一半时所需的时间'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('通过抑制疟原虫的二氢叶酸还原酶，阻碍核酸合成的药物是',\n",
       "  ['氯喹', '青霉素', '青蒿素', '伯氨喹', '乙胺嘧啶'],\n",
       "  ['5'],\n",
       "  'A'),\n",
       " ('山莨菪碱',\n",
       "  ['[图00641.png]',\n",
       "   '[图00642.png]',\n",
       "   '[图00643.png]',\n",
       "   '[图00644.png]',\n",
       "   '[图00645.png]'],\n",
       "  ['1'],\n",
       "  '[图00641.png]'),\n",
       " ('单模静脉滴注给药过程中，稳态血药浓度的计算公式是',\n",
       "  ['[2KY100601.png]',\n",
       "   '[2KY100602.png]',\n",
       "   '[2KY100603.png]',\n",
       "   '[2KY100604.png]',\n",
       "   '[2KY100605.png]'],\n",
       "  ['2'],\n",
       "  '[2KY100606.png]'),\n",
       " ('与普萘洛尔联用，可协同抗心绞痛，并消除心动过缓毒副作用的是',\n",
       "  ['美西律', '硝酸异山梨酯', '硝苯地平', '阿托品', '舒巴坦'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('A、B两种药物制剂的药物剂量－效应关系曲线比较见下图，对A药和B药的安全性分析，正确的是（\\u3000）。[图1]',\n",
       "  ['A药的治疗指数和安全范围大于B药',\n",
       "   'A药的治疗指数和安全范围小于B药',\n",
       "   'A药治疗指数大于B药，A药安全范围小于B药',\n",
       "   'A药治疗指数大于B药，A药安全范围等于B药',\n",
       "   'A药治疗指数等于B药，A药安全范围大于B药'],\n",
       "  ['5'],\n",
       "  '无法判断'),\n",
       " ('以健康受试者进行初步的临床药理学及人体安全性评价是指',\n",
       "  ['临床预试验', 'Ⅰ期临床试验', 'Ⅱ期临床试验', 'Ⅲ期临床试验', 'Ⅳ期临床试验'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('下列口服制剂的生物利用度大小顺序为',\n",
       "  ['溶液剂>包衣片>胶囊剂>片剂>混悬剂',\n",
       "   '溶液剂>混悬剂>片剂>胶囊剂>包衣片',\n",
       "   '溶液剂>混悬剂>胶囊剂>片剂>包衣片',\n",
       "   '溶液剂>胶囊剂>混悬剂>片剂>包衣片',\n",
       "   '溶液剂>混悬剂>包衣片>片剂>胶囊剂'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('患者，女，65岁，因\"反复咳嗽、咳痰10年，气喘2年，再发加重伴发热2天\"入院，多次因上述症状住院治疗，诊断为',\n",
       "  ['双氯西林', '苄星青霉素', '万古霉素', '阿莫西林', '羧苄西林'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('用药过程中，出现109题题干的不良反应，应采取的措施是',\n",
       "  ['停药，静脉注射50%葡萄糖注射液', '停药，注射胰岛素', '停药，使用抗心律失常药', '停药，使用抗癫痫药', '停药'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('属于5α还原酶抑制剂的是', ['他达拉非', '坦洛新', '度他雄胺', '西地那非', '十一酸睾酮'], ['3'], '1、3'),\n",
       " ('具有莨菪烷结构，属于M受体拮抗剂的平喘药是',\n",
       "  ['[YZ12017KDS1019.png]',\n",
       "   '[YZ12017KDS1020.png]',\n",
       "   '[YZ12017KDS1021.png]',\n",
       "   '[YZ12017KDS1022.png]',\n",
       "   '[YZ12017KDS1023.png]'],\n",
       "  ['3'],\n",
       "  '[YZ12017KDS1022.png]'),\n",
       " ('亚硝酸钠滴定法终点的指示方法为', ['结晶紫', '麝香草酚蓝', '淀粉', '永停法', '邻二氮菲'], ['4'], ''),\n",
       " ('以下对',\n",
       "  ['减少ADR的危害', '促进临床合理用药', '促进新药的研制开发', '简化或缩短新药临床试验', '弥补药品上市前研究的不足'],\n",
       "  ['4'],\n",
       "  '2、4'),\n",
       " ('适用于心肌梗死、肾衰竭等引起的休克综合征，也可用于洋地黄和利尿剂无效的心功能不全的强心药是',\n",
       "  ['地高辛', '米力农', '氨力农', '西地兰D', '多巴胺'],\n",
       "  ['5'],\n",
       "  '地高辛'),\n",
       " ('甲氨蝶呤合用复方磺胺甲噁唑，产生的相互作用可能导致',\n",
       "  ['降压作用增强', '巨幼红细胞症', '抗凝作用下降', '高钾血症', '肾毒性增强'],\n",
       "  ['2'],\n",
       "  '1、4'),\n",
       " ('以下属于外科手术抗菌药物治疗性应用的是',\n",
       "  ['口咽部大手术', '经直肠前列腺手术', '开放性骨折', '胃肠穿孔腹膜炎', '先天性心脏病手术'],\n",
       "  ['4'],\n",
       "  '1、2、3、4'),\n",
       " ('在乙酰胆碱中加入了竞争性拮抗药', ['A>B', 'A<B', 'A=B', 'A不一定等于B', '无法判断'], ['1'], 'A≠B'),\n",
       " ('血清白蛋白测定方法为', ['双缩脲法', '澳甲酚氯法', '连续检测法', '免疫比浊法', '琼脂糖电泳法'], ['2'], '1、2'),\n",
       " ('按照美国国家用药错误报告及预防协调委员会制定的用药错误分级标准，其中：药品已发给患者但还未被使用，此种用药错误级别属于',\n",
       "  ['A级', 'B级', 'C级', 'D级', 'E级'],\n",
       "  ['2'],\n",
       "  'A'),\n",
       " ('对氨基水杨酸的抗结核杆菌作用原理是',\n",
       "  ['抑制RNA多聚酶', '抑制蛋白质合成', '抑制分枝菌酸合成', '抑制结核杆菌叶酸的代谢', '抑制二氢叶酸还原酶'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('分子内含有黄嘌呤结构的药物为',\n",
       "  ['[2KY101121.png]',\n",
       "   '[2KY101122.png]',\n",
       "   '[2KY101123.png]',\n",
       "   '[2KY101124.png]',\n",
       "   '[2KY101125.png]'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('含有两个硝基的是', ['硝酸甘油', '硝酸异山梨醇酯', '单硝酸异山梨醇酯', '戊四硝酯', '双嘧达莫'], ['2'], ''),\n",
       " ('与下方药物具有相似临床作用的药物是 [2KY10114.png]',\n",
       "  ['西替利嗪', '奥美拉唑', '地氯雷他定', '多潘立酮', '雷尼替丁'],\n",
       "  ['5'],\n",
       "  '无正确答案'),\n",
       " ('根据药物对胎儿的危害，美国FD', ['阿莫西林', '葡萄糖', '万古霉素', '沙利度胺', '卡马西平'], ['2'], 'D'),\n",
       " ('在中成药活胃胶囊、神曲胃痛片、陈香白露片、复方陈香味片、复方田七胃痛片中，所含有的共同组分是',\n",
       "  ['氧化镁', '碳酸镁', '氢氧化铝', '碳酸氢钠', '次硝酸铋'],\n",
       "  ['4'],\n",
       "  '无正确答案'),\n",
       " ('新生儿茶碱的治疗浓度低限为',\n",
       "  ['2μg/ml', '5～10μg/ml', '10～20μg/ml', '>15μg/ml', '>20μg/ml'],\n",
       "  ['2'],\n",
       "  '>20μg'),\n",
       " ('对10年心血管病风险大于10%的人群，给予阿司匹林，每日',\n",
       "  ['10～25mg', '25～50mg', '75～150mg', '150～300mg', '300～500mg'],\n",
       "  ['3'],\n",
       "  'C'),\n",
       " ('合剂的外文缩写是', ['a.m', 'b.i.d', 'im', 'Mist', 'Sol'], ['4'], 'b.i.d'),\n",
       " ('药物经过1个半衰期，从体内消除的百分数为',\n",
       "  ['99.22%', '99%', '93.75%', '90%', '50%'],\n",
       "  ['5'],\n",
       "  'C'),\n",
       " ('若出现的分层现象经振摇后能恢复原状，其原因是',\n",
       "  ['分散相乳剂ζ（Zeta）电位降低', '分散相与连续相存在密度差', '乳化剂类型改变', '乳化剂失去乳化作用', '微生物作用'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('有关肺炎临床稳定的标准，正确的是',\n",
       "  ['体温＞37.8℃', '心率＞100次/分', '呼吸频率＞24次/分', '收缩压≥90mmHg', '动脉血氧饱和度≤90%'],\n",
       "  ['4'],\n",
       "  '1、2、3'),\n",
       " ('安慰剂作用与药物产生的作用一致，属于',\n",
       "  ['阳性安慰剂', '阴性安慰剂', '交叉耐受性', '快速耐受性', '成瘾'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('下列缓泻药中，适用于肝性脑病患者的是', ['比沙可啶', '酚酞', '硫酸镁', '乳果糖', '甘油'], ['4'], '乳果糖'),\n",
       " ('加入竞争性拮抗剂后，相应的受体激动药的量效曲线将会',\n",
       "  ['平行左移，最大效应不变', '平行右移，最大效应不变', '向左移动，最大效应降低', '向右移动，最大效应降低', '保持不变'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('属于α-葡萄糖苷酶抑制剂伏格列波糖的是',\n",
       "  ['[YX11200SRTX0816.png]',\n",
       "   '[YX11200SRTX0817.png]',\n",
       "   '[YX11200SRTX0818.png]',\n",
       "   '[YX11200SRTX0819.png]',\n",
       "   '[YX11200SRTX0820.png]'],\n",
       "  ['3'],\n",
       "  '[YX11200SRTX0816.png]'),\n",
       " ('以下药物抗肿瘤机制与其他四种不同的是',\n",
       "  ['伊立替康', '多西他赛', '长春新碱', '高三尖杉酯碱', '门冬酰胺酶'],\n",
       "  ['1'],\n",
       "  'D'),\n",
       " ('最常见的不良反应类型是', ['A类反应', 'B类反应', 'C类反应', 'D类反应', 'E类反应'], ['1'], 'C类反应'),\n",
       " ('代表乙型肝炎病毒表面抗体的是',\n",
       "  ['HBcAb', 'HBeAb', 'HBsAb', 'HBeAg', 'HBsAg'],\n",
       "  ['3'],\n",
       "  'HBsAb'),\n",
       " ('5%葡萄糖注射液500ml含有的葡萄糖克数是',\n",
       "  ['25.0', '30.0', '10.0', '33.3', '20.0'],\n",
       "  ['1'],\n",
       "  'C'),\n",
       " ('在苯二氮卓结构的1,2位并合三氮唑结构，其脂溶性增加，易通过血脑屏障，产生较强的镇定催眠作用的药物是',\n",
       "  ['[2016ZT00052.png]',\n",
       "   '[2016ZT00053.png]',\n",
       "   '[2016ZT00054.png]',\n",
       "   '[2016ZT00055.png]',\n",
       "   '[2016ZT00056.png]'],\n",
       "  ['4'],\n",
       "  '[2016ZT00054.png]'),\n",
       " ('可激动γ-氨基丁酸（G', ['卡马西平', '苯妥英钠', '丙戊酸钠', '苯巴比妥', '氯硝西泮'], ['5'], 'B'),\n",
       " ('可引起致死性肺毒性和肝毒性的抗心律失常药物是',\n",
       "  ['普萘洛尔', '胺碘酮', '维拉帕米', '奎尼丁', '利多卡因'],\n",
       "  ['2'],\n",
       "  '胺碘酮'),\n",
       " ('混悬剂中可使ζ电位降低的稳定剂是', ['润湿剂', '助悬剂', '助流剂', '絮凝剂', '反絮凝剂'], ['4'], 'B'),\n",
       " ('母核为嘧啶环的药物是',\n",
       "  ['[2KY100321.png]',\n",
       "   '[2KY100322.png]',\n",
       "   '[2KY100323.png]',\n",
       "   '[2KY100324.png]',\n",
       "   '[2KY100325.png]'],\n",
       "  ['4'],\n",
       "  '[2KY100321.png]'),\n",
       " ('不宜应用喹诺酮类药物的人群是', ['清疡病患者', '肝病患者', '婴幼儿', '老年人', '妇女'], ['3'], '孕妇'),\n",
       " ('根据用药错误监测方法特点，下列说法符合病历审查的是',\n",
       "  ['集中检查者注意力，最高的ADEs预测能力，检测数量超过自我报告',\n",
       "   '最有可能确认患者伤害事件，检测数量超过自我报告',\n",
       "   '高效，检测ADEs比例高',\n",
       "   '数据充分，可识别用药错误和ADE趋势，事件描述可帮助工作人员找到错误原因',\n",
       "   '可在主治医师查房和护士交班时实施'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('药学服务具体内容中，作为药师联系和沟通医师、护师和患者之间的重要纽带是',\n",
       "  ['处方调配', '治疗药物监测', '参与健康教育', '参与临床药物治疗', '药物利用研究和评价'],\n",
       "  ['1'],\n",
       "  'D'),\n",
       " ('李女士来到药房咨询，主诉最近服用下列药品后体重有所增加，请药师确认可能增加体重的药品是',\n",
       "  ['二甲双胍', '辛伐他汀', '米氮平', '阿司匹林', '硝酸甘油'],\n",
       "  ['3'],\n",
       "  '2、3'),\n",
       " ('具有耐酶特点的青霉素类药物是',\n",
       "  ['[YZ12017GJZYYSTG2000T1011.png]',\n",
       "   '[YZ12017GJZYYSTG2000T1012.png]',\n",
       "   '[YZ12017GJZYYSTG2000T1013.png]',\n",
       "   '[YZ12017GJZYYSTG2000T1014.png]',\n",
       "   '[YZ12017GJZYYSTG2000T1015.png]'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('服用2个月后，血压控制未达标，经进一步检查，该患者伴有同型半胱氨酸水平升高，宜联合应用的药品是（\\u3000）。',\n",
       "  ['维生素A', '维生素B6', '维生素C', '烟酸', '叶酸'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('慎用5型磷酸二酯酶抑制剂的人群中，不包括',\n",
       "  ['有色素视网膜炎者', '糖尿病者', '高血压者', '阴茎解剖畸形者', '心力衰竭者'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('《中国药典》规定，如果原料药的含量未规定检测上限时，系指不超过',\n",
       "  ['99.9%', '100%', '100.5%', '101.0%', '105.0%'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('已知1%（g/ml）盐酸普鲁卡因溶液的冰点降低值为0.12度，计算将其1%（g/ml）溶液注射液1000ml调整为等渗溶液所需添加氯化钠的量。已知1%（g/ml）氯化钠溶液的冰点降低值为0.578度',\n",
       "  ['6.7g', '6.9g', '7.1g', '7.3g', '7.5g'],\n",
       "  ['2'],\n",
       "  '将1% (g/mL) 的盐酸普鲁卡因溶液 1000 ml 转换为等渗溶液所需的氯化钠量为 7.1 g'),\n",
       " ('与胆酸不可逆结合，阻碍胆酸的肠肝循环，阻碍胆固醇重吸收的药物是',\n",
       "  ['瑞舒伐他汀', '非诺贝特', '阿昔莫司', '考来替泊', '依折麦布'],\n",
       "  ['4'],\n",
       "  'C'),\n",
       " ('单室模型的药物恒速静脉滴注6．64个半衰期达稳态时',\n",
       "  ['50%', '75%', '90%', '95%', '99%'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('根据美国国家用药错误报告及预防协调委员会制定的分级标准，将用药错误分为九级。差错导致患者生命垂危，需要应用维持生命的措施，属于',\n",
       "  ['A级', 'B级', 'C级', 'D级', 'H级'],\n",
       "  ['5'],\n",
       "  'H级'),\n",
       " ('秋水仙碱可导致下列哪种维生素可逆性的吸收不良',\n",
       "  ['维生素B<SUB>1</SUB>',\n",
       "   '维生素B<SUB>12</SUB>',\n",
       "   '维生素C',\n",
       "   '维生素B<SUB>6</SUB>',\n",
       "   '维生素A'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('结构中含有咪唑并吡啶环的药物是', ['苯妥英钠', '艾司唑仑', '唑吡坦', '丙戊酸钠', '异戊巴比妥'], ['3'], ''),\n",
       " ('抗肿瘤药物中，影响核酸转录的药物是', ['顺铂', '甲氨蝶呤', '放线菌素D', '依托泊苷', '紫杉醇'], ['3'], ''),\n",
       " ('将治疗哮喘的氨茶碱片剂改为栓剂的目的是',\n",
       "  ['改变药物作用的性质', '改变药物作用的速度', '降低药物的毒副作用', '产生靶向作用', '不会影响疗效'],\n",
       "  ['3'],\n",
       "  '不影响疗效'),\n",
       " ('下列关于依那普利的说法正确的是 [YZ12017GJZYYSKSCCSJ3059.png]',\n",
       "  ['依那普利是含有苯丙氨酸结构的药物',\n",
       "   '依那普利分子中只含有4个手性中心',\n",
       "   '口服吸收极差，只能静脉注射给药',\n",
       "   '依那普利结构中含有碱性的赖氨酸基团，是产生药效的关键',\n",
       "   '依那普利代谢产物依那普利拉，具有抑制ACE作用'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('化学结构中含有苯丁氧基的是', ['异丙托溴铵', '沙美特罗', '倍氯米松', '扎鲁司特', '茶碱'], ['2'], 'A'),\n",
       " ('属于处方后记的内容为', ['临床诊断', '医疗机构名称', '开具日期', '用法用量', '药品金额'], ['5'], '1、3、4'),\n",
       " ('β-内酰胺类抗生素的作用机制是',\n",
       "  ['β-内酰胺酶抑制剂，阻止细胞壁的合成',\n",
       "   '二氢叶酸合成酶抑制剂',\n",
       "   '二氢叶酸还原酶抑制剂',\n",
       "   '环氧合酶抑制剂，干扰细菌生长',\n",
       "   'β-内酰胺开环，与细菌发生酰化作用'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('机体钙吸收减少的机制是',\n",
       "  ['组织吸收有自限性',\n",
       "   '药物生物转化障碍',\n",
       "   '经肾排泄的药物消除减慢',\n",
       "   '血浆蛋白含量下降，酸性代谢产物蓄积',\n",
       "   '药物的氧化反应加速，还原和水解反应减慢，对药物的结合反应影响不大'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('应用多黏菌素、磺胺类、顺铂可能引起的尿常规检查异常是',\n",
       "  ['尿沉渣管型异常', '尿沉渣尿酸盐结晶', '尿沉渣结晶异常', '尿沉渣白细胞增多', '尿沉渣胆红素结晶'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('混悬型气雾剂的组成部分不包括', ['抛射剂', '潜溶剂', '助悬剂', '阀门系统', '耐压容器'], ['2'], '无正确答案'),\n",
       " ('用尿药法来测定生物等效性时，集尿时间为',\n",
       "  ['5个生物半衰期', '7个生物半衰期', '9个生物半衰期', '11个生物半衰期', '13个生物半衰期'],\n",
       "  ['2'],\n",
       "  '无特定时间'),\n",
       " ('判断肾盂肾炎是复发还是重新感染，多以在停药后几周再发为依据',\n",
       "  ['3周', '4周', '5周', '6周', '7周'],\n",
       "  ['4'],\n",
       "  '无正确答案'),\n",
       " ('使用特布他林气雾剂24h不应超过多少揿', ['1.25', '6', '24', '200', '800'], ['3'], ''),\n",
       " ('胰岛素抵抗的诊断指标是糖尿病患者1日的胰岛素需要量大于',\n",
       "  ['1.5 U/kg', '1.6 U/kg', '2 U/kg', '2.2 U/kg', '2.5 U/kg'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('可以很方便地对所需要的-级信息资料进行筛选，属于',\n",
       "  ['一级信息', '二级信息', '三级信息', '四级信息', '五级信息'],\n",
       "  ['2'],\n",
       "  '一级信息'),\n",
       " ('配制10％葡萄糖注射液1000ml，需取50％和5％浓度的葡萄糖注射液分别为多少毫升',\n",
       "  ['889，111', '778，222', '333，667', '222，778', '111，889'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('与磺胺类或砜类药物可增强疗效的抗疟药是', ['伯氨喹', '乙胺嘧啶', '氯喹+伯氨喹', '氯喹', '青蒿素'], ['2'], 'B'),\n",
       " ('可能引起男性乳房增大的抗高血压药是（\\u3000）。',\n",
       "  ['阿利克仑（阿利吉仑）', '氨氯地平', '卡托普利', '硝普钠', '甲基多巴'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('下列治疗肠道寄生虫病的药物中，对虫体具有神经-肌肉阻滞作用的是',\n",
       "  ['阿苯达唑', '甲苯咪唑', '枸橼酸哌嗪', '左旋咪唑', '噻嘧啶'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('氯吡格雷抗血小板的作用机制是抑制',\n",
       "  ['血栓烷合成酶', '磷酸二酯酶', '环氧酶', '血小板腺苷环化酶', '血小板糖蛋白Ⅱb/Ⅲa（GPⅡb/Ⅲa）受体'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('\"有时需要利用所提供的参考文献去验证信息的正确性\"是指',\n",
       "  ['一级信息源', '二级信息源', '三级信息源', '四级信息源', '互联网信息'],\n",
       "  ['3'],\n",
       "  '一级信息源'),\n",
       " ('符号F表示', ['消除速率常数', '吸收速率常数', '生物利用度', '表观分布容积', '半衰期'], ['3'], ''),\n",
       " ('消除速度常数的单位是',\n",
       "  ['与时间的单位相同', 'mg/时间的单位', 'ml/时间的单位', '时间的倒数', 'mg•L<SUP>-l</SUP>／时间的单位'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('通过增强γ-氨基丁酸', ['苯巴比妥', '地西泮', '苯妥英钠', '卡马西平', '加巴喷丁'], ['1'], 'B'),\n",
       " ('处理误服毒物不久、神志尚清醒中毒患者的首要措施是',\n",
       "  ['给予氧气吸入', '静脉补液', '导泻与洗肠', '催吐、洗胃', '清除皮肤、黏膜上的毒物'],\n",
       "  ['4'],\n",
       "  'C'),\n",
       " ('在高效液相色谱的测定方法中，公式[图0029.png]适用的方法是',\n",
       "  ['内标法', '外标法', '主成分自身对照法', '标准加入法', '面积归一化法'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('16a位为甲基的药物是',\n",
       "  ['醋酸氢化可的松', '醋酸地塞米松', '醋酸泼尼松龙', '醋酸氟轻松', '醋酸曲安奈德'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('二氢吡啶环上，2 , 6位取代基不同的药物是',\n",
       "  ['氨氯地平', '尼卡地平', '硝苯地平', '非洛地平', '尼莫地平'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('润滑肠壁，软化大便和调节稠度',\n",
       "  ['乳果糖', '比沙可啶', '聚乙二醇粉', '微生态制剂', '开塞露/甘油栓'],\n",
       "  ['5'],\n",
       "  '开塞露/甘油栓'),\n",
       " ('表示多剂量给药体内药量蓄积程度的是', ['F', 'τ', 'R', 'X', 'Cl'], ['3'], 'X'),\n",
       " ('肾上腺素、丙二醇、无菌蒸馏水的处方属于',\n",
       "  ['溶液型气雾剂', '混悬型气雾剂', '乳剂型气雾剂', '喷雾剂', '吸入粉雾剂'],\n",
       "  ['4'],\n",
       "  'A'),\n",
       " ('药物对人体呈剂量相关的反应，是不良反应常见的类型，属于',\n",
       "  ['A类反应（扩大反应）', 'D类反应（给药反应）', 'E类反应（撤药反应）', 'H类反应（过敏反应）', 'B类反应（过度或微生物反应）'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('对该患者健康教育的说法中，错误的是',\n",
       "  ['控制体重', '不必限盐', '适当运动', '减少脂肪摄入', '戒烟限酒'],\n",
       "  ['2'],\n",
       "  '无需健康教育'),\n",
       " ('属于对因治疗的药物作用方式是',\n",
       "  ['胰岛素降低糖尿病患者的血糖',\n",
       "   '阿司匹林治疗感冒引起的发热',\n",
       "   '硝苯地平降低高血压患者的血压',\n",
       "   '硝酸甘油缓解心绞痛的发作',\n",
       "   '青霉素治疗脑膜炎奈瑟菌引起的流行性脑脊髓膜炎'],\n",
       "  ['5'],\n",
       "  'A'),\n",
       " ('患者，男，54岁，两周前通风急性发作，经治疗后病情缓解，后期针对其痛风的治疗不宜选用的药物是',\n",
       "  ['别嘌醇', '秋水仙碱', '非布索坦', '苯溴马隆', '碳酸氢钠'],\n",
       "  ['2'],\n",
       "  'A'),\n",
       " ('掩盖低血糖反应的抗心律失常药是', ['奎尼丁', '胺碘酮', '普萘洛尔', '利多卡因', '维拉帕米'], ['3'], 'B'),\n",
       " ('关于吡格列酮的叙述，错误的是',\n",
       "  ['治疗前、治疗后建议定期监测肝功能',\n",
       "   '餐前服用，服药后即可进餐',\n",
       "   '对于正在使用磺酰脲类药的患者，当开始联合应用吡格列酮时，磺酰脲类药剂量可维持不变',\n",
       "   '对于正在使用二甲双胍的患者，当开始联合应用吡格列酮时，二甲双胍剂量可维持不变',\n",
       "   '对于正在使用胰岛素的患者，当开始联合应用吡格列酮时，胰岛素剂量可维持不变'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('中成药中含氯苯那敏成分，重复应用时，可致',\n",
       "  ['粒细胞减少', '膀胱颈梗阻', '低血糖', '低血钾、低血压', '急性肾衰竭'],\n",
       "  ['2'],\n",
       "  'D'),\n",
       " ('芬必得属于', ['商品名', '化学名', '通用名', '拉丁名', '俗名'], ['1'], ''),\n",
       " ('生物半衰期的表示方式是', ['Cl', 't<SUB>1/2</SUB>', 'β', 'V', 'AUC'], ['2'], ''),\n",
       " ('薄膜包衣片的崩解时限是', ['3min', '5min', '15min', '30min', '60min'], ['4'], ''),\n",
       " ('关于利多卡因的叙述正确的是',\n",
       "  ['为窄谱抗心律失常药，仅用于室性心律失常',\n",
       "   '可治疗阵发性室上性心动过速',\n",
       "   '可用于房颤的复律治疗和复律后的维持',\n",
       "   '可治疗房性期前收缩',\n",
       "   '对短动作电位时程的心房肌有效'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('山莨菪碱的化学结构是',\n",
       "  ['[YZ12017GJZYYSKSQZMNSJ1006.png]',\n",
       "   '[YZ12017GJZYYSKSQZMNSJ1007.png]',\n",
       "   '[YZ12017GJZYYSKSQZMNSJ1008.png]',\n",
       "   '[YZ12017GJZYYSKSQZMNSJ1009.png]',\n",
       "   '[YZ12017GJZYYSKSQZMNSJ1010.png]'],\n",
       "  ['3'],\n",
       "  '[YZ12017GJZYYSKSQZMNSJ1006.png]'),\n",
       " ('胰岛素激活胰岛素受体发挥药效的作用机制是',\n",
       "  ['作用于受体', '影响酶的活性', '影响细胞离子通道', '干扰核酸代谢', '改变细胞周围环境的理化性质'],\n",
       "  ['1'],\n",
       "  'A'),\n",
       " ('属于前药的糖皮质激素是', ['氢化可的松', '醋酸氢化可的松', '泼尼松', '曲安西龙', '曲安奈德'], ['2'], ''),\n",
       " ('对该患者注射胰岛素制剂的注意事项和用药指导的说法，正确的是',\n",
       "  ['在注射胰岛素制剂时，针头可重复使用',\n",
       "   '未使用的胰岛素可以冷冻保存',\n",
       "   '注射胰岛素制剂时，应变换注射部位，两次注射点要间隔2cm',\n",
       "   '开启的胰岛素需要冷藏保存',\n",
       "   '使用中的胰岛素笔芯可以室温保存8周'],\n",
       "  ['3'],\n",
       "  '1错误;3正确'),\n",
       " ('不合格药品为', ['红色', '白色', '绿色', '黄色', '黑色'], ['1'], 'B'),\n",
       " ('以丙烯酸树脂、羟丙纤维素包衣制成的片剂是', ['糖衣片', '咀嚼片', '薄膜衣片', '泡腾片', '口崩片'], ['3'], ''),\n",
       " ('冠状动脉支架置入术前一日起开始口服阿司匹林，每日',\n",
       "  ['10～25mg', '25～50mg', '75～150mg', '150～300mg', '300～500mg'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('某药物在体内按一级动力学消除，如果k=0.0346h-1，该药物的消除半衰期约为（\\u3000\\u3000）',\n",
       "  ['3.46h', '6.92h', '12h', '20h', '24h'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('缺乏证据支持的药物信息属于',\n",
       "  ['EBDIA类', 'EBDIB类', 'EBDIC类', 'EBDID类', 'EBDIE类'],\n",
       "  ['3'],\n",
       "  'EBDIF'),\n",
       " ('《中国药典》规定薄膜包衣片的崩解时限是',\n",
       "  ['15分钟', '5分钟', '30分钟', '3分钟', '60分钟'],\n",
       "  ['3'],\n",
       "  '30分钟'),\n",
       " ('为使所取样品具有代表性，当产品总件数为100时，所取样件数为',\n",
       "  ['100', '50', '11', '10', '9'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('需要做治疗药物监测的是',\n",
       "  ['氨苄西林', '洋地黄毒苷', '阿昔洛韦', '阿奇霉素', '加替沙星'],\n",
       "  ['2'],\n",
       "  '需要监测的药物通常具有血药浓度与疗效之间存在密切关系的特性'),\n",
       " ('可作为退热药的首选，尤其适合老年人和儿童服用的药品是',\n",
       "  ['阿司匹林', '布洛芬', '酮咯酸', '对乙酰氧基酚', '安乃近'],\n",
       "  ['4'],\n",
       "  '对乙酰氧基酚'),\n",
       " ('美洛昔康的结构为 [2KY10100.png] 下列不符合其性质和特点的选项是',\n",
       "  ['属非甾体抗炎药', '具有苯并噻嗪结构', '具有酰胺结构', '结构含有吡啶结构', '该药显酸性，酸性来自于烯醇结构'],\n",
       "  ['4'],\n",
       "  '该药显酸性，酸性来自'),\n",
       " ('氨氯地平的结构式为',\n",
       "  ['[1K20055.png]',\n",
       "   '[1K20056.png]',\n",
       "   '[1K20057.png]',\n",
       "   '[1K20058.png]',\n",
       "   '[1K20059.png]'],\n",
       "  ['2'],\n",
       "  '[1K20058.png]'),\n",
       " ('单室模型静脉注射血药浓度随时间变化的公式是',\n",
       "  ['[YZ12017GJZYYSKSCCSJ2048.png]',\n",
       "   '[YZ12017GJZYYSKSCCSJ2049.png]',\n",
       "   '[YZ12017GJZYYSKSCCSJ2050.png]',\n",
       "   '[YZ12017GJZYYSKSCCSJ2051.png]',\n",
       "   '[YZ12017GJZYYSKSCCSJ2052.png]'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('保湿剂', ['单硬脂酸甘油酯', '甘油', '白凡士林', '十二烷基硫酸钠', '对羟基苯甲酸乙酯'], ['2'], ''),\n",
       " ('经肾脏代谢后才能产生药效的是',\n",
       "  ['维生素D<SUB>3</SUB>', '青霉素', '链霉素', '维生素C', '维生素B<SUB>2</SUB>'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('环戊噻嗪、氢氯噻嗪、呋塞米、氯噻嗪的效价强度和效能见下图，对这四种利尿剂的效价强度和效能说法正确的是（\\u3000）。 [图1]',\n",
       "  ['效能最强的是呋塞米',\n",
       "   '效价强度最小的是呋塞米',\n",
       "   '效价强度最大的是氯噻嗪',\n",
       "   '氢氯噻嗪效能大于环戊噻嗪，小于氯噻嗪',\n",
       "   '环戊噻嗪、氢氯噻嗪和氯噻嗪的效价强度相同'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('育龄期癫痫患者可酌情选用', ['丙戊酸钠', '卡马西平', '乙琥胺', '托吡酯', '苯巴比妥'], ['2'], '1、2、4'),\n",
       " ('含有二苯并氮杂卓结构的是',\n",
       "  ['[2KY100881.png]',\n",
       "   '[2KY100882.png]',\n",
       "   '[2KY100883.png]',\n",
       "   '[2KY100884.png]',\n",
       "   '[2KY100885.png]'],\n",
       "  ['1'],\n",
       "  '[2KY100881.png]'),\n",
       " ('吗啡、阿片、哌替啶、可待因可引起', ['肾结石', '血尿', '对肾脏无毒性', '急性肾小球肾炎', '尿潴留'], ['5'], 'B'),\n",
       " ('具有嘌呤结构，属于磷酸二酯酶抑制剂的平喘药是',\n",
       "  ['[YZ12017KDS1019.png]',\n",
       "   '[YZ12017KDS1020.png]',\n",
       "   '[YZ12017KDS1021.png]',\n",
       "   '[YZ12017KDS1022.png]',\n",
       "   '[YZ12017KDS1023.png]'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('关于别嘌醇的药理作用描述，错误的是',\n",
       "  ['抑制黄嘌呤氧化酶，阻止次黄嘌呤和黄嘌呤代谢为尿酸',\n",
       "   '防止尿酸形成结晶沉积',\n",
       "   '抑制粒细胞侵润和白细胞趋化',\n",
       "   '抗氧化，减少再灌注期氧自由基产生',\n",
       "   '有助于组织内尿酸结晶重新溶解'],\n",
       "  ['3'],\n",
       "  '无正确答案'),\n",
       " ('我国营养学会建议老年人每天应摄取元素钙1000mg，每天从饮食当中可获取400mg，所以每日应补充元素钙600mg。如果建议老年人每天服用葡萄糖酸钙片[分子式Ca（C6H11O7）2 ]，每片含量为0.5g，那么每天服用3次，每次至少应服用',\n",
       "  ['1片', '2片', '3片', '4片', '8片'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('有雷诺综合征，会掩盖低血糖反应的抗心律失常药是',\n",
       "  ['美西律', '普罗帕酮', '普萘洛尔', '胺碘酮', '维拉帕米'],\n",
       "  ['3'],\n",
       "  'A'),\n",
       " ('严重损害骨髓造血机能的药物是', ['青霉素', '庆大霉素', '琥乙红霉素', '链霉素', '甲砜霉素'], ['5'], '2、4'),\n",
       " ('导致眼球震颤毒性反应的苯妥英钠的血浆浓度为',\n",
       "  ['1～2μg/ml', '5～10μg/ml', '10～20μg/ml', '20～40μg/ml', '>200μg/ml'],\n",
       "  ['4'],\n",
       "  '>200μg/ml'),\n",
       " ('二氢吡啶环上，2、6位取代基不同的药物是',\n",
       "  ['尼莫地平', '尼卡地平', '硝苯地平', '尼群地平', '氨氯地平'],\n",
       "  ['5'],\n",
       "  'C'),\n",
       " ('比较单个或多个药物治疗方案或其他干预之间所消耗的成本和结果值（效益）的方法是',\n",
       "  ['成本效益分析', '成本效用分析', '用药频度分析', '药物利用指数分析', '流行病学分析'],\n",
       "  ['1'],\n",
       "  'A'),\n",
       " ('肝功能不全时的药动学改变',\n",
       "  ['对于肝功能不全患者，服药后的一般规律为，半衰期缩短，血药浓度降低',\n",
       "   '对于肝功能不全患者，服药后的一般规律为，半衰期延长，血药浓度增高',\n",
       "   '对于肝功能不全患者，服药后的一般规律为，药物效应不变',\n",
       "   '对于肝功能不全患者，服药后的一般规律为，药物效应增强',\n",
       "   '对于肝功能不全患者，服药后的一般规律为，药物效应减弱'],\n",
       "  ['2'],\n",
       "  '对于肝功能不全患者，服药后的规律一般为，药物的代谢减慢或受阻，血药浓度升高'),\n",
       " ('属于肝药酶诱导剂的抗结核药物是', ['对氨基水杨酸', '利福平', '异烟肼', '吡嗪酰胺', '乙胺丁醇'], ['2'], '利福平'),\n",
       " ('磺胺甲噁唑和甲氧苄啶的作用机制为',\n",
       "  ['两者都作用于二氢叶酸合成酶',\n",
       "   '两者都作用于二氢叶酸还原酶',\n",
       "   '前者作用于二氢叶酸合成酶，后者作用于二氢叶酸还原酶',\n",
       "   '前者作用于二氢叶酸还原酶，后者作用于二氢叶酸合成酶',\n",
       "   '两者都干扰细菌对叶酸的摄取'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('单个样品量足够的随机对照试验结果属于',\n",
       "  ['一级证据', '二级证据', '三级证据', '四级证据', '五级证据'],\n",
       "  ['2'],\n",
       "  '三级证据'),\n",
       " ('联合用药罗红霉素主要干扰辛伐他汀的', ['体内吸收', '体内分布', '肝脏代谢', '肾脏排泄', '肠道排泄'], ['3'], 'C'),\n",
       " ('发热最主要的临床表现是',\n",
       "  ['头痛、咽喉痛、畏寒、乏力、鼻塞或咳嗽',\n",
       "   '体温升高、脉搏加快',\n",
       "   '间歇发作的寒战、高热，继之大汗',\n",
       "   '寒战、胸痛、咳嗽、咳铁锈色痰',\n",
       "   '持续发热、寒战、脉缓、玫瑰疹、肝脾肿大'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('成年人血清中低密度脂蛋白胆固醇的含量是',\n",
       "  ['0.56～1.70mmol/L',\n",
       "   '1.2～1.65mmol/L',\n",
       "   '2.1～3.1mmol/L',\n",
       "   '3.1～5.7mmol/L',\n",
       "   '3.3～5.5mmol/L'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('在硝苯地平渗透泵片中，渗透压活性物质是',\n",
       "  ['氯化钾', '聚环氧乙烷', 'HPMC', '醋酸纤维素', 'PEG4000'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('对由甲氨蝶呤所引发的贫血者，宜应用的药物是',\n",
       "  ['叶酸+维生素B12', '富马酸亚铁', '维生素B12', '烟酸', '亚叶酸钙'],\n",
       "  ['1'],\n",
       "  '亚叶酸钙'),\n",
       " ('肾功能减退时避免使用，但确有指征时可进行TDM应用的抗菌药物是',\n",
       "  ['阿米卡星', '红霉素', '利福平', '四环素', '头孢唑林'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('在睾酮的2，3位并入吡唑环，17位引入甲基，\\u200d雄性化副作用下降，得到的蛋白同化激素是',\n",
       "  ['[2KY101321.png]',\n",
       "   '[2KY101322.png]',\n",
       "   '[2KY101323.png]',\n",
       "   '[2KY101324.png]',\n",
       "   '[2KY101325.png]'],\n",
       "  ['2'],\n",
       "  '[2KY101322.png]'),\n",
       " ('某药以一级速率过程消除，消除速度常数K=0.173h-1，则该药半衰期为',\n",
       "  ['8.0h', '7.3h', '5.5h', '4.0h', '3.7h'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('属于缓释衣材料的是',\n",
       "  ['Poloxamer', 'Eudragit L', 'Carbomer', 'EC', 'HPMC'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('薄膜衣中加入增塑剂的作用是',\n",
       "  ['提高衣层的柔韧性，增加其抗撞击的强度', '降低膜材的晶型转变温度', '降低膜材的流动性', '增加膜材的表观黏度', '使膜材具有挥发性'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('对膀胱颈和平滑肌没有作用，用药时间必须长久，甚至终身的抗前列腺增生药是',\n",
       "  ['特拉唑嗪', '非那雄胺', '西地那非', '睾酮', '普适泰'],\n",
       "  ['2'],\n",
       "  '普适泰'),\n",
       " ('为了充分附着在胃黏膜上形成保护屏障，应于餐前服用的是',\n",
       "  ['复方铝酸铋', '二甲双胍', '多潘立酮', '普伐他汀', '米索前列醇'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('美国国家用药错误报告及预防协调委员会(NCCMERP)制定的\"用药错误\"分级标准是。',\n",
       "  ['分为6级', '分为7级', '分为8级', '分为9级', '分为10级'],\n",
       "  ['4'],\n",
       "  '1分'),\n",
       " ('处方正文书写的内容是', ['患者姓名', '医师签名', '药品通用名', '药师签名', '患者住院病历号'], ['3'], '1、3'),\n",
       " ('属于乙酰胆碱酯酶抑制剂的脑功能改善及抗记忆障碍药品是',\n",
       "  ['吡拉西坦片', '胞磷胆碱片', '艾迪苯醌片', '多奈哌齐片', '银杏叶提取物'],\n",
       "  ['4'],\n",
       "  '多奈哌齐片'),\n",
       " ('左炔诺孕酮的化学结构式是',\n",
       "  ['[图00731.png]',\n",
       "   '[图00732.png]',\n",
       "   '[图00733.png]',\n",
       "   '[图00734.png]',\n",
       "   '[图00735.png]'],\n",
       "  ['4'],\n",
       "  '[图00731.png]'),\n",
       " ('异烟肼和利福平长期联合应用可能引起', ['胆石症', '胃溃疡', '肺气肿', '胰腺炎', '肝坏死'], ['5'], 'B'),\n",
       " ('关于糖皮质激素对特殊人群的影响，错误的是',\n",
       "  ['造成儿童生长迟缓和肾上腺皮质功能受抑制',\n",
       "   '老年人需要预防消化道溃疡、感染、骨质疏松症和高血压',\n",
       "   '可增加胎盘功能不全、新生儿体重减少或死胎的发生率',\n",
       "   '有精神病史的患者避免使用',\n",
       "   '严重肝功能不全者宜选择可的松或泼尼松'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('多次开管或连续使用的滴眼液，使用期限不能超过', ['1d', '10d', '20d', '30d', '1年'], ['4'], ''),\n",
       " ('用于评价表面活性剂性质的参数是', ['pka', 'ED50', 'LD50', 'lgP', 'HLB'], ['5'], 'HLB'),\n",
       " ('严重肾功能不全患者使用时无需调整剂量的药物是',\n",
       "  ['瑞舒伐他汀', '阿托伐他汀', '洛伐他汀', '普伐他汀', '辛伐他汀'],\n",
       "  ['2'],\n",
       "  '1、2、3'),\n",
       " ('结构中有手性中心，在体内R型异构体可转化为\\u200dS型异构体的芳基丙酸类消炎药物是',\n",
       "  ['[2KY101061.png]',\n",
       "   '[2KY101062.png]',\n",
       "   '[2KY101063.png]',\n",
       "   '[2KY101064.png]',\n",
       "   '[2KY101065.png]'],\n",
       "  ['4'],\n",
       "  '[2KY101061.png]'),\n",
       " ('以下通过增加组织与肝脏对胰岛素的敏感性而降糖的是',\n",
       "  ['二甲双胍', '利拉鲁肽', '吡格列酮', '瑞格列奈', '阿卡波糖'],\n",
       "  ['3'],\n",
       "  '1、2、3'),\n",
       " ('成年人血清中高密度脂蛋白胆固醇的含量是',\n",
       "  ['0.56～1.70mmol/L',\n",
       "   '1.2～1.65mmol/L',\n",
       "   '2.1～3.1mmol/L',\n",
       "   '3.1～5.7mmol/L',\n",
       "   '3.3～5.5mmol/L'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('关于非线性药物动力学特点的说法，不正确的是',\n",
       "  ['消除不呈现一级动力学特征',\n",
       "   'AUC与剂量成正比',\n",
       "   '剂量增加，消除半衰期延长',\n",
       "   '平均稳态血药浓度与剂量不成正比',\n",
       "   '可能竞争酶或载体的药物影响其动力学过程'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('碘量法的指示剂为', ['结晶紫', '麝香草酚蓝', '淀粉', '永停法', '邻二氮菲'], ['3'], ''),\n",
       " ('脂质体的膜材', ['微球', 'pH敏感脂质体', '磷脂和胆固醇', '毫微粒', '单室脂质体'], ['3'], ''),\n",
       " ('依托泊苷注射液的溶媒选择要求是A.血小板减少B.急性溶血性贫血C.红人综合征D.肌肉震颤E.抗生素相关性腹泻',\n",
       "  ['先用氯化钠注射液溶解，再用氯化钠注射液或%葡萄糖注射液进一步稀释',\n",
       "   '先用氯化钠注射液溶解，再用5%葡萄糖注射液进一步稀释',\n",
       "   '5%葡萄糖注射液稀释',\n",
       "   '氯化钠注射液稀释',\n",
       "   '先用乳酸钠注射液溶解，再用氯化钠注射液或5%葡萄糖注射液进一步稀释'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('器官移植术后病人极易发热',\n",
       "  ['药物热', '机体产热过多', '感染的伴发症状', '非感染的继发后果', '传染性疾病所伴发症状'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('在经皮给药制剂中，可用作贮库层材料的是',\n",
       "  ['聚苯乙烯', '微晶纤维素', '乙烯-醋酸乙烯共聚物', '硅橡胶', '低取代羟丙基纤维素'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('静脉注射某药，X0=60mg，若初始血药浓度为30μg/ml，其表观分布容积V是',\n",
       "  ['0.3L', '3L', '4L', '27L', '2L'],\n",
       "  ['5'],\n",
       "  '无法计算'),\n",
       " ('安全指数的表示方式是',\n",
       "  ['LD50', 'ED50', 'LD50/ED50', 'LD5/ED95', 'LD1/ED99'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('腹泻后腹痛多不缓解的是', ['痢疾样腹泻', '慢性腹泻', '水泻', '小肠炎性腹泻', '结肠炎性腹泻'], ['4'], ''),\n",
       " ('华法林起效缓慢，深静脉栓塞治疗的初期，需同时联合使用的药品是（\\u3000）。',\n",
       "  ['维生素B1', '维生素B2', '维生素B12', '依诺肝素', '酚磺乙胺'],\n",
       "  ['4'],\n",
       "  '依诺肝素'),\n",
       " ('吡嗪酰胺含有吡嗪环和酰胺基团，据此推测其化\\u200d学结构式为',\n",
       "  ['[2KY101421.png]',\n",
       "   '[2KY101422.png]',\n",
       "   '[2KY101423.png]',\n",
       "   '[2KY101424.png]',\n",
       "   '[2KY101425.png]'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('关于铁剂的应用，下列说法正确的为',\n",
       "  ['正常人维持体内铁平衡需要每日从食物中摄取铁2~2.5mg',\n",
       "   '尽量空腹服用亚铁盐，以促进其吸收',\n",
       "   '钙剂可促进铁剂吸收',\n",
       "   '碳酸氢钠抑制铁剂吸收',\n",
       "   '缺铁性贫血者铁剂的吸收率为45%'],\n",
       "  ['4'],\n",
       "  '1、2'),\n",
       " ('以下药物中，适宜处置蛇类咬伤的药物是', ['凝血酶', '糜蛋白酶', '胃蛋白酶', '胰蛋白酶', '菠萝蛋白酶'], ['4'], 'B'),\n",
       " ('干扰睾酮对前列腺的刺激作用，减少膀胱出口梗阻的是', ['坦洛新', '非那雄胺', '普适泰', '酚苄明', '哌唑嗪'], ['2'], ''),\n",
       " ('老年人用药注意事项，错误的是',\n",
       "  ['老年患者联合用药，一般用药以3～4种以内为宜',\n",
       "   '利尿降压宜选用吲达帕胺',\n",
       "   '降压药物最好不用利血平',\n",
       "   '维生素E摄入过多会抑制静脉血栓形成',\n",
       "   '长期应用肾上腺皮质激素可致高血压、感染扩散及诱发溃疡出血'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('关于难溶性药物速释型固体分散体的叙述，错误的是',\n",
       "  ['载体材料为水溶性',\n",
       "   '载体材料对药物有抑晶性',\n",
       "   '载体材料提高了药物分子的再聚集性',\n",
       "   '载体材料提高了药物的可润湿性',\n",
       "   '载体材料保证了药物的高度分散性'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('患者，男，65岁，患有骨质疏松症。根据该患者饮食习惯，每日需补充元素钙600mg，药师为其推荐碳酸钙（0.5g/片），该患者适宜的用法用量是',\n",
       "  ['1片tid', '2 片tid', '4片qd', '6片qd', '8片tid'],\n",
       "  ['1'],\n",
       "  '1片tid'),\n",
       " ('50%≤FEV1＜80%预计值，FEV1/FVC＜70%属于',\n",
       "  ['0级慢阻肺', 'I级慢阻肺', 'Ⅱ级慢阻肺', 'Ⅲ级慢阻肺', 'Ⅳ级慢阻肺'],\n",
       "  ['3'],\n",
       "  'IV'),\n",
       " ('单室模型静脉滴注给药过程中，血药浓度与时间的关系式是',\n",
       "  ['[YX11200SRTX0905.png]',\n",
       "   '[YX11200SRTX0906.png]',\n",
       "   '[YX11200SRTX0907.png]',\n",
       "   '[YX11200SRTX0908.png]',\n",
       "   '[YX11200SRTX0909.png]'],\n",
       "  ['5'],\n",
       "  '[YX11200SRTX0905.png];[YX11200SRTX0906.png];[YX11200SRTX0907.png];[YX11200SRTX0908.png];[YX11200SRTX0909.'),\n",
       " ('改变细胞周围环境的理化性质',\n",
       "  ['解热镇痛药抑制体内前列腺素的生物合成',\n",
       "   '抗酸药中和胃酸，可用于治疗胃溃疡',\n",
       "   '胰岛素治疗糖尿病',\n",
       "   '抗心律失常药可分别影响Na<SUP>+</SUP>、K<SUP>+</SUP>或Ca<SUP>2+</SUP>通道',\n",
       "   '磺胺类抗菌药通过抑制敏感细菌体内叶酸的代谢而干扰核酸的合成'],\n",
       "  ['2'],\n",
       "  'D'),\n",
       " ('分子中含有类似嘌呤结构，通过抑制黄嘌呤氧化\\u200d酶，减少尿酸生物合成发挥作用的抗痛风药物是',\n",
       "  ['[2KY100991.png]',\n",
       "   '[2KY100992.png]',\n",
       "   '[2KY100993.png]',\n",
       "   '[2KY100994.png]',\n",
       "   '[2KY100995.png]'],\n",
       "  ['2'],\n",
       "  '[2KY100992.png]'),\n",
       " ('血糖正常、尿葡萄糖阳性可以提示患者可能',\n",
       "  ['伴心肌梗死', '伴肾性肾小球肾炎', '伴甲状腺功能亢进', '伴活动性指端肥大症', '伴肾上腺皮质功能亢进'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('含有儿茶酚结构肾上腺素能药物是', ['肾上腺素', '石酸间羟胺', '沙丁胺醇', '沙美特罗', '盐酸麻黄碱'], ['1'], 'B'),\n",
       " ('该治疗药物属于', ['ARB', 'ACEI', '利尿剂', 'β受体阻断剂', '钙通道阻滞剂'], ['2'], ''),\n",
       " ('验证药物对目标适应证患者的治疗作用和安全性是指',\n",
       "  ['临床预试验', 'Ⅰ期临床试验', 'Ⅱ期临床试验', 'Ⅲ期临床试验', 'Ⅳ期临床试验'],\n",
       "  ['4'],\n",
       "  'IV期临床试'),\n",
       " ('分子内含有莨菪醇结构的药物为',\n",
       "  ['[2KY101121.png]',\n",
       "   '[2KY101122.png]',\n",
       "   '[2KY101123.png]',\n",
       "   '[2KY101124.png]',\n",
       "   '[2KY101125.png]'],\n",
       "  ['2'],\n",
       "  '[2KY101121.png]'),\n",
       " ('属前体药物，体内经代谢转化为甲硫醚化合物起\\u200d效的药物是',\n",
       "  ['舒林酸', '萘丁美酮', '贝诺酯', '吡罗昔康', '别嘌醇'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('药物相互作用对临床药效学的影响，协同作用的配伍用药是',\n",
       "  ['阿托品联用吗啡镇痛',\n",
       "   '应用利血平或胍乙啶后导致拟肾上腺素药升压作用增强',\n",
       "   '纳洛酮或纳屈酮用于解救吗啡中毒',\n",
       "   '青蒿素联用乙胺嘧啶、磺胺多辛可延缓抗药性的产生',\n",
       "   '硫酸阿托品联用解磷定'],\n",
       "  ['5'],\n",
       "  'A'),\n",
       " ('HPMCP可做为片剂的辅料使用正确的是', ['糖衣', '胃溶衣', '肠溶衣', '润滑剂', '崩解剂'], ['3'], 'B'),\n",
       " ('地西泮是',\n",
       "  ['[YX11200SRTX0811.png]',\n",
       "   '[YX11200SRTX0812.png]',\n",
       "   '[YX11200SRTX0813.png]',\n",
       "   '[YX11200SRTX0814.png]',\n",
       "   '[YX11200SRTX0815.png]'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('聚氧乙烯脱水山梨醇单油酸酯的商品名称是', ['吐温20', '吐温40', '吐温80', '司盘60', '司盘85'], ['3'], ''),\n",
       " ('结构为去甲睾酮的衍生物，具有孕激素样作用的药物是',\n",
       "  ['[图00761.png]',\n",
       "   '[图00762.png]',\n",
       "   '[图00763.png]',\n",
       "   '[图00764.png]',\n",
       "   '[图00765.png]'],\n",
       "  ['5'],\n",
       "  '[图00761.png]'),\n",
       " ('患者，男，43岁，因社区获得性肺炎入院，入院时9月8日查血常规提示：血小板计数（PLT）88×109/L，9月9日开始给予左氧氟沙星抗感染治疗1周后肺炎治愈，9月11日查血常规提示：血小板计数（PLT）90×109/L，9月20日查血常规提示：血小板计数（PLT）92×109/L，患者既往血常规情况不详。该患者血小板减少与左氧氟沙星的因果关系评价结果是',\n",
       "  ['肯定', '很可能', '可能', '可能无关', '无法评价'],\n",
       "  ['5'],\n",
       "  '无法判断'),\n",
       " ('停用β受体阻断剂时，整个停药过程至少（）周', ['1', '2', '4', '6', '8'], ['2'], 'C'),\n",
       " ('以高TG为主高脂血症首选', ['氟伐他汀', '阿昔莫司', '非诺贝特', '依折麦布', 'ω-3脂肪酸'], ['3'], ''),\n",
       " ('在盐酸异丙肾上腺素气雾剂处方中，可作为抗氧剂的辅料是',\n",
       "  ['HFA-134a', '乙醇', '吐温80', '甘油', '维生素C'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('5岁以上儿童应用硫黄软膏的浓度为', ['2.5%', '5%', '7%', '7.5%', '10%'], ['2'], ''),\n",
       " ('为人体的正常成分，可用于白细胞、血小板减少症的是',\n",
       "  ['叶酸', '重组人促红素', '肌苷', '非格司亭', '维生素B12'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('主要储存于肝，由粪便排出的维生素是',\n",
       "  ['维生素A', '维生素B<SUB>12</SUB>', '烟酸', '叶酸', '泛酸'],\n",
       "  ['1'],\n",
       "  '胆碱'),\n",
       " ('以十七烷酸磷脂为膜材料制备成载药脂质体的是',\n",
       "  ['长循环脂质体', '免疫脂质体', 'pH敏感脂质体', '甘露糖修饰的脂质体', '前体脂质体'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('属于苯二氮草类镇静催眠药的有', ['异戊巴比妥', '阿米替林', '格鲁米特', '氯硝西泮', '甲丙氨酯'], ['4'], '1、2、3'),\n",
       " ('属于抗凝血药，常见出血和血小板减少症的是',\n",
       "  ['依达肝素', '华法林', '达比加群酯', '肝素', '矛头蝮蛇血凝酶'],\n",
       "  ['4'],\n",
       "  '华法林'),\n",
       " ('下列\"给药时间是依据生物钟规律而设定\"的叙述中，最正确的是。',\n",
       "  ['清晨服用驱虫药', '睡前服用血脂调节药', '餐前服用氢氧化铝凝胶', '餐后服用非甾体抗炎药', '早、晚餐餐中服用熊脱氧胆酸'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('含有吩噻嗪结构的是',\n",
       "  ['[2KY100881.png]',\n",
       "   '[2KY100882.png]',\n",
       "   '[2KY100883.png]',\n",
       "   '[2KY100884.png]',\n",
       "   '[2KY100885.png]'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('血浆浓度超过40μg/ml，出现嗜睡、昏迷、严重不良反应的抗癫药物是',\n",
       "  ['卡马西平', '乙琥胺', '丙戊酸钠', '苯妥英钠', '唑吡坦'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('关于限定日剂量（DDD），下列说法错误的是',\n",
       "  ['描述用药频度', '方法具有局限性', '针对某一特定药物', '针对特定适应症', '只适用于成年人'],\n",
       "  ['1'],\n",
       "  '只适用于成年人'),\n",
       " ('为了加速患者的毒物排泄，可以使用的导泻药物是',\n",
       "  ['1∶2000高锰酸钾溶液', '3%鞣酸溶液', '10%硫酸钠溶液', '活性炭', '1%肥皂水'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('《国家非处方药目录》中收载的中枢性镇咳药是', ['可待因', '苯丙哌林', '喷托维林', '羧甲司坦', '氨溴索'], ['3'], ''),\n",
       " ('双室模型静脉滴注给药的血药浓度随时间变化的公式是',\n",
       "  ['[1K20022.png]',\n",
       "   '[1K20023.png]',\n",
       "   '[1K20024.png]',\n",
       "   '[1K20025.png]',\n",
       "   '[1K20026.png]'],\n",
       "  ['5'],\n",
       "  '[1K20021.png]'),\n",
       " ('黄体酮用于尿路结石属于',\n",
       "  ['超适应证给药', '有禁忌证用药', '盲目联合用药', '过度治疗给药', '非适应证给药'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('LD50 / ED50是', ['阈剂量', '效能', '效价强度', '半数有效量', '治疗指数'], ['5'], 'D'),\n",
       " ('该新药批准上市后进行的监测，即售后调研，属于',\n",
       "  ['0期临床试验', 'I期临床试验', 'Ⅱ期临床试验', 'Ⅲ期临床试验', 'Ⅳ期临床试验'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('下列药物中，驾驶员、机械操作者、高空作业者慎用的是',\n",
       "  ['噻托溴铵', '孟鲁司特', '茶碱', '泼尼松', '酮替芬'],\n",
       "  ['5'],\n",
       "  '1, 3'),\n",
       " ('抗甲状腺药治疗分为3个阶段。一般情况下，维持阶段约',\n",
       "  ['3月～6月', '6月～9月', '9月～1年', '1～1.5年', '2～2.5年'],\n",
       "  ['4'],\n",
       "  '1．3个月至6个月'),\n",
       " ('血管紧张素Ⅱ受体拮抗剂中半衰期最长的是', ['氯沙坦', '缬沙坦', '替米沙坦', '贝那普利', '坎地沙坦酯'], ['3'], '未知'),\n",
       " ('适宜餐中给药的是',\n",
       "  ['口服硫酸镁', '液状石蜡', '熊去氧胆酸', '鞣酸蛋白', '维生素B<SUB>2</SUB>'],\n",
       "  ['3'],\n",
       "  'A'),\n",
       " ('表观分布容积的计算公式是',\n",
       "  ['Cl=kV',\n",
       "   't<SUB>1/2</SUB>=0.693/k',\n",
       "   'MRT=AUMC/AUC',\n",
       "   'V=X<SUB>0</SUB>/C<SUB>0</SUB>',\n",
       "   'AUC=FX<SUB>0</SUB>/Vk'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('可用于制备溶蚀性骨架片', ['羟丙基甲基纤维素', '单硬脂酸甘油酯', '大豆磷脂', '无毒聚氯乙烯', '硬脂酸钠'], ['2'], ''),\n",
       " ('在不同药物动力学模型中，计算血药浓度与所向关系会涉及不同参数;双室模型中，慢配置速度常数是（\\u3000\\u3000）',\n",
       "  ['CI', 'Km，Vm', 'MRT', 'Ka', 'β'],\n",
       "  ['5'],\n",
       "  'Km'),\n",
       " ('由代谢产物发展而来的是', ['氨溴索', '乙酰半胱氨酸', '可待因', '苯丙哌林', '右美沙芬'], ['1'], 'B'),\n",
       " ('羟甲基乙酰辅酶', ['横纹肌溶解症', '急性心肌梗死', '十二指肠溃疡', '肾输尿管结石', '糖尿病坏疽'], ['1'], 'A'),\n",
       " ('使激动药与受体结合的量效曲线右移，最大反应不变的是',\n",
       "  ['激动药', '竞争性拮抗药', '部分激动药', '非竞争性拮抗药', '拮抗药'],\n",
       "  ['2'],\n",
       "  '无正确答案'),\n",
       " ('含有一个硝基的是', ['硝酸甘油', '硝酸异山梨醇酯', '单硝酸异山梨醇酯', '戊四硝酯', '双嘧达莫'], ['3'], ''),\n",
       " ('下述关于阿苯达唑的描述，错误的是',\n",
       "  ['具潜在的神经肌肉毒性',\n",
       "   '2岁以下儿童不宜服用',\n",
       "   '治疗蛔虫病、鞭虫病的首选药',\n",
       "   '蛋白尿、化脓性或弥漫性皮炎、各种急性传染病以及癫痫患者不宜使用',\n",
       "   '用于治疗钩虫、蛔虫、鞭虫、蛲虫、旋毛虫等'],\n",
       "  ['1'],\n",
       "  '无正确答案'),\n",
       " ('药物分子中引入卤素',\n",
       "  ['增加药物的水溶性，并增加解离度',\n",
       "   '可与生物大分子形成氢键，增强与受体的结合力',\n",
       "   '增强药物的亲水性，并增加其与受体的结合力',\n",
       "   '明显增加药物的亲脂性，并降低解离度',\n",
       "   '影响药物的电荷分布及作用时间'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('该患者的首选治疗方案应是硝酸酯类联合', ['氨氯地平', '坎地沙坦', '福辛普利', '肝素', '华法林'], ['1'], 'B'),\n",
       " ('患者男，双侧肾动脉狭窄，有哮喘病史，因气短、心悸就诊，体检和实验室检查结果为血压172/96mmHg，血尿酸516μmol/L（正常值180～440μmol/L），血钾5.6mmol/L（正常值3.5～5.5mmol/L应该选用哪一个降压药',\n",
       "  ['氢氯噻嗪', '替米沙坦', '卡托普利', '利血平', '拉西地平'],\n",
       "  ['5'],\n",
       "  'C'),\n",
       " ('反映肝实质细胞损伤的酶为', ['ALT', 'γ-GT', 'CK', 'AMY', 'ChE'], ['1'], 'ALT'),\n",
       " ('眼局部长期应用四环素可的松，可引起的副作用是',\n",
       "  ['结膜炎', '点状角膜炎', '视神经炎', '角膜溃疡', '青光眼'],\n",
       "  ['5'],\n",
       "  '1、2'),\n",
       " ('属于凝血因子X抑制剂，治疗窗宽，无需监测INR的抗凝血药物是',\n",
       "  ['华法林', '肝素', '达比加群酯', '依达肝素', '利伐沙班'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('氨溴索',\n",
       "  ['[图00561.png]',\n",
       "   '[图00562.png]',\n",
       "   '[图00563.png]',\n",
       "   '[图00564.png]',\n",
       "   '[图00565.png]'],\n",
       "  ['2'],\n",
       "  '[图00561.png]'),\n",
       " ('调配差错的处理步骤不包括',\n",
       "  ['停止救治或治疗',\n",
       "   '建立预案',\n",
       "   '立即核对相关的处方和药品，按照预案迅速处理并上报部门负责人',\n",
       "   '根据严重程度采取救助措施',\n",
       "   '为患者提供用药教育'],\n",
       "  ['1'],\n",
       "  '无正确答案'),\n",
       " ('治疗血脂异常的基础应该是',\n",
       "  ['控制饮食', '少饮酒、戒烟', '考虑药物治疗', '应用调节血脂药', '医学营养治疗并长期坚持'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('服用氟西汀后，需间隔多久才能服用单胺氧化酶抑制剂（M', ['3天', '1周', '2周', '3周', '5周'], ['5'], 'B'),\n",
       " ('在临床用药实践中，使用最为广泛的药物信息源是',\n",
       "  ['一级信息源', '二级信息源', '三级信息源', '四级信息源', '五级信息源'],\n",
       "  ['3'],\n",
       "  '三级信息源'),\n",
       " ('药物从体循环向组织、器官或体液转运的过程是（\\u3000）。',\n",
       "  ['药物的吸收', '药物的分布', '药物的代谢', '药物的排泄', '药物的消除'],\n",
       "  ['2'],\n",
       "  '药物的吸收'),\n",
       " ('下列药物中，适用于胸膜炎伴胸痛的咳嗽患者的是',\n",
       "  ['苯丙哌林', '喷托维林', '右美沙芬', '可待因', '羧甲司坦'],\n",
       "  ['4'],\n",
       "  'C'),\n",
       " ('甲睾酮的结构式是',\n",
       "  ['[图00741.png]',\n",
       "   '[图00742.png]',\n",
       "   '[图00743.png]',\n",
       "   '[图00744.png]',\n",
       "   '[图00745.png]'],\n",
       "  ['3'],\n",
       "  '[图00741.png]'),\n",
       " ('下列关于部分激动药描述正确的是',\n",
       "  ['对受体的亲和力很低',\n",
       "   '对受体的内在活性α=0',\n",
       "   '增加剂量能达到完全激动药的最大效应',\n",
       "   '加大剂量可因为占据受体而出现拮抗效应',\n",
       "   '吗啡是部分激动药'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('《中国国家处方集》有别于其他药学综合信息的是',\n",
       "  ['覆盖临床常见的近200种疾患',\n",
       "   '采取“以病带药”的方式编排',\n",
       "   '分为中药卷、化学药品与生物制品卷',\n",
       "   '以优先使用基本药物为药物治疗方案',\n",
       "   '提出选药原则是国家规范处方行为和指导临床合理用药的法规性和专业性指导文件'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('青霉素钠注射剂的皮肤敏感试验药物浓度应为',\n",
       "  ['100U／ml', '250U／ml', '500U／ml', '750U／ml', '1000U／ml'],\n",
       "  ['1'],\n",
       "  '无皮肤过敏试验'),\n",
       " ('关于生物素化依达肝素特点的叙述，不正确的是',\n",
       "  ['短效', '易中和', '选择性', '不需要定期监测', '不易受其他药物或食物的影响'],\n",
       "  ['1'],\n",
       "  '无正确答案'),\n",
       " ('具有17-酯基结构，脂溶性提高，作用时间延长的雌激素药物是',\n",
       "  ['[2KY101291.png]',\n",
       "   '[2KY101292.png]',\n",
       "   '[2KY101293.png]',\n",
       "   '[2KY101294.png]',\n",
       "   '[2KY101295.png]'],\n",
       "  ['5'],\n",
       "  '[2KY101292.png]'),\n",
       " ('应用该药物可引起的水、电解质紊乱是',\n",
       "  ['高钾血症', '高钠血症', '高镁血症', '高尿酸血症', '高氯碱血症'],\n",
       "  ['4'],\n",
       "  '高钾血症'),\n",
       " ('注射剂溶剂是', ['山梨酸', '硬脂酸甘油酯', '乙基纤维素', '滑石粉', '聚乙二醇400'], ['5'], ''),\n",
       " ('治疗作用的初步评价阶段',\n",
       "  ['临床前评价', 'I期临床试验', 'Ⅱ期临床试验', 'Ⅲ期临床试验', 'Ⅳ期临床试验'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('药物在乙醇、水的混合溶剂制剂相互配合使用时，析出沉淀或分层属于',\n",
       "  ['物理配伍变化', '化学配伍变化', '药理配伍变化', '液体配伍变化', '生物配伍变化'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('应当判定为不规范处方的是',\n",
       "  ['药物剂型不合理的处方', '适应证不适宜的处方', '未有医师签名的处方', '重复给药的处方', '无正当理由开具高价药品的处方'],\n",
       "  ['3'],\n",
       "  '无正确答案'),\n",
       " ('\"恒重\"，除另有规定外，系指供试品经连续两次干燥或炽灼后的重量差异在',\n",
       "  ['0.3g以下', '0.5mg以下', '3mg以下', '5mg以下', '0.3mg以下'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('急性肠息肉', ['黏液、脓血便', '稀糊状便', '米泔样便', '柏油样便', '白陶土样便'], ['2'], ''),\n",
       " ('单室模型多剂量静脉注射给药平均稳态血药浓度公式为',\n",
       "  ['[2KY100591.png]',\n",
       "   '[2KY100592.png]',\n",
       "   '[2KY100593.png]',\n",
       "   '[2KY100594.png]',\n",
       "   '[2KY100595.png]'],\n",
       "  ['1'],\n",
       "  '[2KY100596.png]'),\n",
       " ('结构中有吡唑结构，可选择性抑制环氧合酶-2的\\u200d抗炎药物是',\n",
       "  ['[2KY101061.png]',\n",
       "   '[2KY101062.png]',\n",
       "   '[2KY101063.png]',\n",
       "   '[2KY101064.png]',\n",
       "   '[2KY101065.png]'],\n",
       "  ['5'],\n",
       "  '[2KY101062.png]'),\n",
       " ('作用不同的靶点的联合是',\n",
       "  ['维生素C与铁剂同服',\n",
       "   '磷霉素联用其它抗菌药物',\n",
       "   '普萘洛尔联用硝苯地平降血压',\n",
       "   '亚胺培南－西司他丁复方制剂',\n",
       "   '硫酸阿托品联用解磷定解救有机磷中毒'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('判别\"大三阳\"区别于\"小三阳\"的主要检查项目是',\n",
       "  ['抗-HBs（＋）', '抗-HBc（＋）', '抗-HBe（＋）', 'HBeAg（＋)', 'HBsAg（＋）'],\n",
       "  ['4'],\n",
       "  'D'),\n",
       " ('接种流感疫苗，并根据需要加用短效支气管舒张剂，属于慢阻肺分级治疗方案中的',\n",
       "  ['0级', 'Ⅰ级', 'Ⅱ级', 'Ⅲ级', 'Ⅳ级'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('有机药物多数为弱酸或弱碱，在体液中只能部分解离，已解离的形式与非解离的形式同时存在于体液中，当pH=pKa时，分子型和离子型药物所占的比例分别为',\n",
       "  ['90%和10%', '10%和90%', '50%和50%', '33.3%和66.7%', '66.7%和33.3%'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('青蒿素治疗疟疾的作用机制是（）',\n",
       "  ['抑制疟原虫的二氢叶酸还原酶，阻碍核酸合成',\n",
       "   '通过产生自由基，破坏疟原虫的生物膜、蛋白质等最终导致虫体死亡',\n",
       "   '抑制DNA的复制和转录，使DNA断裂',\n",
       "   '杀灭红细胞外期及各型疟原虫的配子体',\n",
       "   '使虫体神经-肌肉去极化，引起痉挛和麻痹'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('PPIs连续应用3个月以上易导致', ['高钾血症', '高钙血症', '低镁血症', '高镁血症', '低钾血症'], ['3'], '1、2'),\n",
       " ('阿司匹林所致溃疡的高危人群不包括',\n",
       "  ['联合抗血小板药', '65岁以下男性', '既往有用药史', '合并幽门螺杆菌感染', '合用非甾体抗炎药'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('中枢性降压药是。', ['可乐定', '利血平', '拉贝洛尔', '肼苯哒嗪', '硝苯地平'], ['1'], '1、2'),\n",
       " ('如果粪便细胞显微镜检查检出上皮细胞，可提示供试者所患疾病的种类属于',\n",
       "  ['痢疾', '结肠癌', '急性肠炎', '肠道炎症', '伪膜性肠炎'],\n",
       "  ['5'],\n",
       "  '无此题项'),\n",
       " ('维生素B2', ['防治坏血病', '防治佝偻病', '防治夜盲症', '习惯性流产的辅助治疗', '防治唇干裂'], ['5'], '1、2'),\n",
       " ('脂溶性维生素（维生素',\n",
       "  ['减少被胃酸破坏', '减少被胃酶破坏', '食物促进其吸收', '延长在胃肠道滞留时间', '使其快速地通过胃肠道'],\n",
       "  ['4'],\n",
       "  '无正确答案'),\n",
       " ('可用于治疗乙型肝炎的药物不包括', ['拉米夫定', 'α-干扰素', '阿德福韦', '阿昔洛韦', '恩替卡韦'], ['4'], 'D'),\n",
       " ('属于药效学作用相加的药物相互作用是',\n",
       "  ['溴丙胺太林合用多潘立酮',\n",
       "   '氢氯噻嗪合用地高辛容易发生心律失常',\n",
       "   '硫酸阿托品联用解磷定解救有机磷中毒',\n",
       "   '辛伐他汀与大环内酯类合用致使前者血浆浓度增大',\n",
       "   '水合氯醛合用格列齐特使后者的游离型血浆药物浓度增大'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('胃溶性的薄膜衣材料是',\n",
       "  ['丙烯酸树脂Ⅱ号', '丙烯酸树脂Ⅲ号', 'EudragitsL型', 'HPMCP', 'HPMC'],\n",
       "  ['5'],\n",
       "  'E'),\n",
       " ('单室模型静脉滴注的稳态血药浓度是', ['Cmax', 't1/2', 'V', 'X0', 'Css'], ['5'], ''),\n",
       " ('患者，男，53岁，体重70kg，因咳嗽、咳痰伴发热就诊，查体后诊断为社区获得性肺炎。肾功能提示：血肌酐（Cr）140μmol/L。给予左氧氟沙星片（规格：0.5g/片）进行治疗。治疗方案为【注：成年男性的肌酐清除率计算公式：Ccr=（140-年龄）×体重/（0.814×Cr）】 [YZH2017GJZYYSKSCCSJ1001.png]',\n",
       "  ['每日给药500mg',\n",
       "   '每日给药750mg',\n",
       "   '首剂500mg，之后每48小时给药500mg',\n",
       "   '首剂500mg，之后每48小时给药250mg',\n",
       "   '首剂500mg，之后每24小时给药500mg'],\n",
       "  ['1'],\n",
       "  '根据公式计算出患者的Ccr约为50ml/min,因此需要调整剂量。建议首次剂量为500mg，然后每48h给药500mg以维持稳定的血药浓度。故正确答案是第3项和第5项的组合。'),\n",
       " ('在阿昔洛韦结构上引入羟甲基得到的抗病毒药物是',\n",
       "  ['[2KY101521.png]',\n",
       "   '[2KY101522.png]',\n",
       "   '[2KY101523.png]',\n",
       "   '[2KY101524.png]',\n",
       "   '[2KY101525.png]'],\n",
       "  ['2'],\n",
       "  '[2KY101522.png]'),\n",
       " ('降压药哌唑嗪的主要不良反应是',\n",
       "  ['心动过缓', '肝功能损害', '首过效应', '首剂现象', '头昏、头痛等'],\n",
       "  ['4'],\n",
       "  '头晕和低血压'),\n",
       " ('单纯收缩期高血压是指',\n",
       "  ['收缩压＜120mmHg和舒张压<80mmHg',\n",
       "   '收缩压140～159mmHg和（或）舒张压90～99mmHg',\n",
       "   '收缩压160～179mmHg和（或）舒张压100～109mmHg',\n",
       "   '收缩压≥180mmHg和（或）舒张压≥110mmHg',\n",
       "   '收缩压≥140mmHg和舒张压<90mmHg'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('药物分子中引入酰胺基的作用是',\n",
       "  ['增加药物的水溶性，并增加解离度',\n",
       "   '可与生物大分子形成氢键，增强与受体的结合力',\n",
       "   '增强药物的亲水性，并增加其与受体的结合力',\n",
       "   '明显增加药物的亲脂性，并降低解离度',\n",
       "   '影响药物的电荷分布及作用时间'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('药品说明书属于', ['一级信息', '二级信息', '三级信息', '四级信息', '五级信息'], ['3'], '一级信息'),\n",
       " ('影响肌肉注射给药的因素有',\n",
       "  ['药物的脂溶性和解离度，分子量和粒子大小，吸收促进剂的选择',\n",
       "   '局部血流量，溶媒的选择，分子量及脂溶性',\n",
       "   '药物的脂溶性和解离度，食物种类，不同剂型',\n",
       "   '基质的选择，药物在基质中释放的快慢',\n",
       "   '制剂的黏度，pH与渗透压及渗透促进剂的选择'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('在常规计量下，5α还原酶抑制剂可使（血清前列腺特异抗原）PS',\n",
       "  ['10%', '20%', '30%', '40%', '50%'],\n",
       "  ['5'],\n",
       "  'C'),\n",
       " ('被动靶向制剂经静脉注射后，积集于骨髓的粒径是',\n",
       "  ['2.5～10μm', '小于7μm', '200～400nm', '小于10nm', '大于7μm'],\n",
       "  ['4'],\n",
       "  '小于7μm'),\n",
       " ('2级高血压（中度）血压水平范围是',\n",
       "  ['收缩压120～139mmHg舒张压80～89mmHg',\n",
       "   '收缩压140～159mmHg舒张压90～99mmHg',\n",
       "   '收缩压160～179mmHg舒张压100～109mmHg',\n",
       "   '收缩压≥180mmHg舒张压≥110mmHg',\n",
       "   '收缩压≥140mmHg舒张压<90mmHg'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('患者，诊断为感染性心内膜炎，血液细菌培养为草绿色链球菌，拟用青霉素G和下列其中一药合用，应选',\n",
       "  ['阿莫西林', '红霉素', '庆大霉素', '奈替米星', '羧苄西林'],\n",
       "  ['3'],\n",
       "  'A'),\n",
       " ('患者男，76岁，8天来夜间咳嗽，痰多，诊断为急性支气管炎，除抗感染治疗外，在选服右美沙芬时应加用的药品是',\n",
       "  ['洛贝林', '安钠咖', '氨茶碱', '可待因', '氯溴索'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('下列关于硫磺的描述中，错误的是',\n",
       "  ['不得与铁制品接触', '可用于痤疮、脂溢性皮炎', '避免接触眼睛和其他黏膜', '儿童慎用', '治疗疥疮时需涂抹全身'],\n",
       "  ['1'],\n",
       "  '无'),\n",
       " ('适用于肝性脑病及长期卧床的老年便秘患者的药物是',\n",
       "  ['比沙可啶', '甘油栓', '硫酸镁', '乳果糖', '聚乙二醇'],\n",
       "  ['4'],\n",
       "  'A'),\n",
       " ('固体分散体增加药物溶解度的主要机理不正确的是',\n",
       "  ['载体使药物提高可湿性', '载体保证药物高度分散', '载体具有抑晶性', '载体是高分子', '药物的高度分散状态'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('由美国卫生系统药师协会出版的《HandbookonInjectableDrug》袖珍本的中译本是',\n",
       "  ['《注射药物手册》',\n",
       "   '《Trissel注射药物手册》',\n",
       "   '《药品注射剂使用指南》',\n",
       "   '《Trissel混合组分的稳定性》',\n",
       "   '《432种静脉注射剂配伍指南》'],\n",
       "  ['3'],\n",
       "  '无正确答案'),\n",
       " ('二甲双胍的不良反应为', ['肝功能异常', '心力衰竭', '头痛', '体重增加', '乳酸性酸中毒'], ['5'], 'B'),\n",
       " ('青霉素钠注射剂皮试药液浓度和皮试用量正确的是',\n",
       "  ['500U皮内0.lml',\n",
       "   '75IU（稀释20倍）皮内0.1ml',\n",
       "   '1mg皮内0.1ml',\n",
       "   '20U（稀释20倍）皮内0.1ml',\n",
       "   '300μg或500μg皮内0.1ml'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('效价强度指的是',\n",
       "  ['药物的内在活性',\n",
       "   '能引起等效反应（一般采用50%效应量）相对剂量或浓度，其值越小则强度越大',\n",
       "   '半数有效量',\n",
       "   '半数致死量',\n",
       "   '治疗指数'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('差错的防范与处理措施是',\n",
       "  ['建立预案', '建立首问负责制', '制定明确的差错防范措施', '药物配伍有禁忌', '为患者提供救助措施'],\n",
       "  ['2'],\n",
       "  'A'),\n",
       " ('利用溶出原理达到缓(控)释目的的方法是',\n",
       "  ['包衣', '与高分子化合物生成难溶性盐', '制成不溶性骨架片', '将药物包藏于亲水性高分子材料中', '制成药树脂'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('药物的非特异性作用',\n",
       "  ['主要与药物基因有关', '与机体免疫系统有关', '与药物的化学结构有关', '主要与药物作用的载体有关', '与药物本身的理化性质有关'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('每天给药3次的外文缩写是', ['bid', 'tid', 'qid', 'qod', 'St'], ['2'], 'qid（每天四次）'),\n",
       " ('当药物对某些组织有特殊亲和性时，这种药物连续应用，该组织中的药物浓度有逐渐升高的趋势，称为',\n",
       "  ['分布', '代谢', '排泄', '蓄积', '转化'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('属于第一信使的是', ['药物', '环磷酸腺苷', '环磷酸鸟苷', '钙离子', '生长因子'], ['1'], ''),\n",
       " ('丙氧酚的右旋体是', ['镇痛药', '镇咳药', '抗疟药', '抗心律失常药', '抗结核药'], ['1'], 'B'),\n",
       " ('以下属于乳酸菌类微生态制剂的是', ['双歧杆菌', '蜡状芽孢杆菌', '地衣芽孢杆菌', '丁酸梭菌', '酪酸梭菌'], ['1'], ''),\n",
       " ('含有甲磺酸酯结构的抗肿瘤药物白消安，在体内的Ⅱ相代谢反应是',\n",
       "  ['甲基化的结合反应', '与硫酸的结合反应', '与谷胱甘肽的结合反应', '与葡萄糖醛酸的结合反应', '与氨基酸的结合反应'],\n",
       "  ['3'],\n",
       "  'C'),\n",
       " ('若该患者肌酐清除率20ml/min，上题所选药物正确的用量和用法是',\n",
       "  ['0.4g，5次/日', '0.4g，4次/日', '0.4g，3次/日', '0.4g，2次/日', '0.4g，1次/日'],\n",
       "  ['3'],\n",
       "  '无法判断'),\n",
       " ('下列二氢吡啶类钙离子拮抗剂中，2,6位取代基不同的药物是',\n",
       "  ['尼莫地平', '尼群地平', '氨氯地平', '硝苯地平', '硝苯吡啶'],\n",
       "  ['3'],\n",
       "  'C'),\n",
       " ('与丙磺舒联合应用，有增效作用的药物是', ['四环素', '氯霉素', '青霉素', '红霉素', '罗红霉素'], ['3'], 'B'),\n",
       " ('青霉素钠注射剂的皮试药液浓度应为',\n",
       "  ['100U/ml', '250U/ml', '500U/ml', '750U/ml', '1000U/ml'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('脂肪乳用于急性肝损伤、急性胰腺炎，属于',\n",
       "  ['无适应证用药', '无正当理由超适应证用药', '不合理联合用药', '过度治疗用药', '有禁忌证用药'],\n",
       "  ['5'],\n",
       "  '无正当理由超适应证用药'),\n",
       " ('盐酸左氧氟沙星注射液不小心喷溅入眼内，引起眼睑红肿、热痛，该不良反应按发生机制分属于',\n",
       "  ['A类反应', 'B类反应', 'C类反应', 'D类反应', 'E类反应'],\n",
       "  ['3'],\n",
       "  'D'),\n",
       " ('生物利用度',\n",
       "  ['表示药物在体内分布的广泛性',\n",
       "   '用来衡量药物吸收速度的快慢',\n",
       "   '用来衡量药物从体内消除速度的快慢',\n",
       "   '用来衡量血管外给药时进入体循环药物的相对数量和速度',\n",
       "   '指血药浓度衰减一半时所需的时间'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('C-3位为氯原子，亲脂性强，口服吸收好的药物是',\n",
       "  ['[2KY101471.png]',\n",
       "   '[2KY101472.png]',\n",
       "   '[2KY101473.png]',\n",
       "   '[2KY101474.png]',\n",
       "   '[2KY101475.png]'],\n",
       "  ['2'],\n",
       "  '[2KY101472.'),\n",
       " ('使用二磷酸果糖时，需要监测血磷水平的是（）',\n",
       "  ['肌酐清除率低于20%的患者',\n",
       "   '肌酐清除率低于30%的患者',\n",
       "   '肌酐清除率低于40%的患者',\n",
       "   '肌酐清除率低于50%的患者',\n",
       "   '肌酐清除率低于60%的患者'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('属于长期用药致病型的是',\n",
       "  ['四环素引起伪膜性肠炎', '己烯雌酚引起子代女性青春期后阴道腺癌', '口服避孕药引起心梗', '胰岛素引起低血糖性休克', '磺胺引起皮疹'],\n",
       "  ['3'],\n",
       "  '1, 2'),\n",
       " ('钙制剂+维生素D+双膦酸盐用于治疗',\n",
       "  ['原发性骨质疏松', '老年性骨质疏松', '妇女绝经后骨质疏松', '抗癫痫药所致的骨质疏松', '肾上腺皮质激素所致的骨质疏松'],\n",
       "  ['2'],\n",
       "  '1、2、3'),\n",
       " ('中度贫血的指标是',\n",
       "  ['Hb＜120g/L', 'Hb＜110g/L', 'Hb＜100g/L', 'Hb90～120g/L', 'Hb60～90g/L'],\n",
       "  ['5'],\n",
       "  'Hb<100 g/L'),\n",
       " ('长期大量服用维生素D会出现',\n",
       "  ['头痛、眼花、烦躁、心律失常、妇女经血不止等',\n",
       "   '低热、烦躁哭闹、惊厥、厌食、体重减轻、骨骼硬化症等',\n",
       "   '视力模糊、乳腺肿大、腹泻、头晕、流感样症状等',\n",
       "   '疲劳、软弱、全身不适、毛发干枯或脱落、皮肤干燥瘙痒、食欲减退、贫血眼球突出等中毒现象',\n",
       "   '腹泻、皮肤红而亮、头痛、尿频、恶心、呕吐等'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('他汀类药在标准计量的基础上，剂量增加1倍，LDL-ch降幅平均增加',\n",
       "  ['3%', '6%', '8%', '9%', '10%'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('相互作用延缓或降低抗药性的联合用药是',\n",
       "  ['阿托品联用氯磷定', '青蒿素联用乙胺嘧啶', '阿托品联用普萘洛尔', '普萘洛尔联用硝苯地平', '甲苯磺丁脲联用氢氯噻嗪'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('选择性单胺氧化酶', ['氯米帕明', '吗氯贝胺', '氟伏沙明', '米氮平', '度洛西汀'], ['2'], 'B'),\n",
       " ('&#10;当创伤应激严重时，由葡萄糖与脂肪提供NPC的比例是',\n",
       "  ['NPC7:3', 'NPC5:5', '150kcal：1gN', '100kcal：1gN', '24～32kcal/kg•d'],\n",
       "  ['2'],\n",
       "  'C'),\n",
       " ('小剂量（日剂量小于0.8mg），在安全级别',\n",
       "  ['维生素B12', '维生素K', '华法林', '硫酸亚铁', '叶酸'],\n",
       "  ['5'],\n",
       "  'C'),\n",
       " ('因摄食蛋白质者宜服用的药物是', ['胰酶', '乳酶生', '胃蛋白酶', '二甲硅油', '胰酶和碳酸氢钠'], ['3'], ''),\n",
       " ('苯巴比妥属于长效药，主要原因是',\n",
       "  ['其结构中5位乙基不易氧化',\n",
       "   '其结构中5位苯基不易氧化',\n",
       "   '其结构中5位异戊基不易氧化',\n",
       "   '其结构中5环己基不易氧化',\n",
       "   '其结构中5位环己烯基不易氧化'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('可抑制细菌β-内酰胺酶的是', ['磷霉素', '替考拉宁', '利福平', '舒巴坦', '左氧氟沙星'], ['4'], 'B'),\n",
       " ('镇静、安定、麻醉、止痛药',\n",
       "  ['乳母应用下列药物会对乳婴产生何种不良影响，胎儿畸形',\n",
       "   '乳母应用下列药物会对乳婴产生何种不良影响，导致新生儿血钙过高',\n",
       "   '乳母应用下列药物会对乳婴产生何种不良影响，可能引起乳婴视神经损害、智力障碍',\n",
       "   '乳母应用下列药物会对乳婴产生何种不良影响，可引起过期妊娠、产程过长和产后出血',\n",
       "   '乳母应用下列药物会对乳婴产生何种不良影响，抑制胎儿神经的活动'],\n",
       "  ['5'],\n",
       "  '1. 胎儿畸形'),\n",
       " ('可用于治疗营养不良、厌食、脚气合并糙皮病，大剂量服用后，尿液可能呈黄色的药物是',\n",
       "  ['维生素A', '复合维生素B', '维生素C', '维生素E', '维生素K<SUB>1</SUB>'],\n",
       "  ['2'],\n",
       "  '维生素B'),\n",
       " ('关于胶体果胶铋用药教育的说法，错误的是(\\u3000)。',\n",
       "  ['胶体果胶铋宜与牛奶同时服用',\n",
       "   '胶体果胶铋使用后口中可能有氨味',\n",
       "   '胶体果胶铋使用后大便可能会变黑',\n",
       "   '妊娠期妇女禁用胶体果胶铋',\n",
       "   '两种铋剂不宜联用'],\n",
       "  ['1'],\n",
       "  '无正确答案'),\n",
       " ('下列药物中不含有咪唑基团的是', ['氟康唑', '奥美拉唑', '西咪替丁', '咪康唑', '兰索拉唑'], ['1'], 'D'),\n",
       " ('患者症状控制后，可改为长期口服β受体阻断剂维持疗效，如需停药，应逐步停药，整个过程至少需',\n",
       "  ['1周', '2周', '3周', '4周', '5周'],\n",
       "  ['2'],\n",
       "  '无正确答案'),\n",
       " ('下列内容不会出现在药历上的是',\n",
       "  ['患者手机号码',\n",
       "   '患者所患疾病',\n",
       "   '患者所用药物的名称、剂量、给药途径等',\n",
       "   '患者所用药物的禁忌证、适应证、主要不良反应',\n",
       "   '患者用药后的疗效和不良反应'],\n",
       "  ['4'],\n",
       "  '无'),\n",
       " ('乳母服用红霉素，乳汁中红霉素的量高于总用药量1%的机制是其',\n",
       "  ['解离度大', '呈弱碱性', '呈弱酸性', '在母体血浆中处于结合状态', '在脂肪与水中都有一定溶解度'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('与左旋多巴联合使用，可以防止药物在外周被多巴脱羧酶代谢的是',\n",
       "  ['甲氧苄啶', '阿托品', '西司他丁钠', '克拉维酸钾', '卡比多巴'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('1，8位以氧原子环合形成吗啉环，结构中具有手\\u200d性中心，药用左旋体的是',\n",
       "  ['[2KY101431.png]',\n",
       "   '[2KY101432.png]',\n",
       "   '[2KY101433.png]',\n",
       "   '[2KY101434.png]',\n",
       "   '[2KY101435.png]'],\n",
       "  ['4'],\n",
       "  '[2KY101431.png]'),\n",
       " ('结构中不含有咪唑环的血管紧张素Ⅱ受体拮抗剂是',\n",
       "  ['缬沙坦', '氯沙坦', '替米沙坦', '坎地沙坦', '厄贝沙坦'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('西地那非用药剂量为50-lOOmg，服药者发生\"蓝视\"的比例可能为',\n",
       "  ['60%', '50%', '30%', '10%', '3%'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('属于胆酸螯合剂调脂药是', ['辛伐他汀', '烟酸', '依替米贝', '氯贝丁酯', '考来替泊'], ['5'], '1、2、4'),\n",
       " ('易被胃酸破坏，口服吸收少，临床一般服用其肠衣片或酯化物的药物是',\n",
       "  ['红霉素', '罗红霉素', '克拉霉素', '克林霉素', '四环素'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('属于溴己新活性代谢产物的是', ['可待因', '苯丙哌林', '右美沙芬', '氨溴索', '乙酰半胱氨酸'], ['4'], 'B'),\n",
       " ('主要用作普通药物制剂溶剂的制药用水的是', ['天然水', '饮用水', '纯化水', '注射用水', '灭菌注射用水'], ['3'], ''),\n",
       " ('以下所列项目中，作为评价药学服务的安全性效果的是',\n",
       "  ['改善病情或症状', '降低发病率或复发率', '减少急诊次数和住院次数', '预防药品不良反应的发生', '提高公众的健康意识，普及康复方法'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('效能表示方式为',\n",
       "  ['TI', 'α', 'E<SUB>max</SUB>', 'pD<SUB>2</SUB>', 'pA<SUB>2</SUB>'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('以下有关双歧三联活菌胶囊治疗腹泻的机制的叙述中，最正确的是。',\n",
       "  ['补充正常的细菌', '减少腹胀和腹泻', '防止蛋白质发酵', '抑制肠内腐败菌生长', '维持肠道正常菌群的平衡'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('单室模型静脉滴注给药，达到稳态血药浓度99%需要几个半衰期',\n",
       "  ['1', '2', '3.32', '4', '6.64'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('药物肌内注射时，其吸收的速率顺序为',\n",
       "  ['混悬液>水溶液>油溶液', '水溶液>混悬液>油溶液', '混悬液>油溶液>水溶液', '水溶液>油溶液>混悬液', '油溶液>水溶液>混悬液'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('医疗器械最重要的质量特性是', ['有效性', '安全性', '适用性', '经济性', '维修性'], ['2'], '可靠性'),\n",
       " ('紧急避孕药的服用时间是在无防护性性生活或避孕失败多长时间以内',\n",
       "  ['12h', '24h', '48h', '72h', '84h'],\n",
       "  ['4'],\n",
       "  '24小时'),\n",
       " ('治疗阿片类药物的依赖性，不包括',\n",
       "  ['美沙酮替代治疗', '可乐定治疗', '东莨菪碱综合治疗', '5-HT<SUB>3</SUB>受体阻断药昂丹司琼治疗', '心理干预'],\n",
       "  ['4'],\n",
       "  'D'),\n",
       " ('含有3-羟基-δ-内酯环的结构片段，需要在体内水解为3，5-二羟基羧酸，才能发挥作用的HMG-Co',\n",
       "  ['辛伐他汀', '氟伐他汀', '普伐他汀', '西立伐他汀', '阿托伐他汀'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('出现差错的类别有',\n",
       "  ['药品与其适应证不符',\n",
       "   '发给患者但未造成伤害',\n",
       "   '处方辨认不清',\n",
       "   '包装相似或读音相似的药品分开码放',\n",
       "   '一张处方药品调配结束后再取下一张处方，以免发生混淆'],\n",
       "  ['2'],\n",
       "  'A'),\n",
       " ('经消化道吸收的农药中毒，加速毒物排泄的方法不包括', ['人工呼吸', '催吐', '洗胃', '导泻', '利尿'], ['1'], 'D'),\n",
       " ('用于改善晚期肿瘤患者的恶液质', ['曲妥珠单抗', '氟他胺', '阿那曲唑', '他莫昔芬', '甲地孕酮'], ['5'], 'B'),\n",
       " ('孕妇贫血的指标是',\n",
       "  ['Hb＜120g/L', 'Hb＜110g/L', 'Hb＜100g/L', 'Hb90～120g/L', 'Hb60～90g/L'],\n",
       "  ['3'],\n",
       "  'Hb<110 g/L'),\n",
       " ('喹诺酮类药物的基本结构是（\\u3000）。[图1]', ['A', 'B', 'C', 'D', 'E'], ['3'], 'D'),\n",
       " ('曲线下面积（单室静脉注射）的计算公式为',\n",
       "  ['[2KY100511.png]',\n",
       "   '[2KY100512.png]',\n",
       "   '[2KY100513.png]',\n",
       "   '[2KY100514.png]',\n",
       "   '[2KY100515.png]'],\n",
       "  ['5'],\n",
       "  '[2KY100516.png]'),\n",
       " ('药学服务是药师对患者的关怀和责任。下列人员中，属于药学服务的重要人群是',\n",
       "  ['门诊患者', '社区患者', '住院患者', '过敏体质者', '药品消费者'],\n",
       "  ['4'],\n",
       "  '1、2、3'),\n",
       " ('该药物的作用机制是',\n",
       "  ['抑制二氢叶酸合成酶', '抑制二氢叶酸还原酶', '抑制DNA回旋酶和拓扑异构酶Ⅳ', '抑制细菌细胞壁合成', '抑制环氧酶'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('头孢羟氨苄的化学结构为',\n",
       "  ['[图00831.png]',\n",
       "   '[图00832.png]',\n",
       "   '[图00833.png]',\n",
       "   '[图00834.png]',\n",
       "   '[图00835.png]'],\n",
       "  ['2'],\n",
       "  '[图00831.png]'),\n",
       " ('以下哪一项不是运动员服用兴奋剂造成的危害结果',\n",
       "  ['抗菌药物对肾脏的损害',\n",
       "   '男性长期应用合成类固醇可导致阳痿、睾丸萎缩及精子生成减少而影响生育',\n",
       "   '女性长期应用合成类固醇可导致月经絮乱、闭经、不孕及出现男性化症状',\n",
       "   '长期服用麻黄素类、可卡因，会产生头痛、心慌、焦虑、失眠及耳鸣',\n",
       "   '利尿药可造成人体严重脱水甚至肾衰竭'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('不易在乳汁中排出的弱酸性抗生素是', ['四环素', '红霉素', '青霉素', '氯霉素', '头孢唑林'], ['3'], 'B'),\n",
       " ('服用利血平可能引起', ['心动过缓', '血钾降低', '血钾升高', '面部潮红', '下肢浮肿'], ['1'], '1、2'),\n",
       " ('分子中含有哌啶的结构，具有μ受体激动作用的药物是',\n",
       "  ['[YZ12017GJZYYSTG2000T1022.png]',\n",
       "   '[YZ12017GJZYYSTG2000T1023.png]',\n",
       "   '[YZ12017GJZYYSTG2000T1024.png]',\n",
       "   '[YZ12017GJZYYSTG2000T1025.png]',\n",
       "   '[YZ12017GJZYYSTG2000T1026.png]'],\n",
       "  ['4'],\n",
       "  '[YZ12017GJZYYSTG2000T1022.png]'),\n",
       " ('不属于抗乙型肝炎病毒的药品是（\\u3000）。',\n",
       "  ['拉米夫定', '恩替卡韦', '泛昔洛韦', '干扰素', '阿德福韦酯'],\n",
       "  ['3'],\n",
       "  '泛昔洛韦'),\n",
       " ('在经皮给药制剂中，可用作控释膜材料的是',\n",
       "  ['聚苯乙烯', '微晶纤维素', '乙烯-醋酸乙烯共聚物', '硅橡胶', '低取代羟丙基纤维素'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('发表在《中国药理学学报》上有关紫杉醇的综述文章，属于',\n",
       "  ['五级信息', '四级信息', '三级信息', '二级信息', '一级信息'],\n",
       "  ['3'],\n",
       "  '三级信息'),\n",
       " ('在处方用药适宜性审核时，应特别注意是否有潜在临床意义的药物相互作用和配伍禁忌。下列药物合用会增加毒性或不良反应的是',\n",
       "  ['阿莫西林和克拉维酸钾', '头孢哌酮和舒巴坦', '苄丝肼和左旋多巴', '甲氧氯普胺和氯丙嗪', '亚胺培南和西司他丁钠'],\n",
       "  ['4'],\n",
       "  'A'),\n",
       " ('下列药物属于酶诱导剂的是', ['氯霉素', '异烟肼', '红霉素', '胺碘酮', '卡马西平'], ['5'], '2、5'),\n",
       " ('口服剂型在胃肠道中吸收快慢的顺序一般认为是',\n",
       "  ['混悬剂＞溶液剂＞胶囊剂＞片剂＞包衣片',\n",
       "   '胶囊剂＞混悬剂＞溶液剂＞片剂＞包衣片',\n",
       "   '片剂＞包衣片＞胶囊剂＞混悬剂＞溶液剂',\n",
       "   '溶液剂＞混悬剂＞胶囊剂＞片剂＞包衣片',\n",
       "   '包衣片＞片剂＞胶囊剂＞混悬剂＞溶液剂'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('单位时间从体内消除的含药血浆体积', ['速率常数', '半衰期', '有效期', '表观分布容积', '清除率'], ['5'], ''),\n",
       " ('患者，女，43岁，在单位例行的年度体检中，发现体检报告单（如下表）中个别数据异常，根据报告单对体检结果描述正确的是 [YZH2017KDS2001.png]',\n",
       "  ['患者可能患有高脂血症、糖尿病', '患者肝功能异常', '患者肾功能正常', '患者近期感染过乙型肝炎病毒', '患者近期注射过乙肝疫苗'],\n",
       "  ['1'],\n",
       "  '无法从提供的表格中获取足够信息来判断患者的身体状况和健康状况'),\n",
       " ('下列保肝药中，对于高血压患者应慎用的是',\n",
       "  ['复方甘草酸苷', '还原型谷胧甘肤学品', '多烯磷脂酰胆碱', '门冬氨酸钾镁', '联苯双酯'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('Ⅰ类手术切口应用第三代头孢菌素，属于',\n",
       "  ['无适应证用药', '无正当理由超适应证用药', '不合理联合用药', '过度治疗用药', '有禁忌证用药'],\n",
       "  ['1'],\n",
       "  'Ⅱ'),\n",
       " ('按物质形态分类的方法是',\n",
       "  ['按分散系统分类法', '按给药途径分类法', '按形态分类法', '按制法分类法', '综合分类法'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('在几种药物治疗方案所得的临床效果完全相同的情况下，比较何种干预方案的成本最小的是',\n",
       "  ['最小成本分析', '成本效果分析', '成本效益分析', '成本效用分析', '成本效能分析'],\n",
       "  ['1'],\n",
       "  '最小成本分析'),\n",
       " ('30%≤FEV1＜50%预计值，FEV1/FVC＜70%属于',\n",
       "  ['0级慢阻肺', 'I级慢阻肺', 'Ⅱ级慢阻肺', 'Ⅲ级慢阻肺', 'Ⅳ级慢阻肺'],\n",
       "  ['4'],\n",
       "  'II级慢性阻塞性肺病'),\n",
       " ('属于曲马多缓释片的溶出曲线的是（\\u3000）。[图1]', ['A', 'B', 'C', 'D', 'E'], ['1'], 'B'),\n",
       " ('含有环状丙二酰脲结构，属国家特殊管理的精神药品是',\n",
       "  ['苯巴比妥', '苯妥英钠', '加巴喷丁', '卡马西平', '丙戊酸钠'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('下列文献中，属于一级信息源的是',\n",
       "  ['《中国药学文摘》', '《中国药学杂志》', '《中国医药年鉴》', '《注射药物手册》', '《中国药典临床用药须知》'],\n",
       "  ['2'],\n",
       "  '1、2'),\n",
       " ('与药品本身药理作用无关的异常反应，一般在长期用药后出现，如非那西汀引起间质性肾炎的是',\n",
       "  ['A型不良反应', 'B型不良反应', 'C型不良反应', '急性毒性反应', '慢性毒性反应'],\n",
       "  ['3'],\n",
       "  'C型不良反应'),\n",
       " ('分子中含有（S）-莨菪酸与莨菪醇所成酯的药物是',\n",
       "  ['[YX11200SRTX0717.png]',\n",
       "   '[YX11200SRTX0718.png]',\n",
       "   '[YX11200SRTX0719.png]',\n",
       "   '[YX11200SRTX0720.png]',\n",
       "   '[YX11200SRTX0721.png]'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('不存在吸收过程的给药途径是', ['静脉注射', '肌内注射', '肺部给药', '腹腔注射', '口服给药'], ['1'], 'B'),\n",
       " ('药物经过3.32个半衰期，从体内消除的百分数为',\n",
       "  ['99.22%', '99%', '93.75%', '90%', '50%'],\n",
       "  ['4'],\n",
       "  'C'),\n",
       " ('适合睡前服用的是', ['吲哚美辛', '奥利司他', '氟伐他汀', '多潘立酮', '泼尼松龙'], ['3'], '多潘立酮'),\n",
       " ('已知头孢克肟干混悬剂的儿童用量为每次按每公斤体重1.5～3.0mg给药，则一名体重为15kg儿童的一次给药剂量为',\n",
       "  ['11.2～22.5mg', '22.5～45mg', '25～50mg', '30～60mg', '32.5～65mg'],\n",
       "  ['2'],\n",
       "  '无法计算'),\n",
       " ('在‘药物综合信息类’三级信息源中，世界最著名的大型药物参考工具书是',\n",
       "  ['医师案头参考', '药物事实与比较', '马丁代尔药物大典', '美国药典药物信息', 'Stockley药物相互作用'],\n",
       "  ['3'],\n",
       "  '马丁代尔药物大典'),\n",
       " ('肾上腺素β受体拮抗剂侧链氨基的取代基一\\u200d般为', ['哌啶基', '芳基', '甲基', '乙基', '异丙基'], ['5'], ''),\n",
       " ('Noyes-Whitney扩散方程可以计算',\n",
       "  ['药物溶出速度',\n",
       "   '体内游离血浆药物浓度和结合型血浆药物浓度的比例',\n",
       "   '药物半衰期和血浆药物浓度的关系',\n",
       "   '药物解离度与pH的关系',\n",
       "   '脂水分配系数与吸收的关系'],\n",
       "  ['1'],\n",
       "  ''),\n",
       " ('可用于检眼镜检查后，抵消睫状肌麻痹剂或扩瞳药作用的是',\n",
       "  ['噻吗洛尔', '乙酰唑胺', '溴莫尼定', '毛果芸香碱', '拉坦前列素'],\n",
       "  ['4'],\n",
       "  'B'),\n",
       " ('以下所列审查处方结果中，可判定为\"用药不适宜处方\"的是',\n",
       "  ['字迹难以辨认', '无适应证用药', '临床诊断缺项或书写不全', '未使用药品规范名称', '无正当理由不首选国家基本药物'],\n",
       "  ['5'],\n",
       "  '无正当理由不首选国家基本药物'),\n",
       " ('老年人服用普萘洛尔容易出现头痛、眩晕、低血压等不良反应，属于',\n",
       "  ['年龄因素', '性别因素', '基础疾病因素', '过敏反应', '遗传因素'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('静脉滴注两性霉素B50mg时，滴注时间应当控制在',\n",
       "  ['0.5h以上', '1h以上', '2h以上', '4h以上', '6h上'],\n",
       "  ['5'],\n",
       "  ''),\n",
       " ('罗格列酮的降糖作用机制是',\n",
       "  ['竞争性抑制α葡萄糖苷酶',\n",
       "   '刺激胰岛β细胞释放胰岛素',\n",
       "   '提高靶组织对胰岛素的敏感性',\n",
       "   '直接补充胰岛素',\n",
       "   '关闭β细胞膜中ATP-依赖性钾通道，打开钙通道'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('以上药物连续应用3个月以上还易导致', ['高钾血症', '高钙血症', '低镁血症', '高镁血症', '低钾血症'], ['3'], '1、2'),\n",
       " ('为人体安全性评价，一般选20~30例健康成年人志愿者，为制定临床给药方案提供依据，称为',\n",
       "  ['I期临床研究', 'Ⅱ期临床研究我）', 'Ⅲ期临床研究', 'IV期临床研究', '0期临床研究'],\n",
       "  ['1'],\n",
       "  'I期临床研究'),\n",
       " ('血液病、创伤及铅、铋中毒可呈现',\n",
       "  ['淋巴细胞增多', '单核细胞增多', '中性粒细胞增多', '嗜酸性粒细胞增多', '嗜碱性粒细胞增多'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('患者已使用，需要监测差错对患者的后果，并根据后果决定是否需要采取措施，此种用药错误属于',\n",
       "  ['A级用药错误', 'B级用药错误', 'C级用药错误', 'D级用药错误', 'E级用药错误'],\n",
       "  ['4'],\n",
       "  'D级用药错误'),\n",
       " ('不经过肝脏CYP450酶系代谢的药物是',\n",
       "  ['瑞舒伐他汀', '阿托伐他汀', '洛伐他汀', '普伐他汀', '辛伐他汀'],\n",
       "  ['4'],\n",
       "  'A'),\n",
       " ('米索前列醇所导致的主要不良反应是', ['腹痛', '黑便', '皮炎', '性功能减退', '便秘'], ['1'], 'A'),\n",
       " ('解痉药654-2是指',\n",
       "  ['天然的山莨菪碱', '人工合成的山莨菪碱', '天然的东莨菪碱', '人工合成的东莨菪碱', '人工合成的丁溴东莨菪碱'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('药物流行病学研究范围为',\n",
       "  ['传染病', '非传染病', '健康问题', '原因不明的疾病', '药物在人群中的应用效应'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('分布是指',\n",
       "  ['药物从用药部分进入体循环的过程',\n",
       "   '药物进入体循环后向各组织、器官或体液转运的过程',\n",
       "   '药物在吸收过程或者进入体循环后，受肠道菌群或体内酶系统的作用，结构发生转变的过程',\n",
       "   '药物或其代谢产物排出体外的过程',\n",
       "   '药物在体内发挥药效的过程'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('非处方药布洛芬，不适用于',\n",
       "  ['感冒、流感的解热', '中度的关节痛', '胃痛', '头痛、牙痛、肌肉痛', '神经痛和痛经'],\n",
       "  ['3'],\n",
       "  ''),\n",
       " ('长期服用异烟肼，应当适当补充',\n",
       "  ['维生素B1', '维生素B2', '维生素B6', '维生素B12', '维生素K'],\n",
       "  ['3'],\n",
       "  '1、2、4'),\n",
       " ('对半衰期短的药物，为了减少血药浓度波动，可采取的方法是',\n",
       "  ['延长给药间隔', '缩短给药间隔的同时减少单剂量', '增加给药剂量', '减少给药剂量', '增加给药剂量的同时延长给药间隔'],\n",
       "  ['2'],\n",
       "  '1、5'),\n",
       " ('利巴韦林是',\n",
       "  ['具有喹啉羧酸结构的药物', '具有咪唑结构的药物', '具有双三氮唑结构的药物', '具有单三氮唑结构的药物', '具有鸟嘌呤结构的药物'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('服用异烟肼进行抗结核治疗的患者，为预防周围神经炎，应补充的维生素是',\n",
       "  ['维生素A', '维生素K', '维生素B2', '维生素C', '维生素B6'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('与两性霉素B合用，可防止或减少肾小管酸中毒发生的药物是',\n",
       "  ['碳酸氢钠', '氨基糖苷类', '卷曲霉素', '多黏菌素', '万古霉素'],\n",
       "  ['1'],\n",
       "  'A'),\n",
       " ('结构中不含咪唑环的血管紧张素Ⅱ受体拮抗剂是', ['福辛普利', '氯沙坦', '赖诺普利', '缬沙坦', '厄贝沙坦'], ['4'], 'B'),\n",
       " ('处理误服毒物不久、神志尚清醒的中毒患者的首要措施是',\n",
       "  ['吸氧', '静脉补液', '导泻与洗肠', '催吐、洗胃', '清除皮肤、黏膜上的毒物'],\n",
       "  ['4'],\n",
       "  'C'),\n",
       " ('在药学服务过程中需要药师特别注意的人群不包括',\n",
       "  ['用药周期长的慢性病患者或需长期用药甚至终生用药的患者\\n',\n",
       "   '患有心脏病的住院患者',\n",
       "   '肝肾功能不全者、血液透析患者、妊娠及哺乳期妇女\\n',\n",
       "   '用药效果不佳，需要重新选择药品或者调整用药方案、剂量、方法的患者',\n",
       "   '患有多种疾病，病情和用药复杂，需同时合并应用多种药品的患者\\n'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('酯类降解的主要途径是', ['光学异构化', '聚合', '水解', '氧化', '脱羧'], ['3'], ''),\n",
       " ('可作为抗氧剂的是', ['微晶纤维素', '硬脂酸镁', '三氯叔丁醇', '氢氟烷烃', '硫代硫酸钠'], ['5'], '1、4'),\n",
       " ('18岁以下儿童禁用的药品是',\n",
       "  ['青霉素类', '头孢菌素类', '碳青霉烯类', '大环内酷类', '喹诺酮类'],\n",
       "  ['5'],\n",
       "  '1、2、3'),\n",
       " ('下述药物中不可用于单纯疱疹性角膜炎的',\n",
       "  ['利巴韦林', '阿昔洛韦', '更昔洛韦', '碘苷', '氧氟沙星'],\n",
       "  ['5'],\n",
       "  '无正确答案'),\n",
       " ('某药物在体内按一级动力学消除，如果k=0.0346h-1，该药物的消除半衰期约为',\n",
       "  ['3.46h', '6.92h', '12h', '20h', '24h'],\n",
       "  ['4'],\n",
       "  ''),\n",
       " ('《英国药典》缩写为', ['USP', 'BP', 'EP', 'JP', 'ChP'], ['2'], 'B'),\n",
       " ('该患者可能的诊断是',\n",
       "  ['痛风', '假性痛风', '风湿性关节炎', '类风湿关节炎', '化脓性关节炎'],\n",
       "  ['1'],\n",
       "  '无法从给定的信息中判断'),\n",
       " ('新生儿茶碱的潜在中毒浓度低限为',\n",
       "  ['2μg/ml', '5～10μg/ml', '10～20μg/ml', '>15μg/ml', '>20μg/ml'],\n",
       "  ['4'],\n",
       "  '>20μg'),\n",
       " ('自我药疗时，抗真菌药用于阴道炎，阴道用药时间一般不宜超过', ['1日', '3日', '5日', '7日', '10日'], ['5'], ''),\n",
       " ('小儿呼吸道感染服用琥乙红霉素颗粒，剂量为30～50mg/（kg·D），分3～4次服用，则体重为20kg的儿童一次剂量为',\n",
       "  ['175～250mg或125～225mg',\n",
       "   '200～333mg或150～250mg',\n",
       "   '215～350mg或175～270mg',\n",
       "   '225～375mg或200～300mg',\n",
       "   '250～375mg或225～325mg'],\n",
       "  ['2'],\n",
       "  ''),\n",
       " ('患者，男，63岁，COPD患者。因近来活动耐力下降就诊。对其因迷走神经张力过高所致的气道狭窄，宜选用的药物是',\n",
       "  ['白三烯调节剂', '异丙托溴铵', '吸入型糖皮质激素', '沙丁胺醇', '茶碱'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('硝酸酯类药物的禁忌证不包括',\n",
       "  ['严重低血压', '重度主动脉瓣狭窄', '缩窄性心包炎', '颅内压增高', '稳定型心绞痛'],\n",
       "  ['5'],\n",
       "  'D'),\n",
       " ('患者，女，34岁，患有慢性肾盂肾炎，医生建议其服用复方磺胺甲噁唑。为了减少不良反应，可建议患者同时服用',\n",
       "  ['维生素C', '氯化铵', '碳酸氢钠', '食醋', '甲氧苄啶'],\n",
       "  ['3'],\n",
       "  'B'),\n",
       " ('属于强效的外用糖皮质激素是', ['氢化可的松', '地塞米松', '卤米松', '曲安奈德', '氟轻松'], ['5'], ''),\n",
       " ('在体内经肝、肾两次羟基化代谢，才具有活性的药物是',\n",
       "  ['维生素D3', '阿法骨化醇', '骨化三醇', '阿仑膦酸钠', '依替膦酸二钠'],\n",
       "  ['1'],\n",
       "  'B'),\n",
       " ('上述药物不良事件中，属于音似药品引发用药错误事件的是',\n",
       "  ['“康泰克PPA事件”', '“万络（罗非昔布）事件”', '“亮菌甲素事件”', '“拜斯亭（西立伐他汀）事件”', '“阿糖胞苷儿科事件”'],\n",
       "  ['5'],\n",
       "  'B'),\n",
       " ('属于影响药物代谢的因素是',\n",
       "  ['血脑屏障', '首过效应', '肾小球过滤', '胃排空与胃肠蠕动', '药物在胃肠道中的稳定性'],\n",
       "  ['2'],\n",
       "  'B'),\n",
       " ('某患者，男，78岁，既往有动脉粥样硬化史，因尿频、尿急就诊。体征和实验室检查结果为：血压166/98mmHg，前列腺增生＞60g，前列腺特异性抗原（P',\n",
       "  ['非那雄胺', '丙酸睾酮', '泼尼松龙', '吲达帕胺', '格列美脲'],\n",
       "  ['1'],\n",
       "  'D'),\n",
       " ('D-对映异构体有活性较大，L-对映异构体毒性较大的药物是',\n",
       "  ['氯苯那敏', '甲基多巴', '氨己烯酸', '普罗帕酮', '乙胺丁醇'],\n",
       "  ['5'],\n",
       "  '氨己烯酸'),\n",
       " ('对意识清楚的急性脑卒中患者，静脉内给药比肝素更有效的药物是',\n",
       "  ['维生素K', '尿激酶', '重组人促红素', '达比加群酯', '双嘧达莫'],\n",
       "  ['2'],\n",
       "  '尿激酶'),\n",
       " ('双室模型消除速度常数为',\n",
       "  ['t<SUB>1/2</SUB>', 'α', 'β', 'k', 't<SUB>0.9</SUB>'],\n",
       "  ['3'],\n",
       "  'k'),\n",
       " ...]"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[i for i in result if i[2][0] != i[3] and i[3] not in ['1','2','3','4','5']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.21697053948564402"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len([i for i in result if i[2][0] != i[3] and i[3] not in ['1','2','3','4','5']]) / len(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "dump_obj('result_001',result)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "result_001\n",
    "\n",
    "使用Promopt: \n",
    "你是一名医学生，正在参加考试。题目为单项选择题。参考下面例子，给出数字编号答案。\n",
    "题目：书写药历是药师进行规范化药学服务的一项工作，下列内容一般不作为药历内容的是 || 选项: 1. 患者基本信息 2. 用药评价 3. 临床诊断要点 4. 用药记录 5. 患者知情同意书 || 答案: 5\n",
    "题目：研究TDM的临床意义不包括 || 选项: 1. 监督临床用药 2. 研究药物在体内的代谢变化 3. 研究治疗无效的原因 4. 确定患者是否按医嘱服药 5. 研究合并用药的影响 || 答案: 3\n",
    "题目：\"\"\"\n",
    "\n",
    "在该Promopt下，不用RAG， 百川2回答正确率 0.3687109019943325\n",
    "\n",
    "错误答案中， 0.21697053948564402 是由于未能遵循指令引起的错误（回答a,b,c)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[0, 11, 17, 24, 41, 51, 53, 55, 58, 62, 70, 72, 74, 76, 78, 96, 99, 105, 107, 109, 111, 121, 126, 129, 132, 138, 141, 143, 164, 167, 169, 171, 172, 178, 190, 203, 205, 208, 213, 215, 218, 234, 236, 244, 254, 257, 259, 261, 266, 293, 295, 300, 303, 310, 313, 316, 319, 322, 334, 336, 338, 343, 348, 350, 352, 354, 356, 357, 358, 359, 360, 361, 363, 380, 384, 393, 395, 400, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 423, 425, 428, 433, 435, 438, 443, 445, 447, 449, 451, 454, 487, 538, 540, 549, 559, 560, 564, 583, 634, 637, 641, 647, 650, 653, 658, 660, 662, 670, 671, 674, 688, 826, 836, 838, 842, 845, 861, 875, 878, 882, 892, 900, 902, 905, 919, 1119, 1184, 1192, 1202, 1203, 1211, 1212, 1213, 1229, 1230, 1231, 1232, 1236, 1248, 1333, 1335, 1340, 1347, 1361, 1365, 1402, 1404, 1408, 1409, 1410, 1412, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1430, 1431, 1432, 1433, 1434, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1453, 1461, 1466, 1468, 1469, 1471, 1475, 1476, 1477, 1479, 1481, 1482, 1485, 1486, 1487, 1489, 1491, 1493, 1494, 1496, 1497, 1500, 1519, 1524, 1583, 1620, 1622, 1629, 1649, 1658, 1671, 1673, 1677, 1680, 1681, 1682, 1691, 1693, 1694, 1705, 1707, 1711, 1716, 1717, 1718, 1719, 1720, 1721, 1739, 1741, 1745, 1751, 1755, 1756, 1758, 1769, 1785, 1789, 1804, 1805, 1825, 1850, 1905, 1906, 1915, 1919, 1921, 1948, 1971, 1972, 1973, 1974, 1977, 1979, 1982, 1995, 1999, 2002, 2005, 2011, 2013, 2016, 2017, 2018, 2019, 2020, 2029, 2031, 2032, 2033, 2034, 2038, 2039, 2040, 2041, 2044, 2061, 2063, 2065, 2067, 2070, 2076, 2079, 2081, 2084, 2086, 2087, 2098, 2099, 2100, 2101, 2103, 2106, 2110, 2111, 2112, 2113, 2118, 2120, 2152, 2154, 2169, 2171, 2181, 2190, 2198, 2218, 2219, 2227, 2235, 2239, 2240, 2244, 2266, 2280, 2282, 2287, 2301, 2309, 2311, 2313, 2314, 2345, 2347, 2356, 2357, 2358, 2373, 2375, 2378, 2384, 2386, 2391, 2392, 2404, 2406, 2407, 2409, 2419, 2420, 2421, 2423, 2426, 2427, 2429, 2447, 2448, 2449, 2458, 2462, 2463, 2465, 2467, 2469, 2471, 2482, 2485, 2487, 2493, 2495, 2512, 2513, 2514, 2515, 2516, 2517, 2519, 2524, 2526, 2527, 2539, 2541, 2543, 2546, 2556, 2575, 2577, 2580, 2584, 2586, 2595, 2599, 2601, 2605, 2619, 2625, 2628, 2630, 2633, 2636, 2638, 2641, 2644, 2662, 2666, 2670, 2673, 2679, 2681, 2684, 2688, 2692, 2695, 2697, 2709, 2713, 2717, 2722, 2728, 2730, 2731, 2732, 2733, 2734, 2735, 2737, 2765, 2767, 2768, 2769, 2771, 2773, 2775, 2776, 2777, 2778, 2780, 2781, 2783, 2784, 2786, 2790, 2792, 2794, 2796, 2798, 2800, 2801, 2803, 2838, 2841, 2843, 2861, 2862, 2864, 2866, 2868, 2869, 2872, 2875, 2876, 2877, 2891, 2901, 2910, 2930, 2931, 2934, 2941, 2958, 2972, 2976, 2995, 3010, 3055, 3142, 3214, 3217, 3220, 3223, 3226, 3235, 3238, 3244, 3248, 3264, 3266, 3273, 3275, 3284, 3287, 3288, 3289, 3294, 3296, 3321, 3330, 3332, 3333, 3334, 3336, 3338, 3340, 3342, 3346, 3350, 3351, 3352, 3353, 3354, 3355, 3356, 3357, 3358, 3374, 3375, 3376, 3377, 3378, 3380, 3381, 3383, 3386, 3398, 3402, 3404, 3408, 3409, 3410, 3411, 3413, 3414, 3415, 3416, 3418, 3434, 3436, 3437, 3438, 3439, 3440, 3445, 3446, 3447, 3449, 3468, 3470, 3471, 3472, 3473, 3476, 3479, 3481, 3483, 3487, 3489, 3491, 3497, 3499, 3519, 3522, 3523, 3524, 3525, 3526, 3533, 3555, 3561, 3562, 3566, 3567, 3569, 3597, 3642, 3644, 3650, 3655, 3657, 3663, 3668, 3680, 3683, 3690, 3691, 3692, 3694, 3699, 3705, 3708, 3709, 3711, 3714, 3738, 3742, 3744, 3746, 3748, 3750, 3752, 3756, 3759, 3761, 3762, 3763, 3764, 3766, 3767, 3776, 3777, 3779, 3781, 3782, 3784, 3786, 3791, 3793, 3796, 3802, 3803, 3819, 3829, 3832, 3836, 3837, 3838, 3839, 3841, 3846, 3858, 3859, 3861, 3862, 3864, 3866, 3868, 3870, 3883, 3885, 3886, 3891, 3893, 3910, 3912, 3917, 3920, 3921, 3923, 3924, 3927, 3944, 3949, 3950, 3953, 3960, 3963, 3967, 3969, 3991, 4003, 4024, 4033, 4038, 4070, 4073, 4076, 4079, 4090, 4093, 4096, 4099, 4102, 4105, 4111, 4114, 4117, 4119, 4144, 4146, 4150, 4151, 4153, 4155, 4156, 4157, 4159, 4161, 4162, 4166, 4167, 4168, 4169, 4170, 4172, 4200, 4203, 4206, 4209, 4211, 4214, 4216, 4219, 4238, 4240, 4243, 4249, 4251, 4254, 4286, 4288, 4312, 4314, 4315, 4316, 4317, 4318, 4319, 4322, 4323, 4324, 4329, 4330, 4331, 4332, 4344, 4345, 4347, 4348, 4349, 4352, 4358, 4359, 4361, 4362, 4383, 4392, 4403, 4406, 4409, 4410, 4415, 4417, 4419, 4421, 4430, 4448, 4450, 4453, 4456, 4458, 4462, 4465, 4473, 4478, 4485, 4487, 4496, 4497, 4498, 4499, 4503, 4505, 4508, 4509, 4510, 4511, 4514, 4518, 4519, 4520, 4536, 4542, 4544, 4546, 4547, 4552, 4553, 4554, 4556, 4557, 4558, 4567, 4569, 4571, 4573, 4577, 4600, 4602, 4606, 4607, 4608, 4609, 4610, 4611, 4613, 4614, 4623, 4626, 4629, 4632, 4634, 4636, 4638, 4639, 4644, 4645, 4646, 4647, 4648, 4664, 4665, 4666, 4667, 4668, 4669, 4670, 4671, 4672, 4676, 4677, 4678, 4679, 4680, 4681, 4682, 4691, 4692, 4693, 4696, 4700, 4702, 4708, 4723, 4725, 4729, 4734, 4736, 4738, 4739, 4742, 4752, 4754, 4756, 4759, 4766, 4779, 4781, 4784, 4786, 4788, 4806, 4807, 4808, 4809, 4810, 4811, 4816, 4818, 4819, 4820, 4821, 4830, 4831, 4832, 4833, 4834, 4838, 4856, 4857, 4858, 4861, 4870, 4888, 4912, 4922, 4926, 4927, 4945, 4948, 4950, 4951, 4957, 4959, 4960, 4970, 4973, 4974, 4981, 4984, 4986, 5108, 5112, 5114, 5125, 5126, 5134, 5137, 5138, 5160, 5161, 5162, 5163, 5165, 5167, 5171, 5172, 5173, 5178, 5180, 5303, 5396, 5399, 5401, 5403, 5405, 5412, 5414, 5418, 5419, 5431, 5440, 5447, 5476, 5481, 5483, 5484, 5485, 5486, 5488, 5490, 5492, 5495, 5536, 5540, 5557, 5559, 5562, 5564, 5576, 5577, 5579, 5581, 5583, 5585, 5595, 5597, 5599, 5600, 5601, 5618, 5643, 5649, 5651, 5652, 5654, 5655, 5659, 5660, 5661, 5662, 5663, 5664, 5665, 5666, 5667, 5668, 5669, 5670, 5671, 5672, 5680, 5681, 5682, 5683, 5684, 5685, 5686, 5688, 5691, 5693, 5697, 5698, 5699, 5700, 5701, 5732, 5734, 5736, 5740, 5749, 5754, 5756, 5775, 5776, 5777, 5778, 5779, 5783, 5784, 5795, 5797, 5799, 5803, 5805, 5812, 5844, 5870, 5871, 5872, 5873, 5874, 5875, 5876, 5879, 5887, 5890, 5891, 5892, 5893, 5896, 5910, 5920, 5926, 5934, 5937, 5938, 5939, 5940, 5941, 5942, 5944, 5957, 5965, 5972, 5974, 5975, 6017, 6019, 6033, 6035, 6036, 6037, 6038, 6039, 6040, 6041, 6042, 6044, 6045, 6050, 6058, 6060, 6083, 6088, 6091, 6101, 6102, 6103, 6104, 6105, 6106, 6108, 6109, 6119, 6121, 6124, 6140, 6144, 6146, 6147, 6149, 6165, 6166, 6167, 6168, 6169, 6170, 6171, 6172, 6174, 6177, 6178, 6180, 6182, 6184, 6188, 6189, 6191, 6193, 6196, 6197, 6198, 6199, 6200, 6202, 6206, 6208, 6217, 6219, 6221, 6227, 6228, 6229, 6230, 6234, 6235, 6236, 6237, 6238, 6240, 6242, 6264, 6265, 6268, 6269, 6271, 6273, 6275, 6277, 6279, 6292, 6294, 6307, 6308, 6309, 6311, 6312, 6313, 6314, 6316, 6318, 6326, 6327, 6329, 6332, 6334, 6340, 6359, 6361, 6362, 6363, 6364, 6365, 6366, 6370, 6372, 6375, 6377, 6384, 6385, 6387, 6389, 6391, 6400, 6401, 6402, 6403, 6404, 6405, 6406, 6408, 6410, 6416, 6422, 6424, 6429, 6431, 6432, 6433, 6434, 6435, 6438, 6440, 6459, 6461, 6462, 6463, 6464, 6465, 6466, 6467, 6468, 6471, 6473, 6484, 6486, 6487, 6488, 6489, 6491, 6494, 6504, 6506, 6509, 6511, 6515, 6517, 6521, 6523, 6525, 6529, 6531, 6532, 6535, 6537, 6560, 6561, 6562, 6564, 6566, 6567, 6569, 6571, 6573, 6578, 6580, 6581, 6585, 6587, 6589, 6591, 6592, 6593, 6595, 6597, 6602, 6604, 6605, 6607, 6617, 6625, 6626, 6628, 6629, 6631, 6632, 6636, 6637, 6638, 6639, 6640, 6641, 6642, 6643, 6644, 6647, 6649, 6650, 6654, 6656, 6672, 6673, 6675, 6677, 6681, 6682, 6684, 6686, 6688, 6699, 6700, 6701, 6702, 6703, 6704, 6722, 6724, 6730, 6732, 6735, 6736, 6739, 6741, 6761, 6764, 6765, 6766, 6767, 6769, 6771, 6780, 6782, 6783, 6784, 6785, 6788, 6790, 6805, 6808, 6809, 6810, 6813, 6815, 6827, 6829, 6830, 6831, 6833, 6835, 6849, 6850, 6853, 6854, 6856, 6857, 6859, 6862, 6864, 6865, 6866, 6871, 6872, 6873, 6892, 6894, 6896, 6898, 6900, 6902, 6915, 6917, 6922, 6923, 6924, 6925, 6927, 6942, 6945, 6947, 6955, 6957, 6961, 6966, 6968, 6972, 6973, 6975, 6985, 6987, 7001, 7003, 7004, 7006, 7008, 7012, 7014, 7016, 7019, 7021, 7028, 7029, 7030, 7032, 7034, 7036, 7052, 7053, 7054, 7056, 7058, 7070, 7071, 7072, 7076, 7078, 7080, 7082, 7083, 7084, 7086, 7088, 7097, 7099, 7103, 7104, 7105, 7108, 7110, 7115, 7116, 7117, 7121, 7122, 7123, 7124, 7125, 7128, 7130, 7131, 7133, 7149, 7150, 7151, 7152, 7153, 7154, 7155, 7158, 7160, 7163, 7165, 7167, 7172, 7176, 7178, 7183, 7185, 7186, 7187, 7195, 7197, 7201, 7202, 7204, 7206, 7210, 7212, 7215, 7217, 7239, 7241, 7246, 7247, 7248, 7251, 7253, 7263, 7265, 7266, 7268, 7270, 7275, 7277, 7278, 7279, 7287, 7289, 7293, 7295, 7296, 7297, 7299, 7301, 7308, 7310, 7311, 7336, 7345, 7357, 7358, 7359, 7360, 7361, 7362, 7365, 7369, 7370, 7375, 7377, 7379, 7382, 7400, 7402, 7403, 7404, 7405, 7406, 7411, 7412, 7413, 7414, 7415, 7416, 7417, 7423, 7436, 7446, 7450, 7456, 7475, 7483, 7489, 7503, 7513, 7518, 7519, 7520, 7522, 7524, 7526, 7528, 7544, 7546, 7547, 7548, 7549, 7550, 7557, 7560, 7563, 7565, 7566, 7568, 7570, 7579, 7580, 7581, 7582, 7583, 7588, 7595, 7597, 7599, 7602, 7605, 7609, 7610, 7627, 7629, 7632, 7635, 7639, 7641, 7642, 7643, 7644, 7648, 7653, 7658, 7660, 7663, 7673, 7674, 7676, 7678, 7680, 7682, 7684, 7685, 7689, 7692, 7694, 7695, 7696, 7697, 7698, 7699, 7700, 7701, 7707, 7727, 7729, 7731, 7733, 7735, 7736, 7738, 7744, 7748, 7750, 7751, 7752, 7753, 7755, 7757, 7758, 7767, 7768, 7769, 7772, 7774, 7775, 7776, 7777, 7782, 7787, 7790, 7792, 7812, 7814, 7817, 7818, 7820, 7822, 7823, 7826, 7828, 7831, 7836, 7838, 7841, 7846, 7848, 7849, 7850, 7859, 7860, 7862, 7864, 7865, 7868, 7870, 7871, 7872, 7887, 7888, 7889, 7890, 7894, 7900, 7905, 7916, 7918, 7920, 7922, 7924, 7926, 7930, 7935, 7936, 7939, 7945, 7948, 7950, 7951, 7952, 7966, 7969, 7970, 7971, 7972, 7973, 7977, 7978, 7979, 7985, 7998, 7999, 8000, 8004, 8010, 8011, 8012, 8013, 8016, 8020, 8021, 8023, 8042, 8043, 8044, 8045, 8046, 8047, 8048, 8055, 8058, 8059, 8060, 8061, 8062, 8071, 8072, 8077, 8082, 8089, 8090, 8091, 8092, 8093, 8108, 8111, 8116, 8118, 8120, 8122, 8128, 8130, 8132, 8133, 8134, 8136, 8140, 8143, 8145, 8155, 8156, 8157, 8158, 8159, 8160, 8166, 8167, 8172, 8176, 8194, 8198, 8200, 8201, 8202, 8203, 8204, 8205, 8206, 8209, 8210, 8212, 8213, 8214, 8217, 8220, 8221, 8222, 8223, 8232, 8233, 8234, 8235, 8236, 8243, 8250, 8252, 8260, 8265, 8268, 8269, 8271, 8288, 8291, 8297, 8301, 8303, 8305, 8309, 8310, 8312, 8313, 8314, 8315, 8324, 8326, 8327, 8328, 8329, 8330, 8343, 8360, 8366, 8369, 8370, 8373, 8374, 8376, 8377, 8379, 8381, 8382, 8391, 8392, 8393, 8403, 8406, 8407, 8411, 8412, 8413, 8414, 8415, 8416, 8418, 8419, 8435, 8436, 8438, 8440, 8441, 8447, 8464, 8479, 8481, 8484, 8486, 8487, 8491, 8492, 8493, 8495, 8497, 8498, 8513, 8516, 8518, 8519, 8523, 8526, 8527, 8528, 8529, 8538, 8539, 8540, 8546, 8554, 8556, 8557, 8558, 8559, 8562, 8579, 8580, 8582, 8585, 8586, 8588, 8589, 8590, 8595, 8597, 8599, 8604, 8607, 8617, 8619, 8621, 8624, 8625, 8626, 8627, 8632, 8634, 8641, 8660, 8664, 8666, 8668, 8670, 8672, 8676, 8681, 8683, 8688, 8690, 8692, 8694, 8707, 8709, 8711, 8713, 8715, 8718, 8720, 8725, 8726, 8728, 8730, 8731, 8732, 8756, 8758, 8761, 8764, 8767, 8768, 8772, 8774, 8779, 8783, 8785, 8796, 8798, 8800, 8802, 8804, 8811, 8816, 8817, 8818, 8834, 8836, 8837, 8839, 8844, 8846, 8855, 8858, 8860, 8862, 8867, 8872, 8875, 8877, 8878, 8900, 8907, 8910, 8915, 8918, 8920, 8923, 8932, 8935, 8940, 8946, 8947, 8948, 8952, 8953, 8954, 8955, 8956, 8958, 8959, 8960, 8963, 8980, 8981, 8982, 8983, 8984, 8985, 8988, 8991, 8992, 8993, 8994, 8998, 8999, 9000, 9001, 9002, 9003, 9004, 9005, 9017, 9023, 9025, 9033, 9038, 9041, 9043, 9045, 9047, 9069, 9076, 9085, 9090, 9091, 9093, 9095, 9097, 9099, 9100, 9109, 9110, 9113, 9116, 9117, 9118, 9119, 9123, 9124, 9125, 9126, 9127, 9133, 9153, 9158, 9165, 9166, 9167, 9169, 9172, 9176, 9177, 9185, 9186, 9187, 9190, 9193, 9194, 9195, 9200, 9201, 9202, 9203, 9204, 9209, 9214, 9231, 9233, 9235, 9239, 9242, 9244, 9250, 9252, 9253, 9259, 9269, 9275, 9279, 9280, 9281, 9283, 9286, 9287, 9288, 9292, 9293, 9294, 9300, 9317, 9319, 9320, 9321, 9322, 9323, 9324, 9325, 9327, 9330, 9331, 9332, 9336, 9337, 9338, 9341, 9344, 9345, 9346, 9360, 9363, 9364, 9365, 9366, 9367, 9368, 9372, 9375, 9377, 9379, 9381, 9383, 9387, 9389, 9390, 9406, 9408, 9410, 9418, 9420, 9422, 9424, 9426, 9430, 9433, 9435, 9437, 9439, 9449, 9450, 9451, 9452, 9453, 9454, 9459, 9460, 9461, 9480, 9484, 9491, 9495, 9496, 9497, 9498, 9499, 9533, 9539, 9547, 9554, 9556, 9559, 9564, 9567, 9569, 9585, 9589, 9591, 9595, 9602, 9603, 9604, 9605, 9606, 9607, 9630, 9635, 9640, 9662, 9723, 9724, 9739, 9744, 9749, 9794, 9815, 9818, 9822, 9827, 9838, 9865, 9868, 9870, 9872, 9874, 9878, 9885, 9901, 9903, 9905, 9907, 9911, 9915, 9918, 9924, 9926, 9928, 9930, 9931, 9935, 9941, 9942, 9953, 9957, 9958, 9961, 9963, 9966, 9968, 9971, 9988, 9991, 9993, 9998, 9999, 10001, 10004, 10006, 10009, 10024, 10076, 10081, 10100, 10102, 10103, 10105, 10107, 10112, 10114, 10115, 10118, 10119, 10120, 10126, 10133, 10135, 10136, 10138, 10149, 10152, 10155, 10160, 10162, 10168, 10172, 10174, 10176, 10177, 10180, 10182, 10185, 10251, 10252, 10254, 10256, 10258, 10260, 10264, 10267, 10269, 10270, 10271, 10272, 10273, 10298, 10438, 10439, 10441, 10442, 10443, 10444, 10445, 10446, 10447, 10448, 10449, 10453, 10454, 10455, 10456, 10457, 10458, 10459, 10460, 10461, 10462, 10471, 10473, 10475, 10476, 10477, 10479, 10480, 10481, 10483, 10484, 10485, 10486, 10490, 10491, 10492, 10493, 10494, 10500, 10523, 10528, 10533, 10534, 10536, 10542, 10545, 10547, 10548, 10550, 10552, 10553, 10554, 10556, 10557, 10558, 10568, 10571, 10575, 10587, 10589, 10592, 10595, 10623, 10625, 10626, 10630, 10631, 10633, 10635, 10636, 10640, 10641, 10664, 10666, 10667, 10669, 10670, 10671, 10678, 10679, 10680, 10682, 10683, 10684, 10695, 10697, 10698, 10699, 10700, 10701, 10702, 10705, 10707, 10709, 10713, 10715, 10717, 10719, 10720, 10721, 10731, 10735, 10737, 10739, 10740, 10747, 10750, 10752, 10754, 10756, 10758, 10760, 10762, 10792, 10797, 10821, 10823, 10827, 10829, 10841, 10843, 10846, 10848, 10851, 10853, 10859, 10860, 10861, 10862, 10863, 10864, 10865, 10891, 10909, 10932, 10934, 10936, 10938, 11055, 11063, 11079, 11080, 11081, 11087, 11088, 11098, 11100, 11101, 11121, 11122, 11137, 11140, 11150, 11169, 11174, 11176, 11177, 11178, 11180, 11181, 11183, 11184, 11188, 11192, 11193, 11195, 11218, 11221, 11226, 11228, 11230, 11232, 11235, 11236, 11237, 11239, 11240, 11241, 11249, 11250, 11251, 11252, 11253, 11254, 11255, 11282, 11290, 11296, 11306, 11308, 11309, 11310, 11311, 11314, 11319, 11321, 11339, 11345, 11357, 11367, 11368, 11371, 11375, 11378, 11379, 11381, 11386, 11388, 11390, 11391, 11393, 11394, 11396, 11412, 11414, 11417, 11420, 11431, 11433, 11435, 11437, 11442, 11460, 11467, 11468, 11472, 11477, 11480, 11483, 11484, 11500, 11503, 11507, 11511, 11512, 11514, 11516, 11521, 11530, 11534, 11537, 11539, 11548, 11550, 11553, 11560, 11584, 11592, 11609, 11616, 11620, 11626, 11641, 11655, 11657, 11662, 11665, 11666, 11681, 11693, 11694, 11695, 11705, 11706, 11707, 11724, 11725, 11726, 11728, 11729, 11730, 11734, 11736, 11738, 11741, 11745, 11747, 11748, 11757, 11758, 11759, 11761, 11762, 11763, 11764, 11769, 11777, 11779, 11781, 11783, 11800, 11804, 11806, 11809, 11811, 11813, 11815, 11818, 11824, 11835, 11837, 11839, 11841, 11844, 11854, 11857, 11858, 11862, 11863, 11864, 11885, 11887, 11888, 11889, 11893, 11894, 11895, 11897, 11908, 11912, 11914, 11916, 11920, 11921, 11923, 11924, 11926, 11942, 11944, 11951, 11956, 11958, 11963, 11965, 11968, 11972, 11975, 11986, 11989, 11993, 11995, 11998, 11999, 12003, 12005, 12006, 12009, 12011, 12031, 12032, 12034, 12036, 12039, 12041, 12047, 12050, 12051, 12052, 12063, 12069, 12074, 12078, 12083, 12085, 12086, 12087, 12089, 12105, 12107, 12110, 12112, 12116, 12117, 12118, 12143, 12148, 12156, 12157, 12158, 12159, 12160, 12161, 12162, 12179, 12182, 12184, 12186, 12194, 12196, 12199, 12206, 12207, 12210, 12212, 12215, 12218, 12235, 12239, 12240, 12258, 12260, 12261, 12274, 12277, 12281, 12296, 12298, 12299, 12301, 12307, 12312, 12319, 12322, 12327, 12331, 12334, 12345, 12348, 12352, 12354, 12355, 12356, 12358, 12359, 12361, 12362, 12363, 12367, 12368, 12369, 12372, 12373, 12376, 12377, 12378, 12379, 12382, 12401, 12405, 12409, 12411, 12413, 12416, 12419, 12423, 12430, 12447, 12451, 12454, 12457, 12460, 12466, 12468, 12472, 12530, 12532, 12534, 12535, 12537, 12539, 12541, 12547, 12550, 12552, 12554, 12566, 12567, 12570, 12572, 12576, 12579, 12580, 12581, 12584, 12585, 12586, 12587, 12593, 12597, 12599, 12618, 12620, 12622, 12624, 12626, 12633, 12635, 12637, 12638, 12640, 12642, 12644, 12706, 12728, 12742, 12744, 12748, 12763, 12765, 12766, 12767, 12768, 12770, 12771, 12773, 12774, 12779, 12787, 12788, 12789, 12790, 12793, 12804, 12806, 12808, 12810, 12818, 12820, 12822, 12825, 12827, 12831, 12832, 12833, 12848, 12850, 12852, 12854, 12858, 12860, 12866, 12874, 12876, 12917, 12919, 12921, 12923, 12926, 12928, 12930, 12932, 12933, 12941, 12943, 12944, 12945, 12946, 12947, 12948, 12949, 12950, 12968, 12973, 12978, 12982, 12988, 12991, 12995, 13010, 13015, 13021, 13024, 13030, 13033, 13035, 13054, 13055, 13060, 13062, 13067, 13083, 13084, 13085, 13086, 13101, 13192, 13194, 13197, 13201, 13203, 13204, 13209, 13211, 13214, 13219, 13222, 13226, 13227, 13239, 13240, 13241, 13242, 13247, 13253, 13258, 13262, 13264, 13266, 13276, 13278, 13281, 13283, 13284, 13290, 13296, 13298, 13299, 13300, 13317, 13319, 13324, 13327, 13328, 13329, 13340, 13392, 13394, 13397, 13403, 13407, 13420, 13422, 13425, 13427, 13428, 13429, 13430, 13433, 13434, 13435, 13436, 13437, 13448, 13449, 13450, 13453, 13456, 13457, 13461, 13462, 13463, 13464, 13469, 13473, 13476, 13478, 13494, 13497, 13499, 13501, 13504, 13509, 13516, 13520, 13521, 13523, 13525, 13527, 13536, 13540, 13543, 13548, 13554, 13556, 13559, 13560, 13575, 13578, 13592, 13593, 13604, 13625, 13627, 13631, 13633, 13639, 13641, 13651, 13652, 13653, 13654, 13655, 13660, 13663, 13665, 13666, 13667, 13668, 13669, 13670, 13671, 13672, 13703, 13712, 13720, 13721, 13722, 13724, 13726, 13730, 13732, 13743, 13747, 13749, 13751, 13753, 13757, 13759, 13762, 13764, 13766, 13769, 13774, 13777, 13781, 13785, 13789, 13792, 13795, 13815, 13832, 13910, 13924, 13926, 13927, 13928, 13929, 13930, 13931, 13933, 13934, 13935, 13937, 13938, 13939, 13940, 13941, 13950, 13955, 13958, 13960, 13983, 13987, 13990, 13997, 14000, 14003, 14005, 14008, 14010, 14022, 14026, 14030, 14033, 14035, 14041, 14050, 14054, 14057, 14059, 14075, 14093, 14099, 14106, 14108, 14109, 14111, 14113, 14115, 14126, 14128, 14129, 14130, 14131, 14132, 14138, 14140, 14144, 14145, 14148, 14149, 14150, 14151, 14152, 14154, 14178, 14179, 14180, 14181, 14182, 14189, 14200, 14202, 14214, 14219, 14221, 14226, 14229, 14260, 14266, 14268, 14277, 14278, 14280, 14281, 14283, 14285, 14293, 14295, 14298, 14301, 14303, 14309, 14318, 14321, 14334, 14336, 14359, 14363, 14365, 14366, 14368, 14370, 14372, 14379, 14380, 14382, 14383, 14385, 14386, 14393, 14405, 14406, 14408, 14409, 14410, 14412, 14415, 14417, 14418, 14420, 14422, 14428, 14431, 14434, 14435, 14437, 14439, 14441, 14443, 14445, 14464, 14466, 14470, 14472, 14476, 14479, 14486, 14489, 14491, 14493, 14495, 14497, 14499, 14507, 14509, 14510, 14511, 14512, 14513, 14514, 14515, 14516, 14518, 14522, 14523, 14524, 14528, 14551, 14553, 14554, 14555, 14557, 14559, 14561, 14562, 14568, 14570, 14571, 14573, 14575, 14576, 14577, 14578, 14581, 14593, 14596, 14598, 14601, 14602, 14603, 14609, 14610, 14611, 14612, 14614, 14616, 14617, 14618, 14654, 14655, 14660, 14664, 14665, 14703, 14726, 14733, 14735, 14775, 14777, 14779, 14781, 14785, 14792, 14801, 14803, 14804, 14806, 14822, 14828, 14838, 14840, 14842, 14861, 14864, 14868, 14878, 14880, 14910, 14912, 14922, 14924, 14931, 14944, 14946, 14947, 14949, 14951, 14956, 14957, 14994, 14995, 14997, 15000, 15001, 15002, 15006, 15009, 15011, 15012, 15013, 15016, 15018, 15020, 15021, 15023, 15025, 15026, 15028, 15029, 15031, 15041, 15042, 15043, 15044, 15045, 15046, 15047, 15048, 15049, 15053, 15054, 15055, 15057, 15060, 15061, 15062, 15063, 15081, 15082, 15087, 15092, 15099, 15101, 15102, 15103, 15106, 15109, 15110, 15111, 15120, 15121, 15124, 15129, 15131, 15132, 15137, 15138, 15139, 15140, 15156, 15157, 15158, 15160, 15162, 15164, 15170, 15174, 15183, 15192, 15194, 15204, 15206, 15208, 15210, 15212, 15215, 15216, 15218, 15220, 15221, 15222, 15223, 15224, 15325, 15327, 15332, 15341, 15342, 15345, 15348, 15354, 15356, 15359, 15360, 15362, 15363, 15364, 15366, 15368, 15383, 15384, 15385, 15386, 15387, 15388, 15389, 15390, 15391, 15392, 15393, 15397, 15398, 15399, 15400, 15401, 15402, 15403, 15404, 15405, 15406, 15407, 15408, 15409, 15410, 15418, 15421, 15423, 15424, 15427, 15429, 15431, 15433, 15462, 15467, 15469, 15475, 15476, 15478, 15480, 15491, 15494, 15498, 15501, 15504, 15506, 15512, 15517, 15519, 15520, 15521, 15550, 15552, 15554, 15556, 15558, 15562, 15563, 15566, 15568, 15569, 15577, 15578, 15580, 15582, 15584, 15589, 15591, 15593, 15595, 15597, 15603, 15610, 15617, 15635, 15638, 15640, 15643, 15646, 15649, 15653, 15660, 15663, 15666, 15677, 15679, 15681, 15688, 15698, 15707, 15709, 15730, 15737, 15746, 15757, 15759, 15761, 15764, 15768, 15770, 15771, 15772, 15773, 15774, 15775, 15802, 15807, 15828, 15830, 15831, 15833, 15835, 15837, 15839, 15841, 15844, 15845, 15850, 15853, 15856, 15859, 15876, 15884, 15886, 15888, 15892, 15894, 15896, 15898, 15908, 15909, 15911, 15913, 15915, 15916, 15921, 15929, 15931, 15935, 15938, 15939, 15941, 15943, 15961, 15963, 15967, 15969, 15971, 15974, 15976, 15977, 15982, 15984, 15987, 15988, 15989, 15990, 15991, 15992, 15993, 15996, 15999, 16009, 16013, 16015, 16016, 16020, 16021, 16022, 16024, 16025, 16026, 16027, 16053, 16082, 16123, 16125, 16126, 16128, 16130, 16132, 16134, 16139, 16157, 16160, 16164, 16187, 16190, 16192, 16200, 16208, 16224, 16227, 16230, 16233, 16245, 16248, 16268, 16270, 16271, 16272, 16273, 16277, 16297, 16303, 16304, 16310, 16312, 16313, 16314, 16315, 16316, 16334, 16380, 16406, 16408, 16411, 16417, 16418, 16421, 16424, 16428, 16439, 16441, 16444, 16447, 16451, 16452, 16458, 16461, 16463, 16465, 16466, 16468, 16494, 16500, 16503, 16504, 16505, 16506, 16507, 16508, 16511, 16514, 16518, 16530, 16534, 16537, 16542, 16544, 16546, 16548, 16550, 16573, 16574, 16575, 16576, 16578, 16580, 16584, 16585, 16587, 16591, 16592, 16601, 16602, 16604, 16606, 16608, 16609, 16611, 16612, 16613, 16618, 16626, 16628, 16629, 16630, 16632, 16635, 16636, 16637, 16638, 16640, 16641, 16642, 16658, 16661, 16662, 16663, 16667, 16671, 16673, 16675, 16676, 16677, 16679, 16681, 16683, 16761, 16766, 16787, 16794, 16797, 16803, 16817, 16818, 16821, 16824, 16832, 16834, 16835, 16836, 16837, 16855, 16857, 16858, 16860, 16861, 16862, 16867, 16869, 16873, 16875, 16876, 16877, 16879, 16888, 16891, 16893, 16897, 16904, 16905, 16906, 16908, 16910, 16929, 16931, 16932, 16934, 16936, 16937, 16939, 16940, 16942, 16943, 16948, 16950, 16955, 16960, 16974, 16976, 16977, 16979, 16982, 16984, 16985, 16990, 16991, 16992, 16993, 16994, 16995, 16998, 17004, 17020, 17021, 17022, 17023, 17024, 17027, 17029, 17030, 17031, 17032, 17037, 17044, 17049, 17051, 17053, 17065, 17067, 17069, 17072, 17075, 17078, 17081, 17083, 17088, 17093, 17097, 17121, 17123, 17124, 17126, 17128, 17130, 17131, 17133, 17135, 17141, 17147, 17149, 17150, 17151, 17152, 17155, 17157, 17158, 17159, 17192, 17205, 17209, 17210, 17211, 17212, 17224, 17226, 17228, 17231, 17235, 17238, 17245, 17247, 17250, 17259, 17262, 17264, 17268, 17280, 17282, 17283, 17284, 17285, 17286, 17291, 17292, 17293, 17296, 17317, 17318, 17319, 17320, 17323, 17324, 17325, 17328, 17330, 17331, 17333, 17335, 17337, 17338, 17340, 17350, 17351, 17352, 17353, 17354, 17355, 17356, 17358, 17360, 17361, 17362, 17366, 17367, 17369, 17371, 17373, 17379, 17401, 17406, 17410, 17411, 17413, 17418, 17420, 17422, 17425, 17426, 17435, 17436, 17438, 17440, 17442, 17446, 17447, 17448, 17451, 17452, 17453, 17454, 17469, 17471, 17473, 17475, 17478, 17481, 17484, 17492, 17495, 17498, 17501, 17505, 17510, 17512, 17525, 17527, 17530, 17535, 17537, 17541, 17544, 17548, 17551, 17568, 17570, 17573, 17575, 17576, 17584, 17606, 17612, 17618, 17620, 17622, 17624, 17638, 17647, 17706, 17710, 17711, 17713, 17715, 17718, 17722, 17729, 17731, 17733, 17736, 17737, 17738, 17740, 17742, 17744, 17746, 17748, 17750, 17751, 17753, 17755, 17771, 17772, 17774, 17775, 17776, 17778, 17779, 17781, 17783, 17786, 17787, 17788, 17789, 17790, 17797, 17805, 17807, 17808, 17810, 17812, 17814, 17819, 17821, 17832, 17835, 17836, 17837, 17838, 17839, 17840, 17841, 17843, 17848, 17852, 17854, 17855, 17856, 17858, 17859, 17860, 17861, 17862, 17864, 17866, 17867, 17868, 17869, 17870, 17886, 17891, 17896, 17898, 17899, 17902, 17904, 17906, 17910, 17911, 17912, 17913, 17914, 17916, 17919, 17920, 17921, 17931, 17933, 17936, 17941, 17944, 17950, 17951, 17952, 17953, 17955, 17957, 17959, 17961, 17964, 17966, 17968, 17990, 17992, 17994, 17998, 18000, 18001, 18003, 18006, 18007, 18009, 18011, 18013, 18015, 18016, 18017, 18033, 18036, 18040, 18041, 18042, 18043, 18045, 18048, 18050, 18051, 18052, 18055, 18056, 18057, 18060, 18064, 18065, 18066, 18067, 18069, 18074, 18075, 18092, 18094, 18098, 18103, 18105, 18106, 18109, 18111, 18115, 18120, 18123, 18127, 18130, 18131, 18140, 18141, 18142, 18143, 18145, 18152, 18159, 18161, 18162, 18163, 18164, 18165, 18166, 18167, 18168, 18188, 18189, 18190, 18191, 18198, 18199, 18200, 18210, 18224, 18227, 18229, 18230, 18231, 18232, 18234, 18237, 18242, 18243, 18244, 18245, 18248, 18251, 18266, 18267, 18268, 18269, 18273, 18277, 18283, 18287, 18290, 18292, 18304, 18305, 18306, 18307, 18309, 18315, 18324, 18326, 18348, 18352, 18361, 18365, 18366, 18369, 18383]\n",
      "0 0 1\n",
      "﻿现代药学的发展历程主要经历了三个阶段，即：传统的以药品供应为中心的阶段；参与临床用药实践，促进合理用药为主的临床药学阶段；更高层次的以患者为中心，改善患者生命质量的药学服务阶段。药学服务的变化反映了现代医药学服务模式和健康理念，体现“以人为本”的宗旨，是时代进步赋予药师的使命,同时也是科学发展和药学技术进步的结果。 159\n",
      "1 0 2\n",
      "﻿现代药学的发展历程主要经历了三个阶段，即：传统的以药品供应为中心的阶段；参与临床用药实践，促进合理用药为主的临床药学阶段；更高层次的以患者为中心，改善患者生命质量的药学服务阶段。药学服务的变化反映了现代医药学服务模式和健康理念，体现“以人为本”的宗旨，是时代进步赋予药师的使命,同时也是科学发展和药学技术进步的结果。一、药学服务的内涵药学服务是在临床药学工作的基础上发展起来的，与传统的药学基础服务(供应、调剂)有很大的区别。药学服务于1990年由美国学者倡导，其含义是药师应用药学专业知识向公众(包括医护人员、患者及家属)提供直接的、负责任的、与用药相关的服务，以期提高药物治疗的安全、有效、经济和适宜性，改善和提高人类生活质量。药学服务最基本的要素是“与药物有关”的“服务”。所谓服务，即不仅以实物形式，还要以提供信息和知识的形式满足患者在药物治疗上的特殊需要。药学服务中的“服务”不同于一般行为上的功能。它包含的是药师对患者的关怀和责任，由于这种服务与药物有关，其服务应涉及全社会所有用药的患者，包括住院、门诊、社区和家庭患者。因此，药学服务具有很强的社会属性。药学服务的社会属性还表现在不仅服务于治疗性用药，还要关注预防用药和保健用药。药学服务在完成传统的处方调剂、药品检验、药品供应外，更是一种更高层次的临床实践，即必须在患者药物治疗全程中实施并获得效果，涵盖了患者用药相关的全部需求，包括选药、用药、疗效跟踪、用药方案与剂量调整、不良反应规避、疾病防治和公众健康教育等。 642\n",
      "2 1 3\n",
      "一、药学服务的内涵药学服务是在临床药学工作的基础上发展起来的，与传统的药学基础服务(供应、调剂)有很大的区别。药学服务于1990年由美国学者倡导，其含义是药师应用药学专业知识向公众(包括医护人员、患者及家属)提供直接的、负责任的、与用药相关的服务，以期提高药物治疗的安全、有效、经济和适宜性，改善和提高人类生活质量。药学服务最基本的要素是“与药物有关”的“服务”。所谓服务，即不仅以实物形式，还要以提供信息和知识的形式满足患者在药物治疗上的特殊需要。药学服务中的“服务”不同于一般行为上的功能。它包含的是药师对患者的关怀和责任，由于这种服务与药物有关，其服务应涉及全社会所有用药的患者，包括住院、门诊、社区和家庭患者。因此，药学服务具有很强的社会属性。药学服务的社会属性还表现在不仅服务于治疗性用药，还要关注预防用药和保健用药。药学服务在完成传统的处方调剂、药品检验、药品供应外，更是一种更高层次的临床实践，即必须在患者药物治疗全程中实施并获得效果，涵盖了患者用药相关的全部需求，包括选药、用药、疗效跟踪、用药方案与剂量调整、不良反应规避、疾病防治和公众健康教育等。二、药学服务的对象药学服务的对象是广大公众，包括患者及家属、医护人员和卫生工作者、药品消费者和健康人群。其中尤为重要的人群包括：①用药周期长的慢性病患者，或需长期或终生用药者；②病情和用药复杂，患有多种疾病，需同时合并应用多种药品者；③特殊人群，如特殊体质者、肝肾功能不全者、过敏体质者、小儿、老年人、妊娠及哺乳期妇女、血液透析者，听障、视障人士等；④用药效果不佳，需要重新选择药品或调整用药方案、剂量、方法者；⑤用药后易出现明显的药品不良反应者；⑥应用特殊剂型、特殊给药途径者；⑦药物治疗窗窄需做监测者。另外，医师在为患者制定给药方案及护士在临床给药时，针对药物的配伍、组方、注射剂溶媒的选择、溶解和稀释浓度、滴注速度、不良反应、禁忌证、药物相互作用等各种问题，均需要得到药师的帮助。 826\n",
      "3 2 4\n",
      "二、药学服务的对象药学服务的对象是广大公众，包括患者及家属、医护人员和卫生工作者、药品消费者和健康人群。其中尤为重要的人群包括：①用药周期长的慢性病患者，或需长期或终生用药者；②病情和用药复杂，患有多种疾病，需同时合并应用多种药品者；③特殊人群，如特殊体质者、肝肾功能不全者、过敏体质者、小儿、老年人、妊娠及哺乳期妇女、血液透析者，听障、视障人士等；④用药效果不佳，需要重新选择药品或调整用药方案、剂量、方法者；⑤用药后易出现明显的药品不良反应者；⑥应用特殊剂型、特殊给药途径者；⑦药物治疗窗窄需做监测者。另外，医师在为患者制定给药方案及护士在临床给药时，针对药物的配伍、组方、注射剂溶媒的选择、溶解和稀释浓度、滴注速度、不良反应、禁忌证、药物相互作用等各种问题，均需要得到药师的帮助。三、执业药师与药学服务执业药师(LicensedPharmacist)是指经全国统一考试合格，取得《执业药师资格证书》并经注册登记，在药品生产、经营、使用单位中执业的药学技术人员。药师应通过用药指导、审核处方和用药咨询等药学服务工作，在减少医疗差错、增进病患用药质量方面提供更多专业保障。在医院药房中，药师可以参与到制定危重急症、疑难杂症治疗方案、慢性病长期照护、住院患者用药历史追踪、判断处方用药适宜性、药物配伍禁忌审查建议、提供医护人员药物相关咨询、病患用药指导与咨询、肠外营养注射液和化疗药物配置、肝肾功能不全患者的剂量调整等工作中。药品经营企业尤其是药品零售企业(社会药店),是直接面对消费者提供药品和用药服务的药品流通终端环节，其经营条件、经营行为、服务能力和服务质量的优劣，与人民群众的健康息息相关。因为地利和身份原因，社会药店的药师更有可能贴心了解社区周围居民的生活方式和就医用药情况。社区药店与药师可能成为公众最容易接近和接触的基层健康服务机构与人员。药师更有必要掌握相关专业知识和必要服务技能，为公众提供整体性、持续性、便利性的优质药学服务和健康支持。同时，药师应积极走进社区，为社区群众整理药柜，建立药历和健康档案，在整体健康服务工作中承担起更重要的作用，患者在不同医院或者诊所治疗时，分别开药，这些药品是否会产生严重药物相互作用或有重复用药情形，药师应能够为其把关。另外，药学服务是一个系统持续的工作，各个执业领域的药师(包括生产和批发企业或者其他岗位)都需要建立以消费者为中心的服务理念，主动参与到药学服务工作中，为保障公众正确、安全、有效、合理用药提供优质的服务。药学服务是高度专业化的服务过程，要求药师以合理用药为核心，以提高患者生命质量为目的。药师作为团队成员之一服务于患者，必须用自己独有的知识和技能来保证药物使用获得满意的结果。提供药学服务的药师必须具有药学专业背景，具备扎实的药学专业知识(同时了解一定的中药学专业知识)、临床医学基础知识以及开展药学服务工作的实践经验和能力，并具备药学服务相关的药事管理与法规知识、人文知识及高尚的职业道德。 1232\n",
      "4 3 4\n",
      "三、执业药师与药学服务执业药师(LicensedPharmacist)是指经全国统一考试合格，取得《执业药师资格证书》并经注册登记，在药品生产、经营、使用单位中执业的药学技术人员。药师应通过用药指导、审核处方和用药咨询等药学服务工作，在减少医疗差错、增进病患用药质量方面提供更多专业保障。在医院药房中，药师可以参与到制定危重急症、疑难杂症治疗方案、慢性病长期照护、住院患者用药历史追踪、判断处方用药适宜性、药物配伍禁忌审查建议、提供医护人员药物相关咨询、病患用药指导与咨询、肠外营养注射液和化疗药物配置、肝肾功能不全患者的剂量调整等工作中。药品经营企业尤其是药品零售企业(社会药店),是直接面对消费者提供药品和用药服务的药品流通终端环节，其经营条件、经营行为、服务能力和服务质量的优劣，与人民群众的健康息息相关。因为地利和身份原因，社会药店的药师更有可能贴心了解社区周围居民的生活方式和就医用药情况。社区药店与药师可能成为公众最容易接近和接触的基层健康服务机构与人员。药师更有必要掌握相关专业知识和必要服务技能，为公众提供整体性、持续性、便利性的优质药学服务和健康支持。同时，药师应积极走进社区，为社区群众整理药柜，建立药历和健康档案，在整体健康服务工作中承担起更重要的作用，患者在不同医院或者诊所治疗时，分别开药，这些药品是否会产生严重药物相互作用或有重复用药情形，药师应能够为其把关。另外，药学服务是一个系统持续的工作，各个执业领域的药师(包括生产和批发企业或者其他岗位)都需要建立以消费者为中心的服务理念，主动参与到药学服务工作中，为保障公众正确、安全、有效、合理用药提供优质的服务。药学服务是高度专业化的服务过程，要求药师以合理用药为核心，以提高患者生命质量为目的。药师作为团队成员之一服务于患者，必须用自己独有的知识和技能来保证药物使用获得满意的结果。提供药学服务的药师必须具有药学专业背景，具备扎实的药学专业知识(同时了解一定的中药学专业知识)、临床医学基础知识以及开展药学服务工作的实践经验和能力，并具备药学服务相关的药事管理与法规知识、人文知识及高尚的职业道德。 889\n"
     ]
    }
   ],
   "source": [
    "import re\n",
    "\n",
    "# Open the file and read the contents\n",
    "with open('book1.txt', 'r') as f:\n",
    "    contents = f.readlines()\n",
    "\n",
    "# Define the patterns to match\n",
    "patterns = ['^\\([一二三四五六七八九十]+\\)', '^[0-9]+\\.', '^\\([0-9]+\\)','^[一二三四五六七八九十]+']\n",
    "\n",
    "# Loop through the contents and find the start line number of the patterns\n",
    "start_line_numbers = [0]\n",
    "for i, line in enumerate(contents):\n",
    "    for pattern in patterns:\n",
    "        if re.match(pattern, line):\n",
    "            start_line_numbers.append(i)\n",
    "            break\n",
    "\n",
    "# Print the start line numbers\n",
    "print(start_line_numbers)\n",
    "processing_blocks = start_line_numbers[:5]\n",
    "\n",
    "vectors_content = []\n",
    "\n",
    "for idx in range(len(processing_blocks)):\n",
    "    if idx > 0:\n",
    "        ln_start = idx - 1\n",
    "    else:\n",
    "        ln_start = 0\n",
    "    if idx > len(processing_blocks) - 2:\n",
    "        ln_end =  len(processing_blocks) - 1\n",
    "    else:\n",
    "        ln_end = idx + 1\n",
    "    print(idx, ln_start, ln_end)\n",
    "    \n",
    "    context_content = ''.join(contents[processing_blocks[ln_start]:processing_blocks[ln_end]]).replace('\\n', '').replace(' ', '')\n",
    "    print(context_content, len(context_content))\n",
    "    vectors_content.append(context_content)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['\\ufeff\\n',\n",
       " '\\n',\n",
       " '\\n',\n",
       " '\\n',\n",
       " '\\n',\n",
       " '\\n',\n",
       " '现代药学的发展历程主要经历了三个阶段， 即：传统的以药品供应为中心的阶段；参与临床用药实践，促进合理用药为主的临床药学阶段；更高层次的以患者为中心，改善患者生命质量的药学服务阶段。药学服务的变化反映了现代医药学服务模式和健康理念，体现“以人为本”的宗旨，是时代进步赋予药师的使命,同时也是科学发展和药学技术进步的结果。\\n',\n",
       " '\\n',\n",
       " '\\n',\n",
       " '\\n',\n",
       " '\\n',\n",
       " '一 、 药学服务的内涵             \\n',\n",
       " '\\n',\n",
       " '药学服务是在临床药学工作的基础上发展 起来的，与传统的药学基础服务(供应、调 剂)有很大的区别。药学服务于1990年由美国 学者倡导，其含义是药师应用药学专业知识向 公众(包括医护人员、患者及家属)提供直接 的、负责任的、与用药相关的服务，以期提高 药物治疗的安全、有效、经济和适宜性，改善 和提高人类生活质量。\\n',\n",
       " '药学服务最基本的要素是“与药物有关” 的“服务”。所谓服务，即不仅以实物形式，  还要以提供信息和知识的形式满足患者在药物  治疗上的特殊需要。药学服务中的“服务”不  同于一般行为上的功能。它包含的是药师对患者的关怀和责任，由于这种服务与药物有关， 其服务应涉及全社会所有用药的患者，包括住 院、门诊、社区和家庭患者。因此，药学服务 具有很强的社会属性。药学服务的社会属性还 表现在不仅服务于治疗性用药，还要关注预防用药和保健用药。\\n',\n",
       " '药学服务在完成传统的处方调剂、药品检 验、药品供应外，更是一种更高层次的临床实 践，即必须在患者药物治疗全程中实施并获得 效果，涵盖了患者用药相关的全部需求，包括 选药、用药、疗效跟踪、用药方案与剂量调整、 不良反应规避、疾病防治和公众健康教育等。\\n',\n",
       " '\\n']"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "contents[0:17]"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "iit",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.15"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
